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SUMMARY
This thesis reports the investigation of four Human Cytomegalovirus (HCMV) genes (UL23, 
UL24, UL43 and US22) which belong to the twelve-member HCMV US22 gene family. 
US22 family genes are specific to the Betaherpesvirus subfamily and all Betaherpesviruses 
investigated to date code for a similar number of US22 family members, suggesting that the 
family plays an important role in the Betaherpesvirus life cycle. The family is relatively little 
studied and the functions provided by family members are in almost all cases unknown.
Antibodies against UL43 and US22 gene products were already available so glutathione-s- 
transferase (GST)-fusion proteins or synthetic peptides were used to generate antibodies to 
the HCMV UL23 and UL24 gene products. The anti-UL23 antibodies specifically recognised 
pUL23 in extracts of both pUL23 expressing bacterial cells and purified HCMV particles. 
The anti-UL24 antibodies specifically recognised pUL24 in extracts of both pUL24 
expressing bacterial cells and in infected human foetal foreskin fibroblast (HFFF-2) cells. 
The anti-UL43 antibodies specifically recognised pUL43 in extracts of both pUL43 
expressing bacterial cells and in infected HFFF-2 cells, while the anti-US22 antibodies 
specifically recognised pUS22 in infected cell extracts. The apparent molecular mass of 
pUL23, pUL24 and pUL43 did not differ when made in prokaryotic or eukaryotic cells and in 
each case was consistent with the size expected from the published DNA sequence.
The UL24 and UL43 gene products were expressed with early-late (E-L) and true-late (L) 
kinetics, respectively. pUL23 could not be detected in infected cell extracts and therefore the 
temporal classification of UL23 gene expression could not be determined. Kinetic class 
designations for pUL24 and pUL43 were confirmed by time course experiments which 
showed that pUL24 could be detected from as early as 12 h PI, reaching a plateau level at 84 
h PI, while pUL43 was not detectable before 60 h PI.
In order to investigate whether pUL23, pUL24, pUL43 and pUS22 were structural or non- 
structural proteins, HCMV (strain AD 169) particles were purified from the culture medium 
of infected HFFF-2 cells. Three types of particles were resolved in glycerol 
potassium/tartrate gradients - virions, dense bodies and non-infectious enveloped particles 
(NIEPs). Western immunoblotting showed that pUL24 and pUL43 were present in all 
particle types. pUL23 and pUS22 were present in low amounts in virions and dense bodies, 
and although not investigated, due to low particle numbers, are expected to be present in 
NIEPs. To confirm that these were virus particle components and not simply associated with 
co-purifying cell debris, purified virus particles were examined in the electron microscope 
(EM). The presence of pUL23, pUL24, pUL43 and pUS22 in virus particles was confirmed 
by immuno-gold tagging of the tegument region of virions and the matrix component of 
dense bodies. The envelope was removed from purified virus particles by treatment with 
detergent and pUL23, pUL24, pUL43 and pUS22 each separated with the capsid/tegument 
fraction, confirming their status as HCMV tegument proteins.
The intracellular location of pUL24, pUL43 and pUS22 in HCMV infected HFFF-2 cells was 
investigated by immunofluorescence. pUS22 was confirmed to be present in the nucleus 
throughout infection. In contrast, pUL24 and pUL43 were non-nuclear proteins that 
accumulated in the perinuclear region, concentrating in a structure juxtaposed to the nucleus. 
The intracellular distribution of the four proteins was further investigated at the level of cell 
ultra-structure by immuno-gold thin section EM. With the exception of their presence in 
cytoplasmic virus particles pUL23, pUL24 and pUL43 were exclusively located in large 
cytoplasmic protein aggregates, which correlate with the juxtanuclear structure visualised by 
immunofluoresence. pUS22 on the other hand appeared to be distributed throughout the 
cell. The protein aggregates manifested in two forms: complex structures which appeared to 
lack a boundary membrane and smaller, membrane-bound aggregates resembling dense 
bodies.
It has been suggested that the juxtanuclear structure is a site of HCMV tegument acquisition 
and particle maturation, and the findings reported here are in agreement with this 
proposition. The pUL23, pUL24 and pUL43 tegument proteins could only have been
acquired by particles interacting with the protein aggregates and indeed tegumented, but non­
enveloped, particles were frequently associated with the complex-type protein aggregates.
While the HCMV UL43 gene is known to be non-essential, it was not known whether or not 
the UL23 and UL24 genes were required for virus replication in vitro. In order to isolate and 
propagate knockout mutant viruses in essential genes it is necessary to produce 
complementing cell lines. Retinal pigmented epithelial cells (RPE) and HFF cells 
immortalised due to expression of either human telomerase reverse transcriptase (hTERT) or 
the Human Papillomavirus (HPV) type 16 E6/E7 transforming genes, respectively, were 
employed to construct cell lines expressing pUL23, pUL24 and pUL43. Several cloned 
hTERT-RPE cell lines constitutively and stably expressing pUL4-3 were successfully obtained. 
However, irrespective of the cell line used, no pUL23 or pUL24 expressing line was obtained.
In order to investigate the function provided by the HCMV UL23 and UL24 genes attempts 
were made to generate UL23 and UL24 deletion mutants. Precise deletions in the UL23 or 
UL24 open reading frame (ORF) were engineered and replaced with the E. coli guanosine 
phosphoribosyl transferase (gpt) gene, to serve as a selectable marker gene. However, after 
four rounds of virus replication in the presence of mycophenolic acid and xanthine to enrich 
for gpt containing virus, followed by four rounds of plaque picking, all of the plaques yielded 
the wild type DNA fragment profile in Southern blots. Inability to isolate a UL23 or UL24 
deletion mutant was probably due to the poor efficiency of transfection of HFFF-2 cells 
and/or to a low level of recombination between the HCMV plasmid mutation and the wild 
type virus genome during the initial stages of the experiment.
The most important finding from this investigation was the demonstration that pUL23, 
pUL24, pUL43 and pUS22 are tegument proteins. Three other US22 family products 
(pUL36, pTRSl and pIRSl) are documented tegument components. Thus, at least seven of 
the twelve US22 family genes code for tegument proteins, suggesting that the products of the 
remaining five might be similarly located. This demonstrates for the first time a common 
biological feature among the US22 family members.
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Chapter 1
INTRODUCTION
1.1 The clinical problem
Human cytomegalovirus (HCMV), a member of the Betaherpesvirinae subfamily of the 
Herpesviridae (Roizman, 1996), is an ancient vims with a global distribution. HCMV infection 
has been detected even in geographically isolated populations, such as the Brazilian Tiriyo 
Indians (Britt and Alford, 1996). While there is a relatively high (~95 %) degree of sequence 
similarity between the different HCMV strains that have been investigated to date, short 
regions of hypervariable sequence have also been identified, indicating that there may be 
thousands of strains of HCMV in circulation worldwide. HCMV is estimated to infect ~50 
% of the North American population outside urban areas and up to ~90 % within cities. 
Transmission of HCMV requires direct person-to-person contact; the vims is excreted in 
most bodily secretions and breast-feeding is thought to be the most common source of 
transmitted vims (Mocarski, 1996). HCMV is of considerable medical importance. Since 
Rubella has been controlled by a vigorous vaccination programme HCMV has taken over as 
the leading cause of neonatal abnormalities, including deafness, physical abnormality and/or 
mental retardation (Fisher et al!, 2000). In the United States it is estimated that about 40,000 
infants, congenitally infected with HCMV, are born each year and of these, 4,000 to 6,000 
exhibit permanent neurological damage (Britt and Alford, 1996). HCMV also poses a life- 
threatening risk to immunosuppressed individuals, including allograft recipients and HIV 
infected patients and is responsible for the distressing blindness (Retinitis) that can affect 
some AIDs patients. However, the introduction of highly active anti-retroviral therapy 
(HAART) has decreased the incidence of cytomegalovirus disease in HIV-infected persons by 
>80 % (Salmon-Ceron, 2001). In recent years animal to human xenotransplantation has been 
considered a possible solution to the problem of organ supply. One of the major risks in this
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procedure is zoonotic transmission of viruses. While animal cytomegaloviruses are generally 
considered to be species specific it has been reported that at least one animal cytomegalovirus 
(baboon CMV) was recoverable from a patient following baboon liver transplant in a human 
patient (Michaels et al, 2001). Baboon CMV has also been shown to be capable of replicating 
in human fibroblast cells, demonstrating the potential for zoonotic transmission (Michaels et 
al, 1997).
Resources generated to control HCMV infection in the population include HCMV vaccines 
and anti-HCMV drugs. The live HCMV (strain Towne) vaccine, which is now commonly 
used as a laboratory strain, exhibits some biological differences when compared to clinical 
isolates, including altered growth characteristics in vitro and reduced trypsin sensitivity (Britt 
and Alford, 1996). The Towne strain virus grows poorly in humans and although able to 
induce humoral and cell mediated immunity in seronegative hosts (Gonczol and Plotkin, 
1990), the vaccine induced only a limited protective response when normal volunteers were 
subsequently challenged with wild-type virus (Plotkin et al., 1989). The limited immunity and 
lack of understanding of the determinants of viral virulence has hindered widespread use of 
the vaccine. There is also an understandable reluctance to vaccinate women of child-bearing 
age with a potentially teratogenic virus in case they may unknowingly be pregnant at the time 
of vaccination (Britt and Alford, 1996). More recently, attention has focused on subunit 
vaccines, particularly those directed against the viral glycoprotein gB; the major antigen 
eliciting viral neutralising antibodies (Speckner et al, 1999).
The anti-HCMV drug ganciclovir, a nucleoside analogue and a derivative of acyclovir, is 
licensed to treat HCMV induced retinitis in immunocompromised patients but has been 
associated with myelotoxicity. Foscarnet, a pyrophosphate analogue, has also been used to 
treat HCMV infections but is nephrotoxic and is used only in life-threatening cases or when 
other anti-viral drugs are no longer effective (Chan et al., 2001). Clearly, there is a continued 
need to develop more effective and less toxic anti-HCMV therapies. The molecular genetic 
investigation of HCMV, in so much as it identifies new potential antiviral targets, will play an 
important role in facilitating new intervention strategies for HCMV. One herpesvirus 
characteristic that makes intervention strategies difficult to sustain is the ability of
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herpesviruses to establish life-long latent or persistent infections. In the case of the 
A.lphaherpesvirus, Herpes Simplex Virus-1 (HSV-1), a latent infection is established in sensory 
neurons. HCMV latency is associated with bone marrow CD34+ myeloid progenitor cells 
(Hahn et al, 1998). However, it has not been conclusively established if HCMV establishes a 
true non-replicating latent infection in a specific cell type, as typified by HSV-1, or persists by 
low-level replication (Mocarski, 1996). In HSV-1 latently infected cells a specific set of viral 
RNAs, called Latency Associated Transcripts (LATs) are expressed (Roizman and Sears, 
1996). During natural infection with HCMV a small percentage of bone marrow-derived 
mononuclear cells become latently infected. The latent HCMV genome is distributed at low 
copy number (2 to 13 genomes per cell) and is in unit-length circular form, which is a 
characteristic of herpesvirus latent DNA (Slobedman and Mocarski, 1999). HCMV infected 
granulocyte-macrophage progenitors fail to support productive viral replication but 
Cytomegalovirus Latency-Associated Transcripts (CLTs) are expressed from the major 
immediate-early gene promoter (MIEP) locus. There are sense CLTs, coded for in the same 
direction as productive phase transcripts but using two novel start sites in the MIEP, and 
anti-sense CLTs, coded for in the opposite direction and complementary to IE1 exons 2-4. 
The sense and anti-sense CLTs code for proteins of 94 amino acids (aa) and 152 aa, 
respectively (Kondo et al., 1994; Kondo et al, 1996). Sense CLTs are expressed during in vitro 
HCMV productive infections of dTHP-1 cells, (monocyte derived macrophages), endothelial 
cells and human fibroblasts (Lunetta and Wiedeman, 2000). They are also expressed during 
the majority of natural productive infections, and antibodies to both the 94 aa and 152 aa 
proteins can be detected in serum from seropositive individuals (Kondo et al, 1996). The 
finding that HCMV CLTs are also expressed during productive infections is in accord with 
the finding that the HSV-1 major 2.0 kilo base pairs (kbp) LAT is also expressed during acute 
infection of ganglia, but at lower abundance than during latent infection (Lunetta and 
Wiedeman, 2000).
Due to species specificity no direct animal model exists for HCMV. Nevertheless, murine 
cytomegalovirus (MCMV) has been extensively used as a surrogate system, from which 
parallels can be inferred for HCMV in studies designed to investigate viral transmission, 
pathogenesis, acute infection and/or reactivation after immunosuppression, transfusion or
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transplantation (Xiao et al, 2000). However, since MCMV does not cross the placenta, its 
utility as a model for congenital HCMV infection is questionable. More recently, however, 
Guinea pig cytomegalovirus (GPCMV) has been reported to be a more accurate model for 
HCMV foetal infection, since this virus does cross the placenta and gives rise to infections 
that share many biological similarities with those of HCMV (McGregor and Schleiss, 2001).
1.2 Organisation of the HCMV genome and functions of viral genes
The HCMV double stranded linear DNA genome (—230 kbp) is larger than that of any other 
known herpesvirus. Like HSV-1, the HCMV genome has a class E organisation and so exists 
in the form of four genome isomers. The genome is organised as two unique regions, US 
and UL, which are flanked by inverted repeats sequences which permit the genome segments 
to invert relative to each other. One orientation was arbitrarily selected as the prototype (P) 
arrangement, with the others generated by inversion of the short unique sequences (IS), the 
long unique region (IL) and both the short and long regions (ISL). It remains to be 
determined whether each of the genomic inversions of HCMV is equally viable (Mocarski, 
1996). Recent evidence from an HCMV (ADI69) Bacterial Artificial Chromosome (BAC) 
produced in E.coli (strain DH10B), where only two of the four possible isomers were 
generated, showed that both isomers were infectious when transfected into HFF cells. Due 
to the absence of terminal fragments it was not possible to identify the two isomers that were 
present (Borst et al, 1999).
The complete DNA sequence (229,354 bp) of HCMV strain ADI 69 was published by Chee 
et al.’ (1990), and the genome was predicted to encode at least 208 Open Reading Frames 
(ORFs) of more than 100 amino acids in length. ORFs were numbered sequentially and 
given a prefix identifying their location in the genome (e.g. TRL, UL, IRL, IRS, US or TRS) 
(Figure 1). In some cases, families of related ORFs appear to have been generated by gene 
duplication events. Nine different gene families have been recognised: RL11, US6, US22,
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GCR, UL25, UL82, US1, US 12 and US2. The nine gene families are represented by colour 
coding in Figure 1. The number of ‘real genes’ coded for by HCMV has been difficult to 
determine, but it is clear that the AD 169 sequence is incomplete compared to clinical isolates. 
The laboratory strains of HCMV (ADI 69, Towne, Davis) all lack a number of genes that are 
present in the U L/b’ region of the genome in the low passage Toledo strain and in clinical 
isolates. Even Toledo, however, differs from clinical isolates in that the sequences in the 
UL/b’ region are in inverse orientation (Cha et al., 1996) and because Toledo, like the other 
lab strains, lacks the endothelial cell tropism exhibited by fresh clinical isolates (Bolovan-Fritts 
and Wiedeman, 2001). There are at least two isolates of A D I69 currendy in circulation, the 
sequenced genotype (Chee et al., 1990) and the more common genotype that contains an 
additional 929 bp sequence in the UL42/UL43 region (Dargan et al, 1997).
Comparison between the published DNA sequences of HCMV and other Betaherpesviruses has 
proved a very powerful tool for evaluation of proposed ORFs, assessment of gene 
conservation, and identification of functional elements in particular proteins. Such 
comparisons provide the core data for viral evoluntionary studies (Davison, 1993). Recently, 
the presumed entire gene content of HCMV (i.e. strain A D I69 sequence plus the Toledo 
UL/b’ region sequence) has been re-evaluated by comparison to the chimpanzee CMV 
sequence (241,087 bp). The estimated number of ORFs encoding protein (i.e. ‘real genes’) 
contained in the putative wild type HCMV genome has now been rationalised to 164 to 167 
genes (Dr. Andrew Davison, personal communication.). The DNA sequences of several 
Betaherpesviruses have been reported and compared with that of HCMV (strain A D I69). The 
DNA sequence of MCMV (Smith strain) has been published and shown to consist of a 
230,278 bp unique sequence with short direct repeats at either end (class F organisation). At 
the genetic level there are significant similarities to HCMV strain AD 169, particularly in the 
78 centrally located ORFs. Homologues of the HCMV UL25, UL82, US22 and GCR gene 
families are coded for by MCMV but there appear to be no homologues of the HCMV RL11, 
US1, US2, US6 or US12 gene families (Rawlinson et al, 1996). The 229,896 bp DNA 
sequence of rat CMV (Maastricht strain) has been reported and contains all but one of the 
ORFs that are conserved between MCMV and HCMV (Vink et al., 2000). The DNA 
sequence of human herpesvirus 6 (HHV-6) (strain U1102) has been published and contains
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102 predicted genes, arranged co-linearly with those of HCMV (Class A organisation). The 
HHV-6 genome (159,321 bp) is smaller than that of HCMV, but both genomes are densely 
packed with minimal splicing. HCMV and HHV-6 appear to be closely related exhibiting 
approximately 67 % homologous proteins, however, at the ends of the genome the HHV-6 
homology with HCMV diverges and the HCMV glycoprotein families RL11, US6 and US 12 
are not present in HHV-6 (Gompels et al, 1995). The human herpesvirus 7 (HHV-7) (strain 
RK) genome (144,861 bp) is very closely related to that of HHV-6 and is predicted to encode 
84 genes (Megaw et al, 1998). Most recently, the DNA sequence of the Tupaia (Tree Shrew) 
herpesvirus, another Betaherpesvirus, was published (Class F organisation). Analysis of the 
195,857 bp sequence predicted 158 genes, of which 76 genes had significant homology to 
genes in HCMV. Six gene families were recognised, although there appear to be no 
homologues of some US22 family genes (TRS1, IRS1, UL24 or UL43) (Bahr and Darai, 
2001).
The HCMV genome contains a set of over 40 conserved herpesvirus-common ‘core’ genes 
(Figure 1 and Table 1). These are arranged in blocks that maintain relative position and 
orientation in the genomes of different herpesviruses and reflect evolution from a common 
ancestor (Davison, 1993). Few herpesvirus genes are spliced and overall the genomes have 
relatively few polyadenylation signals. The following HCMV genes have been predicted to be 
spliced: UL22A (Rawlinson and Barrell, 1993), UL36-38 (Kouzarides et al, 1988), UL65 
(Davis and Huang, 1985), UL83 (Ruger et al., 1987), UL89 (Costa et al, 1985), UL111A 
(Lockridge et al, 2000), UL112-113 (Wright et al, 1988), UL115-116, UL117-118 (Leatham et 
al, 1991), UL122-123 (Stenberg et al, 1989), US3 (Chan et al, 1996) and US6 (Jones and 
Muzithras, 1991). The products of at least 45 HCMV ORFs (TRL4-TRL14, UL1-UL10, 
UL16, UL18, UL20, UL33, UL128, IRS1, US1-US13, US27; UL24; UL36; UL42 and UL43 
(Mocarski, 1996; Dr. Peter Ghazal personal communication; Patterson and Shenk, 1999; 
Dargan et al, 1997, respectively)) are dispensable for virus growth in cell culture. Overall, the 
products of a large number (approximately 70 %) of HCMV ORFs have not been identified. 
The assignment of gene function to many HCMV ORFs is based only on sequence similarity 
to apparently homologous genes in HSV-1. In the case of dispensable viral genes, 
investigation of HCMV gene function has been inhibited due to the lack of a direct HCMV
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animal model system. Molecular genetic investigation of the virus is made problematic by the 
slow replication kinetics of the virus, the friable nature of the naked HCMV DNA and the 
poor transfection efficiency of HCMV permissive cell lines (i.e. Human Foetal Fibroblasts 
(HFF)). Very few human cell lines are fully permissive for HCMV infection and HFF cells, 
which give the highest yields of infectious progeny, are associated with deletion of viral 
sequences in the UL/b’ region of the genome upon prolonged passage of the virus.
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Figure 1. Schematic representation of gene arrangement on the HCMV 
strain AD169 genome. Broad bands represent repeat regions (TRL/IRL; 
IRS/TRS), thin bands represent unique long (UL) and unique short (US) 
regions. The nine gene families are colour-coded. Size of blocks relates to 
predicted size of ORFs (Chee et al., 1990). Spliced genes are marked with 
thin line. Direction of blocks indicates direction of transcription. The core 
genes (red) are contained within the UL region. Diagram courtesy of Dr. 
Andrew Davison

Table 1. HCMV herpesvirus ‘core genes* and homologous genes in HSV-1.
HCMV
gene
Function, where known in HCMV HSV-1
gene
Function, where known in HSV-1 
(Umene, 1998)
Control:
UL69
(E-L)
Tra«i-activator (Winkler et al, 2000) UL54,
ICP27
(I-E)
Multifunctional regulatory protein; 
stimulation of viral DNA synthesis; early-late 
transition; host shutoff; inhibition of host 
RNA splicing; nucleotidylylated; 
phosphorylated (essential)
Nucleotide m etabolism :
UL45
(?)
Homologue of large subunit of 
ribonucleotide reductase (RR). Small 
subunit of RR not encoded, presumed 
non-functional (Lembo et al, 2000)
UL39,
ICP6
(I-E)
Ribonucleotide reductase large subunit 
(essential)
UL72
(E-L)
Predicted 388aa dUTPase, but lacks 
active site sequence (McGeoch, 1990).
UL50
(E)
Deoxyuridine triphosphatase, dUTPase (non 
essential)
UL114
(E)
Uracil-DNA-glycosylase (non- 
essential) (Prichard et al, 1996)
UL2
(E)
Uracil-DNA glycosylase (non essential)
DNA replication:
UL105
(E)
Component of DNA helicase-primase 
complex (essential) (Pari and Anders, 
1993)
UL5
(E)
Component of DNA helicase-primase 
complex; possesses helicase motifs (essential)
UL102
(L)
Primase associated factor (essential) 
(Pari and Anders, 1993)
UL8
(E)
Component of DNA helicase-primase 
complex (essential)
UL70
(E-L)
Component of DNA helicase-primase 
complex (essential) (Pari and Anders, 
1993)
UL52
(E)
Component of DNA helicase-primase 
complex (essential)
UL57
(E)
Single-stranded DNA-binding protein UL29, 
ICP8 (E)
Single-stranded DNA-binding protein 
(essential)
UL54 (E) DNA polymerase, (essential) (Pari and 
Anders, 1993)
UL30 (E) DNA polymerase (essential)
UL44
(E-L)
DNA polymerase processivity factor. 
(Ripalti et al., 1995) (essential) (Pari 
and Anders, 1993)
UL42
(E)
DNA polymerase processivity factor 
(essential)
Capsid com ponents:
UL86
(E-L)
Major capsid protein (MCP). HCMV 
pUL86 forms hexamers and 
pentamers of capsid shell.
UL19,
VP5
(E-L)
Major capsid protein (MCP); forms hexamers 
and pentamers of the icosahedral shell 
(essential)
UL85
(E-L)
Minor capsid protein (mCP); with 
pUL46 forms intercapsomeric triplex
UL18,
VP23
(E-L)
Minor capsid protein (mCP); with VP 19c 
forms intercapsomeric triplexes (essential)
UL49A
(?)
Small capsid protein (SCP) (Borst et 
al, 2001)
UL35,
VP26
(L)
Small capsid protein (SCP) present on outer 
tip of VP5 hexons but not pentons (non 
essential)
UL46
(E-L)
Minor capsid binding protein (mC- 
BP), with pUL85 forms
UL38,
VP19c
Minor capsid protein with VP23 forms 
intercapsomeric triplexes (essential)
9
intercapsomeric triplex. No aa 
similarity to HSV-1 VP19c (Gibson et 
al, 1996)
(L)
UL80
(L)
Protease, containing 5 conserved sites. 
Auto-proteolytic cleavage at sites 643 
and 256, then at 143 for de-activation
UL26,
VP24 and
VP21
(L)
Serine protease cleaving itself and UL26.5; 
VP24 (N-portion and protease domain of 
UL26) and VP21 (C-portion of UL26 and 
involved in scaffold formation of B capsid) 
(essential)
UL80A
(L)
Assembly (scaffolding) protein for 
cleavage maturation in the nucleus. 
Self interaction, via N-terminal 
sequences, important for interaction 
with MCP (Oien et al., 1997)
UL26.5,
VP22a
(E-L)
Internal protein of immature capsids; 
assembly protein involved in scaffold 
formation of B capsids (non essential)
Tegum ent com ponents:
UL99,
pp28
(L)
Localised to surface of cytoplasmic 
capsids (Wing and Huang, 1995)
UL11
(E-L)
Myristylated tegument protein; role in 
envelopment and transport of virions (non 
essential)
UL97
(E-L)
Serine/threonine kinase. 
Phosphorylates ganciclovir (GCV). 
(essential) (Prichard et al., 1999)
UL13,
VP18.8
(E-L)
Protein kinase (non essential)
UL48
(L)
Structural protein UL36,
VP1/2
(L)
Very large tegument protein, ~273 kDa; 
required for release of viral DNA from 
capsids (essential)
UL77
(E)
Predicted 642aa UL25
(E-L)
Required for DNA cleavage/packaging; 
influences penetration
Envelope com ponents:
UL55,
gB
(E)
Role in cell entry, binds heparin 
sulphate. Binding to ligand 
upregulates cellular transcription 
factors Sp-1 and NF-kB (Yurochko et 
al., 1997) (essential) (Britt and Mach, 
1996)
UL27,
gB
(E)
Role in cell entry. Binds heparan sulphate; 
fusion; binds tegument proteins including 
VP16 (essential)
UL75,
gH
(E-L)
Mediates fusion of the virus envelope 
during virus entry (essential) 
(Mocarski and Courcelle, 2001)
UL22,
gH
(L)
Heterodimer; complexes with gL; role in cell 
entry (essential)
UL115,
gL
(L)
Complexes with gH, role in cell entry 
(probably essential)
UL1,
gL
(E-L)
Complexes with gH; role in cell entry, 
(essential)
o'P 'lo
ti
Integral membrane protein, 
complexes with gN (Mach et al, 2000)
UL10,
gM
(L)
Probable integral membrane protein. 
Complexes with gN (non essential)
UL73,
gN
(E-L)
Complexes with gM (Mach et al., 
2000). Highly polymorphic
UL49A,
gN
(L)
Possible membrane glycoprotein. Complexes 
with gM (non essential)
1 UL50 
(?)
Predicted 397aa UL34
(?)
Membrane-associated phosphoprotein 
(essential)
DNA packaging and 
morphogenesis:
UL56
(E)
Terminase subunit. 130 kDa protein, 
interacts with pUL89. (Buerger et al., 
2001)
UL28,
ICP18.5
(E)
Required for DNA cleavage/packaging. Role 
in capsid maturation, (essential)
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UL51
(?)
Predicted 157a/a protein UL33
(?)
Role in capsid assembly/DNA cleavage and 
packaging (essential)
UL98
(E-L)
DNA, alkaline exonuclease (Sheaffer 
etal, 1997)
UL12
(E)
DNA alkaline nuclease involved in 
maturation/packaging of progeny genomes 
(non essential)
UL104
(E)
Predicted 697aa UL6
(E-L)
DNA cleavage/packaging; constituent of 
nucleocapsid but not required for capsid 
formation. Possibly portal protein (essential)
UL87
(?)
Predicted 941 aa UL21
(E-L)
Role in virion morphogenesis (non essential)
UL89
(E-L)
Terminase subunit (Underwood et al., 
1998)
UL15
(E-L)
Possible terminase? Required for DNA 
cleavage/packaging (essential)
Unknown Function:
UL47
(E-L)
Predicted 982aa UL37
(E-L)
Possible interaction with ICP8 (UL29) 
(essential)
UL103
(L)
Predicted 249aa UL7
(E-L)
Unknown (not known if essential)
UL95
(E-L)
Predicted 531 aa UL14
(E-L)
Unknown (not known if essential)
UL94
(L)
p53, plays a central role in regulation 
of UL94 promoter (Wing et al., 1998). 
Function unknown
UL16
(E-L)
Unknown (non essential)
UL93
(L)
Predicted 594aa UL17
(E-L)
Unknown (essential)
UL76
(?)
Predicted 325aa. Regulatory protein 
(Wang et al., 2000b)
UL24
(E)
Unknown, syncytium formation (non 
essential)
UL53
(E)
Predicted 376aa UL31
(L)
Unknown; nucleotidylylated phosphoprotein 
(essential?)
UL52
(L)
Predicted 668aa UL32
(L)
Required for DNA cleavage/packaging 
(essential)
UL71
9 2  . .
Predicted 411aa UL51
(E-L)
Unknown (non essential)
HCMV gene function is provided (with reference where applicable) and the function of the homologous gene in
HSV-1 is provided (Umene, 1998). HCMV genes are only classified as essential or non-essential where this has 
been specifically demonstrated. Kinetic Class is given in parentheses (Immediate-Early, I-E; Early, E; Early- 
Late, E-L; Late, L).
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1.3 The virus replication cycle
1.3.1 Kinetic class of virus gene expression
The replication cycle of HCMV is slow compared to that of other herpesviruses, and 
infectious virus progeny are not detected before 48-72 h PI (Mocarski, 1996). The 
transcription of all herpesvirus genes occurs in a tighdy regulated cascade and therefore genes 
can be classified into kinetic classes: immediate-early, early and late.
Immediate-Early (I-E) genes are transcribed by host cell RNA polymerase II and are the first 
viral gene products made in the infected cell. Four immediate-early gene loci (UL36-38, 
IE1/IE2, TRS1/IRS1, US3) are expressed from non-continuous regions on the HCMV 
genome (Mocarski, 1996). IE2, the major transactivator, operates co-operatively with IE1 
and accessory proteins (e.g. UL36-38, TRS1, IRS1) to regulate early and late gene expression.
Early (E) genes are the second set of viral genes to be transcribed. Transcription requires the 
presence of immediate-early proteins and is not affected by inhibitors of viral DNA 
replication, such as phosphonoacetic acid (PAA) or ganciclovir (GCV). Early gene products 
generally code for enzymes and proteins involved in DNA synthesis, packaging and 
maturation.
Late genes are the last set of viral genes to be transcribed and generally encode structural 
proteins. Late genes are divided into two subsets; 'early-late* (E-L) transcripts are first 
detected 12-36 h PI and proteins are made only in minor amounts in the presence of viral 
DNA inhibitors; ‘true-late’ (L) protein accumulation is stricdy dependent on viral DNA 
replication.
While this simplistic scheme provides a convenient system by which individual HCMV genes 
can be grouped, in truth the reality is more complex, as there is a delay between transcript 
production and protein synthesis in the case of some genes, indicating that translational
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control mechanisms contribute to overall regulation of gene expression. For example, 
expression of gpUL4 is repressed at the translational level by the presence of a short 
upstream open reading frame (uORF2) within the UL4 transcript leader. Thus, although the 
UL4 mRNA is detectable at 6 h PI and reaches a plateau after 24 h PI the UL4 protein 
product is detectable only at 48 h PI. Mutation of uORF2 eliminates ribosomal stalling and 
results in abundant early expression of gpUL4 (Alderete et al, 2001).
1.3.2 HCMV induced effects on intracellular signalling
Binding of HCMV particles, via envelope glycoproteins, to cell surface receptors and co­
receptors results in the immediate stimulation of several cellular signalling pathways, including 
the mitogen-activated protein kinase (MAPK) pathway, which leads to an increase in nuclear 
factor NF-kB binding to DNA, and a phospholipase C (PLC) pathway, which leads to Ca2+ 
release and second messenger activity (Fortunato et a l, 2000). Binding of glycoprotein gB to 
its cell surface receptor results in activation of a subset of host cell genes normally induced by 
interferon (IFN)-a, a response normally associated with the cell anti-viral response (Navarro 
et al., 1998; Boyle et al, 1999; Preston et al, 2001), although the vims utilizes a different 
signalling pathway to that normally induced by IFN-a. Indeed, the virus-induced signalling 
mechanism does not lead to nuclear localisation and assembly of ISGF3, but rather leads to 
the formation of a novel complex, that binds the interferon stimulated reponse element 
(ISRE) and which contains interferon-regulatory factor 3 (IRF-3) and CREB-binding protein 
(Fortunato et al, 2000). The benefit the vims derives from induction of this subset of IFN- 
inducible cellular genes immediately after infection is unknown. Later in infection, the cells 
become refractory to IFN-a mediated stimulation and several cellular genes, including major 
histocompatibility complex (MHC) Class I, IRF-1, MxA and 2’5’-oligoadenylate synthetase 
are affected. HCMV infection is also known to repress IFN-y signal transduction, including 
repression of IFN-y induced upregulation of MHC Class II gene transcription. If cells are 
infected prior to exposure to IFN-y, a dramatic reduction in the signalling factors JAK 1
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(Janus Kinase 1) and p48 is responsible for the down-regulation of MHC Class II 
transcription (Sedmak et al, 1994; Miller et al., 1998). However, if cells are exposed to IFN-y 
prior to, or during, infection then down-regulation of MHC Class II transcription is achieved 
by a different signalling mechanism, involving inhibition of transcription of Class II 
Transactivator (OITA), which itself is required for the trans-activation of the MHC Class II 
gene (Le Roy etal., 1999).
Infection of fibroblasts with HCMV results in stimulation of extracellular—signal regulated 
kinases (ERKs), due to inhibition of a cellular phosphatase. Stimulation of ERKs activity 
appears to be bi-phasic. At early times (within the first 24 h PI) ERK activity is transient and 
dependent on viral immediate-early gene expression. At late times PI, ERK2 activation may 
also be induced by binding of the T cell chemokine RANTES to the HCMV US28 CC- 
chemokine receptor expressed on the surface of infected cells, resulting in an increase in 
intracellular Ca2+, and presumably second messenger activity (Billstrom and Worthen, 2001). 
Thus, the kinase activity of ERKs appears to be required at all stages of HCMV replication. 
ERK kinase is responsible for phosphorylation of another cellular protein, p90 ribosomal 
kinase (p90RSK), which operates to up-regulate cAMP-response element binding protein 
(CREB) and to inactivate CDC2/cyclin B regulatory kinase MYT1 and thus has a role in 
establishing an optimal cellular environment for virus growth (Fortunato et al, 2000; Richards 
et al, 2001). ERKs are also involved in protein/protein interactions with viral gene products, 
since ERK2 has been shown to phosphorylate IE2 (Harel and Alwine, 1998).
Binding of HCMV to a host cell receptor induced the immediate (maximum levels 15-30 min 
PI) activation of phosphatidylinositol 3-kinase (PI3-K), a protein kinase involved in 
intracellular signalling pathways. A second tier of PI3-K activation, which followed viral I-E 
protein expression was detected at 4 h PI (Johnson et al, 2001). PI3-K is responsible for 
activation of the cellular transcription factor, NF-kB, and the protein kinases Akt and 
p70S6K. The phosphorylated form of Akt has been shown to be involved in inhibition of 
apoptosis (Kandel and Hay, 1999). In uninfected cells the NF-kB heterodimer (p65 and p50 
subunits) is cytoplasmic and bound to an inhibitor molecule, IkB (Baldwin, 1996). Following 
stimulation of a kinase pathway, IkB is phosphorylated and degraded in an ubiquitin-mediated
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manner. NF-kB then translocates to the nucleus, binds DNA and activates many genes, 
including several anti-apoptosis genes (Romashkova and Makarov, 1999). Johnson et al, 
(2001) hypothesise that PI3-K, induced by HCMV infection, phosphorylates and degrades 
IkB, resulting in activation of NF-kB, which may then bind the HCMV MIEP to induce viral 
I-E protein synthesis. The importance of the early stimulation of PI3-K for HCMV 
replication was shown by experiments in which PI3-K activity was specifically inhibited. 
There was a decrease in I-E and E gene expression and DNA replication was strongly 
inhibited, resulting in a reduction in infectious virus progeny of ~ 10,000 fold (Johnson et al, 
2001). Thus, in some host cells at least, the mitogenic pathway involving PI3-K activity plays 
an important role in facilitating HCMV lytic cycle replication.
HCMV infection generally results in arrest of the cell cycle progression at the G i/S transition 
point, although cells infected during the S phase can complete the cycle before arresting in at 
the next Gi (Fortunato et al!, 2000). HCMV mediated control over cell cycle progression 
operates by controlling expression of several key regulatory proteins, including cyclins A, B, 
D and E (Salvant et al, 1998) and by eliminating the function of the tumour suppressor 
proteins, p53 (Fortunato and Spector, 1998) and retinoblastoma protein, Rb (Poma et al, 
1996). In synchronised cells infected in Go, cyclin D1 levels are decreased, while the level of 
the mitotic cyclin (cyclin B) is markedly increased at early times PI. The levels of cyclin E and 
its associated kinase are increased, and consequently the cell moves into Gi. Cyclin E 
activation is critical, since inhibition of its kinase, CDK2, blocks HCMV replication 
(Bresnahan et al, 1997). The activation of cyclin E is dependent on viral early gene expression 
and is associated with changes in the Rb-related protein p i30 (McElroy et al, 2000). Infected 
cells are maintained at the G i/S transition and are unable to replicate their DNA because the 
predominant S-phase cyclin (cyclin A) is expressed in negligible amounts and is barely 
detectable.
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1.3.3 The major stages in the HCMV replication cycle
Following cell surface binding and membrane fusion, the de-enveloped virus enters the 
cytoplasm, at which stage it may shed some tegument proteins. HCMV can penetrate many 
cell types, including epithelial cells, fibroblasts, smooth muscle cells, endothelial cells and 
macrophages. Undifferentitated, transformed or anueploid cells are non-permissive for 
HCMV lytic replication. Most peripheral blood monocytes are also non-permissive, although 
a latent infection can occur, but upon their differentiation to macrophages the cells then 
become permissive and the virus reactivates (Sinzger and Jahn, 1996). In some cases HCMV 
inter-strain differences in endothelial cell tropism have been shown to be due to differences in 
the ability of the virus to transport the infecting capsids towards the nucleus, rather than to 
differences in the ability of the virus to enter cells perse (Sinzger et al, 2000). Such inter-strain 
differences presumably lie in genes encoding tegument or capsid proteins. By analogy with 
HSV-1, it is likely that HCMV nucleocapsids are transported along microtubules to dock at a 
nuclear pore, where the viral DNA is released into the nucleus (Sodeik etal., 1997).
The linear HCMV genome circularises upon its entry into the nucleus and becomes 
associated with a region in the nucleus known as a promyelocytic protein (PML)-oncogenic 
domain (POD) (also known as ND10). PODs are spherical structures with an average 
diameter of 0.3 to 0.5 pm, consisting of a central core surrounded by an electron-dense 
capsule. Several dozen PODs form in the nucleus of most cells and are located within inter­
chromatin regions and associated with the nuclear matrix, although their function in normal 
uninfected cells is unknown (Wilkinson et al, 1998; Drouin et al., 2001). In HCMV infected 
cells, the periphery of PODs has been implicated as the site of initiation of immediate-early 
gene transcription. A nuclear compartment, where DNA replication occurs, is also associated 
with the periphery of PODs (Ishov et al., 1997).
Compared to other herpesviruses there is a significant delay before HCMV DNA synthesis is 
initiated, presumably caused by the slow build up of early gene products, some of which are 
required for viral DNA replication. It is thought that herpesvirus DNA replicates by a ’rolling 
circle' mechanism, generating long concatamers, which are subsequently cleaved to unit
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length for packaging. It is assumed that recombination and genome inversion also occur 
between concatemeric DNA molecules. Eleven HCMV genes (UL36-38, UL44, UL54, 
UL57, UL70, UL84, UL102, UL105, UL112-113, IE1/IE2, TRS1/IRS1) are essential for 
transient complementation of oriLyt-dependent DNA replication (Pari and Anders, 1993). 
Several of these genes are herpesvirus core genes (Table 1) and homologous to HSV-1 genes 
required for viral DNA replication, including the DNA polymerase (UL54), polymerase 
processivity factor (UL44), single stranded DNA binding protein (UL57) and the three 
protein components of the helicase-primase complex (UL70, UL102, UL105). The functions 
of the remaining HCMV genes (UL36-38, UL84, UL112-113, IE1/IE2, TRS1/IRS1) 
required for DNA replication in the transient replication system are not fully understood, but 
HCMV DNA replication may require more than the six herpesvirus-common replication 
functions.
Concatemeric virus DNA is cleaved to unit length by the activity of the terminase enzyme 
(coded for by HCMV genes UL56 and UL89) and packaged into pre-formed capsids, which 
are translocated to patches in the inner nuclear membranes, where they may acquire some 
tegument proteins before envelopment by budding through the inner nuclear membrane into 
the lumen of the nuclear membrane. Passage of the virus from the nucleus to the cell surface 
has been the topic of much research and forms part of the discussion section of this thesis.
17
200nm
Nucleocapsid
Tegument
Genome
Membrane
Glycoprotein complex I 
Glycoprotein complex III
Figure 2. Cut away diagram of the HCMV virion. The envelope and 
tegument is cut away to reveal the iscosahedral nucleocapsid. Surface 
glycoprotein complexes are shown as spheres. Diagram obtained from 
www.biografix.de, with permission from Dr. Marko Reschke.
1.4 Structural components of HCMV particles
Three types of virus-related particles are released into the extracellular medium from HCMV 
infected cells in culture. These are the mature infectious virion and two non-infectious 
particles; the so-called non-infectious enveloped particle (NIEP) and the dense body. Dense 
bodies and NIEPs can be distinguished from virions and each other by morphology in the 
electron microscope and by biochemical analysis. Dense bodies, which are present only in 
the cytoplasm of infected cells, lack the nucleocapsid and DNA of the virion and are 
predominately composed of a single tegument protein pp65 (pUL83) (Irmiere and Gibson, 
1983). Whether dense bodies are produced during in vivo infection or whether they represent 
an artefact of the in vitro culture systems is controversial. In support of the latter view, it has 
been noted that dense bodies are not produced in tissue culture cells infected with MCMV 
(Mocarski, 1996). It has been suggested that dense bodies may consist of surplus cellular and 
viral products accumulated in a storage vacuole that is subsequently voided into the extra­
cellular medium (Seven et al., 1992). NIEPs are similar to virions in protein composition and 
particle morphology. However, the capsid structure lacks the DNA genome, and instead 
contains an additional capsid shell scaffolding protein, which is absent in the mature 
infectious particle (Irmiere and Gibson, 1983). As with dense bodies, it is not clear whether 
NIEPs are made in vivo and these may also be produced as an artefact of the in vitro culture 
system.
As has been reported for HSV-1 (Roizman and Sears, 1996), several forms of HCMV 
nucleocapsid structures (A, B and C capsids) can be identified in infected cells. Type A 
capsids are empty and lack the DNA genome, whereas B capsids also lack the genome but 
contain the scaffolding proteins, are present in the nucleus but are not yet enveloped. Type C 
capsids are present in the cytoplasm of infected cells and in fully mature enveloped virions 
(Gibson, 1996). Herpesvirus virions (Figure 2) are composed of the double-stranded viral
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DNA genome packaged inside the icosahedral-shaped capsid, which is embedded in a 
complex amorphous protein layer known as the tegument, and the whole then enclosed 
within a lipid bilayer envelope decorated with surface viral glycoprotein spikes (Roizman, 
1996). To date, approximately 30 HCMV genes are reported to code for products that are 
contained in the virion particle. A similar number of HSV-1 genes (at least 34) have also been 
reported to code for particle proteins (Rixon, 1993; Steven and Spear, 1997).
1.4.1 The capsid
The icosahedral capsid composed of 162 capsomeres (150 hexons and 12 pentons) is a group 
characteristic of herpesviruses. However, certain features of the capsid shell can vary 
between members of the family. The HCMV capsid shell is larger than that of HSV-1 
(diameters of 130 nm and 125 nm, respectively) and has to accommodate a genome that is 
some 37 % larger than HSV-1. A comparison of HCMV and HSV-1 capsid shell architecture 
showed differences in hexamer spacing and relative tilt, in morphology at the tips of the 
hexons, and in the average diameter of the scaffold (Butcher et al., 1998). While the internal 
volume of the HCMV capsid was some 17 % larger than that of HSV-1 this was insufficient, 
of itself, to account for packaging of the larger HCMV genome and it was subsequendy 
shown that the HCMV genome was more densely packed than that of HSV-1 (average inter­
layer spacing of 23 A, versus 26 A, respectively) (Bhella et al., 2000).
Assembly of the herpesvirus capsid shell occurs in the nucleus and in HSV-1 involves the 
products of six genes that encode seven proteins; five of which constitute the capsid structure 
[UL19 (VP5), UL38 (VP19c), UL18 (VP23), UL35 (VP26), UL26 (VP24)] and two 
scaffolding proteins that are required for capsid assembly but do not form part of the final 
capsid structure [UL26 (VP21) and UL26.5 (VP22a)] (Oien et al., 1997). Homologous genes 
and proteins are coded for by HCMV and other herpesviruses (Table 1). The HCMV capsid 
shell contains at least four proteins: the major capsid protein (MCP) (pUL86), the minor 
capsid protein (mCP) (pUL85), mCP binding protein (mC-BP) (pUL46) and the small capsid
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protein (SCP) (UL48/49) (Gibson, 1996). The HCMV MCP, a 1,370 amino acid protein, is 
the main protein constituent of the capsid, comprising the pentamers and hexamers of the 
capsid. The HCMV mCP and mC-BP are present in the ratio 2:1 and constitute the inter­
capsomeric triplex, that links adjacent capsomeres, and are the homologues of HSV-1 VP23 
and VP19c. The HSV-1 VP26 protein is not essential for the production of a stable capsid 
shell structure and its location at the tips of the hexon is thought to direct tegument 
attachment (Zhou et al\, 1995). The HCMV SCP is less well studied than its HSV-1 
counterpart (VP26), but in contrast to VP26, the SCP has been shown to be essential for 
generation of infectious progeny in tissue culture cells (Borst et al\, 2001). The role of capsid 
shell proteins in interaction with tegument proteins is relatively little studied. However, it has 
been demonstrated that HCMV tegument proteins are attached to the pentons, hexons and 
triplexes of HCMV capsids (Chen et al., 1999). HSV-1 tegument proteins have also been 
shown to be attached to the pentons (Zhou et al, 1995).
The HCMV 'Assembly protein1 (pUL80A), is a 36kDa scaffolding protein, derived from the 
carboxyl-terminal half of the HCMV UL80 85kDa gene product. It is one of four proteins 
that are auto-proteolytically cleaved from pUL80 by the HCMV protease activity, which is 
located within the amino-terminal half of pUL80. pUL80A, like its HSV-1 counterpart 
pUL26.5, forms a scaffold around which the capsid shell is assembled. Self-interaction, via 
N-terminal sequences, are required for scaffold assembly, and C-terminal sequences are 
required for interactions with the MCP (Oien et al, 1997). Once assembled, protease cleavage 
of a short C-terminal region allows the scaffolding proteins to vacate the nucleocapsid, 
leaving space to accommodate the viral genome. As no DNA molecule is packaged in 
NIEPs the pUL80A remains associated with the capsid, suggesting that pUL80A may be 
directly involved in packaging of the genome. Since pUL80A is not a component of the 
mature virion this protein too must be removed at some stage during genome packaging.
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1.4.2 The envelope
The envelope of HCMV particles is composed of viral proteins embedded in a host derived 
membrane (Mocarski, 1996). Compared to other herpesviruses, HCMV codes for a relative 
abundance (~50) of putative glycoprotein (gp) genes, many of which appear to have no 
homologues in other herpesviruses (Chee et al, 1990). Most of the glycoproteins encoded by 
the virus have yet to be studied and the functions they provide are unknown. It is not even 
yet clear which are expressed on the surface of the infected cell and/or in the virion envelope.
At least eight HCMV glycoproteins with homologues in other herpesviruses are known to be 
involved in forming glycoprotein complexes (gel, gcll and gcIII) in the virion envelope. 
HCMV gB (gpUL55) (— 150 kDa) is the major envelope glycoprotein and homodimeric 
molecules of gB are linked by disulphide bonds to form glycoprotein complex gel. HCMV 
gB binds to heparin sulphate on the cell surface and is essential for virus penetration, fusion 
of infected cells and cell to cell spread of infection (Boyle and Compton, 1998; Singh and 
Compton, 2000). The nascent HCMV gB protein is proteolytically cleaved into two 
components (a 446 amino acid 55 kDa C-terminal fragment and a 460 amino acid 93 kDa N- 
terminal fragment), which remain coupled by disulphide bonding (Mocarski, 1996).
HCMV gB is the major antigen for induction of complement-dependent neutralising 
antibodies and is an important candidate for generation of a subunit vaccine. Vaccine 
development, however, is complicated by the finding that at least four major genotypes of gB 
exist in the population, along with several rare variants (reviewed in Pignatelli et al!, 2001). 
Nearly all HCMV infected individuals develop anti-gB antibodies, targeted primarily to the 
AD-1 region (amino acids 552-635). Neutralization reaches 50 % efficiency at best, indicating 
that during natural infection the virus may escape the immune system by inducing production 
of non-neutralizing gB antibodies, or by producing viruses with variant gBs (Speckner et al'
1999).
Another abundant and important constituent of the HCMV envelope is the glycoprotein 
complex gcll, which consists of gM (gpULlOO) and gN (UL73) (Mach et al!, 2000). It is
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probable that the gcll complex contains more than a single gM/gN dimer (Hobom et al.,
2000). The gcll complex binds heparin and is thought to play a role in virus entry and 
membrane fusion. Homologues for gM and gN are known for HSV-1, where they also form 
a complex. However, while the gM/gN complex was essential for replication of HCMV, it 
was not essential for HSV-1, although the HSV-1 mutants replicated to lower titres and 
exhibited reduced virulence in vivo (MacLean et al, 1993).
HCMV glycoproteins gH (gpUL75), gL (gpUL115) and gO (gpUL74) form complex gcIII, 
which is involved in membrane fusion and virus penetration. Homologues for gH and gL are 
also coded for by HSV-1 where they are essential genes with a function in virus release and 
entry (Desai et al, 1988). gH is also a target for complement-independent anti-CMV 
neutralising antibodies (Mocarski, 1996). While complexes gel, gcll and gcIII all promote 
membrane fusion, the mere binding of gB or gH by themselves to cell surface receptors 
induced signal transduction resulting in a increase in the levels of the Spl and NF-kB 
transcription factors (Yurochko et al., 1997).
The envelope of HCMV particles also contains gene products that exhibit homology to G- 
coupled receptors (GCRs) (UL33, UL78, US27, US28) and C-C chemokine receptors (US28) 
(Margulies et al., 1996; Zipeto et al, 1999; Beisser et al, 2001). GCRs are known to transduce 
extracellular signals to alter intracellular processes and the HCMV GCR genes may function 
similarly during the initial virus binding stage of infection. The HCMV envelope associated 
C-C chemokine receptor (US28) remains expressed on the surface of latently-infected THP-1 
monocytes. It has been suggested that circulating infected monocytes expressing US28 in vivo 
might promote dissemination of HCMV by adhering to CX3C expressing endothelial cells 
(Beisser et al., 2001).
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Table 2. HCMV tegument proteins
HCMV
Gene
(Kinetic
Class)
Function of HCMV Protein Homologues in Betaherpesviruses a -
herpes
MCMV HHV-6 HHV-7 Rat Tupaia HSV-1
UL18
(L)
Glycoprotein. Immune 
evasion, homologue of 
MHC Class I
ml 44 rl44
UL25
(L)
Phosphoprotein (Zini et al., 
1999)
M25 U14 U14 R25 T25 UL9?
UL26
(E)
Phosphoprotein 
(Baldick and Shenk, 1996)
M26 R26 T26
UL32,
ppl50
(L)
Phosphoprotein.
(Baxter and Gibson, 2001)
M32 U ll U ll R32 T32
UL36
(I-E)
Phosphoprotein 
Viral inhibitor of Fas 
mediated apoptosis (vICA) 
(Skaletskaya et al., 2001)
M36 U16/
U17
U16/
U17
R36 T36
UL47
(E-L)
Phosphoprotein. Unknown, 
function (Baldick and Shenk, 
1996).
M47 U30 U30 R47 T47 UL37
UL48
(L)
Phosphoprotein. Unknown. 
Function. HSV-1 homolog 
needed for release of DNA 
from capsid
M48 U31 U31 R48 T48 UL36
UL56
(E)
Terminase subunit (Giesen et 
al., 2000a)
M56 U40 U40 R56 T56 UL28
UL65 Phosphoprotein Protein 
Kinase (Davis et al., 1984)
UL69
(E-L)
Phosphoprotein. Trans- 
activator of MIEP (Winkler 
and Stamminger, 1996)
M69 U42 U42 R69 T69 UL54
UL77
(E)
HSV-1 homolog role in 
capsid assembly.
M77 U50 U50 R77 T77 UL25
UL82
(PP71)
(L)
Phosphoprotein 
Trcm-activator of MIEP (Liu 
and Stinski, 1992)
M82 U54 U54 R82 T82
UL83
(pp65)
(E-L)
Phosphoprotein 
Protein kinase? 
(Schmolke et al., 1995)
M83 U54 U54 R83 T82
UL87
(?)
HSV-1 homolog 
nucleotidylated virion 
protein
M87 U58 U58 R87 T87 UL21
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UL88 Phosphoprotein. Unknown, 
function (Baldick and Shenk, 
1996)
M88 U59 U59 R88 T88
UL94
(L)
Phosphoprotein. Unknown 
function
M94 U65 U65 R94 T94 UL16
UL97
(E-L)
Phosphoprotein.
Serine/thronine kinase 
(Wagner et al, 2000)
M97 U69 U69 R97 T97 UL13
UL99,
pp28
(L)
Phosphoprotein. Unknown 
function. HSV-1 homolog 
required for vims 
envelopment
M99 R99 T99 UL11
IRS1
(LB)
Phosphoprotein 
Tra«j-activator of MIEP 
(Romanowski et al, 1997)
Ml 43 U95 U95
TRS1
(I-E)
Phosphoprotein 
Tra/w-activator of MIEP 
(Romanowski et al, 1997)
Ml 43 U95 U95
Members of the US22 gene family are underlined. HCMV functional homologues in MCMV (Rawlinson et al., 
1996), HHV-6 (Gompels et al., 1995), HHV-7 (Megaw et al, 1998; Nicholas, 1996), Rat CMV (Vink et al, 2000), 
Tupaia (Tree Shrew) herpesvirus (Bahr and Darai, 2001) and Alphaherpesvirus HSV-1 (a) (Umene, 1998) are
provided.
1.4.3. The tegument
The tegument of HCMV particles, which constitutes —40 % of the virion protein mass, 
contains a high proportion of phosphoproteins (Table 2) (Gibson, 1996). Most of the 
HCMV tegument proteins listed in table 2 have homologues in other Betaherpesviruses and the 
Alphaherpesvirus, HSV-1, implying an important herpesvirus conserved function/s. Several 
genes (e.g. UL32, UL36, UL82, UL88) appear to have no homologues in HSV-1, but have 
homologues in the other Betaherpesviruses, indicating an important Betaherpesvirus-specific 
function.
The HCMV tegument contains in excess of 20 proteins (Table 2) representing a significant 
genetic investment in this structure. Investigation of the role of the tegument and its 
importance for HCMV replication is at an early stage. It seems probable, however, that the 
function provided by tegument proteins will be complex and possibly inter-related and
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multifunctional. Some tegument proteins may perform key architectural roles or function to 
facilitate virus egress. Others, delivered to cells at the time of infection, may operate prior to 
immediate-early protein synthesis, to induce a favourable intracellular environment for lytic 
replication in the infected cell. Such tegument proteins may be determinants of tissue tropism 
or be involved in abrogating host defences. The HCMV tegument contains several proteins, 
including pp71 (pUL82), pUL69 and pTRSl/pIRSl that can /ra«.r-activate the virus I-E genes 
and/or other viral or cellular promoters. Trawj-activation by these proteins is described in 
section 1.6.
The major HCMV tegument components are pp65 (pUL83 or ‘lower matrix protein’) and 
ppl50 (pUL32 or ‘basic phosphoprotein’), which are both highly immunogenic (Gibson, 
1996; Mocarski, 1996). pp65 is an abundant virion protein (~18 % of total virion protein 
mass) and is the main protein constituent of dense bodies (~95 % of particle mass) (Irmiere 
and Gibson, 1983). Surprisingly, this abundant protein appears to be dispensable (Schmolke 
et al, 1995). After infection with virus or dense bodies in cells treated with CHX (i.e. prior to 
immediate-early protein synthesis) pp65 localises to the nucleus, although its function at this 
time is as yet not understood (Hensel et al, 1995). The UL83 gene is /ra/w-activated by 
IE1/IE2, via a mechanism that involves an octamer sequence in the UL83 promoter, to 
express pp65 as an early-late protein (Depto and Stenberg, 1989). Following its translation, 
pp65 is present in the nucleus of infected cells throughout the replication cycle, but at late 
times PI is also found in the cytoplasm (Hensel et al, 1995). pp65 is strongly associated with 
the nuclear matrix and accumulates along the nuclear periphery where it is associated with 
nuclear lamins (Sanchez et al, 1998). The UL83 product exhibits serine/threonine protein 
kinase activity, (although it has no homology to any other known protein kinase) and is 
capable of both autophosphorylation and phosphorylation of the major immediate early 
protein IE1. It is thought that phosphorylation of IE1 prevents cleavage of IE1 into peptides 
that are bound by MHC Class I and presented at the cell surface where they would be 
recognised by T cells (Gilbert et al, 1996). pp65 also binds a cellular protein, 'Polo-like kinase 
activity' (PIK1), and may affect intracellular signalling by altering PIK1 activity, nucleotide 
preference, substrate specificity or sub cellular location (Gallina et al, 1999).
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The UL32 gene product (ppl50) is a tegument protein that is essential (Zipeto et al, 1993) for 
virus replication and constitutes about 20 % of the total virion mass. ppl50 is post- 
translationally modified by O-linked glycosylation, (a modification frequently associated with 
proteins that localise to nuclear membranes) and is one of the most immunogenic proteins 
present in the virus particle. HCMV seropositive individuals have high titres of anti-ppl50 
antibodies (Gibson, 1996; Mocarski, 1996). ppl50 could be detected in the nucleus of 
infected cells at early times PI (up to 48 h) where it was associated with both viral assembly 
compartments and the nuclear membrane, but at 72 h PI it was exclusively cytoplasmic 
(Hensel et al, 1995). In contrast, more recent investigations have failed to detect ppl50 in the 
nucleus at all, but have shown it to be present in the cytoplasm throughout infection, 
accumulating in a stable juxtanuclear structure (Sanchez et al, 2000b). The function of ppl50 
is unknown but, like its Simian CMV (SCMV) gene homologue, HMCV ppl50 is tightly 
bound to the capsid (Trus et al, 1999; Chen et al, 1999) by an interaction involving the MCP 
and the conserved sequence in the N-terminus of the ppl50 protein (Baxter and Gibson,
2001). Given its intimate interaction with the capsid structure it is likely that ppl50 provides 
an anchor for attachment of additional tegument proteins that subsequently build around the 
particle. If ppl50 is acquired as a tegument protein in the nucleus (Hensel et al, 1995) then it 
is possible that it might also play a role in the nuclear egress of particles.
The UL99 gene is expressed with true-late kinetics to yield pp28, a highly immunogenic 
protein that is a component of the virion tegument (Landini et al, 1987). In infected cells 
pp28 was exclusively located in the cytoplasm in a compartment that overlaps the ER-Golgi- 
intermediate compartment (Sanchez et al, 2000a). Thus, virus particles must acquire pp28 
tegument protein from a site in the cytoplasm. The MCMV M99 gene (homologue of 
HCMV UL99) was also expressed with late gene kinetics producing a protein that is also a 
tegument component (Cranmer et al, 1994). The function of pp28 is unknown, but its 
homologue in HSV-1, (gene UL11), produces a N-terminal myristylated tegument protein, 
exclusively located in the cytoplasm and has roles in virus envelopment and virion particle 
translocation (Loomis et al, 2001).
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In HCMV infected cells pp28, pp65 and ppl50 and three envelope glycoproteins (gB, gH, 
gp65) all localised to the same cytoplasmic juxtanuclear structure. This structure only 
developed late in infection when production of progeny virus was increasing rapidly. Indeed, 
pp28 levels were not readily detectable until this structure had formed (Sanchez et al, 2000b). 
The derivation of the juxtanuclear structure is unclear, but it was not derived from 
components of the ER, ER-Golgi-intermediate compartment, cis or medial Golgi, or 
lysosomes, but it did partially colocalise with the trans-Golgi network and appeared to lie in 
close proximity to the microtubule organising centre. Based on their observations, Sanchez et 
al, (2000b), proposed that this accumulation of tegument and envelope proteins in the 
juxtanuclear structure might represent a cytoplasmic site of HCMV particle tegumentation 
and maturation. In this regard it is of interest to note that the mature cleaved form of gB was 
found within the cytoplasmic juxtanuclear structures, suggesting retrieval of gB from a 
cytoplasmic compartment distal to the Golgi. This is deduced because gB cleavage is 
accomplished by furin, within the late secretory/endocytic vesicles (Vey et al., 1995).
pUL25 is an 82 kDa tegument protein expressed with true-late kinetics and is a major target 
for the anti-HCMV antibody response (Baldick and Shenk, 1996; Zini et al, 1999; Lazzarotto 
et al, 2001). The MCMV M25 gene (homologous to HCMV UL25) also encodes a tegument 
protein. However, M25 is additionally associated with chromatin in the nucleus of infected 
cells and may function as a transcriptional /ra/w-activator (Dallas et al, 1994; Wu et al, 1999). 
In contrast, HCMV pUL25 appeared to be present only in the cytoplasm of infected cells 
where it localised to large dense-body-like structures in the cytoplasm (Zini et al, 1999). It 
seems probable that the dense-body-like structures described by Zini et al, (1999), are the 
same cytoplasmic juxtanuclear structures described by Sanchez et al, (2000b), in which the 
ppl50, pp28 and pp65 tegument proteins have all been detected.
UL56 is a herpesvirus core gene, homologous to HSV-1 gene UL28 (Table 1). Both are 
essential genes that code for a subunit of the viral terminase enzyme (Buerger et al, 2001). 
Terminase activity is required for the cleavage of concatameric DNA, an essential step in 
packaging of the viral genome. pUL56 contains nuclear localisation signals and is transported 
into the nucleus by cellular importin. pUL56 can be detected in the infected cell nucleus from
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about 12 h PI where it is associated with virus replication compartments (Giesen et al, 2000a; 
Giesen et al., 2000b). pUL56 exhibits endonuclease activity in vitro and this is probably the 
function it provides in the terminase complex during HCMV DNA packaging. HCMV 
pUL56 binds the AT rich core sequence in pac\ (5’-TAAAAA) and pac2 (5’-TTTTAT), 
sequences contained within the repeat V  sequences, to form a protein-DNA complex 
(Bogner et al., 1998). Unexpectedly, pUL56 was demonstrated to be a structural protein 
separating with the capsid/tegument fraction when virions were de-enveloped by treatment 
with detergent (Bogner et al, 1993). Given its function as part of an enzymatic terminase 
activity this is a counter-intuitive finding — more so since its partner protein, pUL89, has not 
been reported as a structural component. It is possible that pUL56, by itself, remains bound 
to the genomic termini after cleavage and is packaged along with the genome. This might 
explain the absence of pUL56 in dense bodies (Bogner et al., 1993). However, even this 
seems an unlikely explanation since only two molecules of pUL56 could be packaged/virion 
and it seems unlikely that the sensitivity of Western immunoblotting would be sufficient to 
detect this. Dubious thought it might appear, the HSV-1 homologue (UL28) of HCMV 
UL56 has also been reported to be a virus particle component (Taus and Baines, 1998).
UL94, a herpesvirus core gene (Table 1), expresses a 36 kDa protein with true-late kinetics. 
The function provided by this tegument protein has yet to be determined. However, this 
true-late gene is notable for the novel way in which gene expression is regulated. Transient 
transfection assays show that UL94 contains a positive regulatory element (PRE) downstream 
of the UL94 mRNA start site, and a negative regulatory element (NRE) upstream of the 
TATA box (Wing et al, 1996; Wing et al, 1998). The PRE is dominant over the NRE at late 
times of infection whereas at early times no PRE activity can be detected. The NRE 
therefore has a pivotal role in controlling pUL94 levels early in infection. The NRE contains 
binding sites for cellular p53, which is involved in transcriptional regulation and progression 
of cellular DNA synthesis. Thus, p53 plays a central role in regulation of the UL94 promoter, 
which is not activated prior to onset of viral DNA replication.
The pUL97 tegument protein is expressed with early-late kinetics and phosphorylated within 
1 hour of synthesis (van Zeijl et al, 1997). pUL97 is transported to the nucleus where it
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functions as a protein kinase and is responsible for the phosphorylation of pUL44 
(polymerase processivity factor), which is a protein required for viral DNA replication 
(Prichard et al., 1999). The replication of a HCMV UL97 deletion mutant is severely impaired 
in tissue culture, indicating that although not strictly essential, pUL97 plays an important role 
during replication. The pUL97 tegument protein delivered to the newly infected cell may 
facilitate the initial rounds of viral DNA replication. Alternatively pUL97 may have a more 
general role as a phosphotransferase, phosphorylating cellular and/ or viral proteins early in 
the infectious cycle. pUL97 also activates the nucleoside analogue ganciclovir (GCV) by 
phosphorylation to GCV-mono-phosphate. Cellular enzymes complete the conversion of 
GCV-mono-phosphate to GCV-tri-phosphate, which causes chain termination when 
incorporated into the growing DNA strand. Viral resistance to GCV is associated with 
mutations in UL97 or to mutations in UL54 (DNA polymerase). Remarkably, the MCMV 
homologue M97 does not phosphorylate GCV. MCMV is, however, sensitive to GCV, 
indicating that mouse cell enzymes are capable of conversion of GCV to GCV-tri-phosphate. 
A recombinant MCMV expressing HCMV UL97 gene exhibited enhanced susceptibility to 
GCV (Wagner et al, 2000).
HCMV has evolved a complex system of mechanisms to escape host immunosurveillance. 
An example of such a complex interlocking system is provided by the way in which the virus 
is able to down regulate MHC Class I and II molecule expression on the surface of infected 
cells (Wiertz et al, 1996; Miller et al, 2001). This is achieved by co-operative function of 
glycoproteins expressed from genes US2, US3, US6 and US11. gpUS2 and gpUSll induce 
the rapid export of MHC Class I from the ER to proteosomes (Ben Arieh et al, 2001; Benz et 
al, 2001). gpUSll dislocates newly synthesised class I molecules from the ER to the cytosol, 
where they are degraded by the proteosome (Wiertz et al, 1996). The reticulum-lumenal 
domain of gpUS2 allows tight interaction with class I molecules encoded by the HLA-A 
locus, but not HLA-B7, HLA-B27, HLA-Cw4, HLA-E, and such differentiation between the 
products of distinct MHC Class I loci may explain why HCMV appears to have multiple 
strategies for MHC Class I down regulation (Gewurz et al, 2001). Indeed, Machold et al, 
(1997), showed that gpUS2 and gpUSll have different specificities for MHC Class I 
molecules. gpUS3 forms a complex with MHC Class I preventing its transport to the cell
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surface, while gpUS6 inhibits the transporter associated with antigen presentation (TAP) so 
that peptides are inhibited from presentation to MHC Class I in the ER (Jones et a l 1996; 
Lehner et al, 1997). To avoid natural killer cell destruction of infected cells which lack surface 
MHC Class I molecules at least two other HCMV genes are expressed. UL40 codes for a 
glycoprotein which upregulates expression of HLA-E, a non-classical MHC Class I molecule 
that inhibits NK cell lysis by interacting with the NK surface C-type lectin receptor 
CD94/NKG2A (Tomasec et al., 2000; Ulbrecht et al, 2000), while the UL18 gene codes for a 
surface glycoprotein (gpULl 8) that mimics the MHC Class I molecule.
Of the genes involved in immune regulation only gpUL18 is a tegument protein (Table 2). 
Since gpUL18 is delivered to the cell at the time of infection it must be assumed that its 
function is required very early (Baldick and Shenk, 1996). gpUL18 may be required at this 
time because the I-E gpUS3 protein prevents expression of I-E protein derived antigens, 
resulting in a reduction of MHC Class I molecules on the cell surface. As one would expect, 
none of these immune evasion genes, including the UL18 tegument protein is required for 
growth in tissue culture cells (Browne et al, 1992; Jones and Muzithras, 1992).
On the basis that MCMV gene ml 44 and HCMV UL18 both encoded MHC Class I-like 
products it has been considered that these genes are homologues, however, ml 44 does not 
share amino acid sequence similarity or even genome co-linearity with HCMV UL18 
(Rawlinson et al, 1996). Even at the level of protein folding there are differences between 
ml 44 and pUL18. While the gpUL18 molecular structure exhibits a groove, similar to that 
seen in MHC Class I molecules, and which could serve as a binding site for endogenous 
peptides, ml 44 has a substantial deletion within the counterpart of its alpha-2 domain and is 
not capable of forming a groove that could bind peptides (Chapman and Bjorkman, 1998). 
These results suggest that UL18 and ml 44 differ structurally and might provide different 
functions. The rat CMV gene rl44 encodes a 36 kDa protein and the gene has 19 % and 30 
% homology to HCMV UL18 and MCMV m l44 genes, respectively. DNA sequence analysis 
suggests that rl44 is also unlikely to be capable of binding antigenic peptides. Like the 
HCMV UL18 mutant an rl44 null mutant has been shown to grow as well as wild type virus 
in a variety of cell lines (Beisser et al, 2000).
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The tegument of HCMV particles contains an antibody Fc receptor capable of binding all 
subtypes of human IgG, but not other immunoglobulin isotypes. The Fc receptor is likely to 
be involved in preventing antibody-mediated clearance of HCMV (Stannard and Hardie, 
1991; Antonsson and Johansson, 2001). Recently, HCMV ORFs TRL11 and IRL11 have 
been shown to encode a glycoprotein of 34 kDa, and this has tentatively been identified as the 
Fc receptor (Lilley et al, 2001).
Unexpectedly, the HCMV tegument has also been reported to contain a specific subset of 
viral transcripts, termed ‘virion RNAs’ originating from ORFs UL21.5, UL109, IRL4 and 
IRL7 (Bresnahan and Shenk, 2000a; Greijer et al\, 2000). The functions provided by the 
products of these genes are unknown. It is known, however, that pUL21.5 localises to the 
Golgi network and that the TRL4/IRL4 gene is the most abundantly transcribed gene at early 
times. Curiously, no protein product has been identified for this major early transcript in 
infected cells, and it is therefore possible that it operates as a functional mRNA molecule. It 
is assumed that delivery of virion RNAs to the cytoplasm of the host cell allows for their 
immediate translation, prior to transcription of the infecting genome.
Several host cell proteins, including p2-microglobulin, annexin II, an actin-like protein and 
enzymes, such as capsid-associated protein phosphatase PP2A and DNA polymerase, have 
also been reported to be associated with particles, although the functions provided remain to 
be investigated (Baldick and Shenk, 1996; Gallina e ta l,1999; Michelson et al, 1996).
In summary, the tegument contains a complex set of proteins, which are delivered to the 
infected cell at the time of infection; some proteins are involved directly or indirecdy in 
initiating lytic infection and others in abrogating host defences. It is interesting to note that 
some of the most immunogenic proteins expressed by HCMV (ppl50, pp65, pUL25 and 
pp28) are tegument proteins and are therefore protected from antibodies by the viral 
envelope (Lazarotto et a l 2001). Although 3-D imaging studies of the HCMV tegument 
structure are in their infancy, early results indicate that tegument proteins are not haphazardly 
arranged but that the structure is likely to be highly ordered (Chen et al., 1999). It is possible 
that some tegument proteins might be acquired in the nucleus and others in the cytoplasm of 
infected cells.
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1.5 The HCMV US22 gene family
The HCMV US22 gene family has been relatively little studied and contains 12 loosely related 
gene members (Table 3). The function/s provided by family members is for the most part 
unknown. pTRSl, pIRSl and pUL36 are known to be components of the virus tegument 
and pIRSl, pUL36 and pUL43 have been demonstrated to be dispensable (Romanowski et al, 
1997; Jones and Muzithras, 1992; Patterson and Shenk, 1999; Dargan et al, 1997). There are 
homologues for most of the HCMV US22 gene family members in other Betaherpesviruses; 
HHV-6 (Gompels et al, 1995), HHV-7 (Megaw et al, 1998; Nicholas, 1996), MCMV 
(Rawlinson et al, 1996), Rat CMV (Vink et al\, 2000) and Tupaia (Tree shrew) herpesvirus 
(Bahr and Darai, 2001), but US22 family genes have not been identified in Alphaherpesviruses or 
Gammaherpesviruses. Each of the sequenced Betaherpesviruses codes for a similar number of 
US22 famliy genes, suggesting that the family per se provides important functions during 
Betaherpesvirus replication.
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Table 3 US22 gene family members
HCMV US22 
Gene
HCMV ORF 
Location 
(size-amino acids)
HHV-6 HHV-7 MCMV Rat Tree
Shrew
UL23 27866-28717
(342)
U2(P),
-UL29
U2 M23 (P) /  
m25.1
R23 T23
UL24 28936-30009
(358)
U3 U3 M24 R24
UL28 34757-35893
(379)
U7 U5/7spliced M28 R28 T28
UL29 35926-37005
(360)
U8 U8 T29
UL36 EX1 49354-49863
(67)
U17 U17EX1
(IE-B)
M36EX1 R36 T36
UL36 EX2 48246-49751
(408)
U16 (P), 
~US23
U17EX1
(IE-B)
M36EX2 R36 T36
UL43 54825-56093
(423)
U25 (P), 
-UL24
U25 M43 (P) R43
IRS1 190631-193231
(846)
U95(P), 
-MCMV IE2
U95 (P), 
-MCMV IE2
m l 43 * rl43*
US22 210803-212581
(593)
DR7 DR7
Spliced
ml 39 
m25.2 
ml28Ex3 
IE2
rl39 T5
US23 212646-214439
(592)
ml 40 
ml 43
rl40 T2
US24 214520-216034
(500)
ml41 rl41 T3
US26 216659-218503
(603)
DR2 DR2
spliced
m l 42 rl42
TRS1 227044-229470
(788)
U95 (P), 
-MCMV IE2
U95 (P), 
-MCMV IE2 
DR1 spliced 
DR6spliced
m l 43 *
ml28Ex3
IE2
r!43*
The table lists the HCMV US22 gene homologues in HHV-6 (Gompels et al., 1995), HHV-7 (Megaw et al., 1998;
Nicholas, 1996), MCMV (Rawlinson et al., 1996) and Tupaia (Tree Shrew) herpesvirus (Bahr and Darai, 2001). 
Note that the number of such genes is also generally conserved. (P) means positional homologue with the 
closest (~) homologous gene by FASTA scoring provided. * refers to nearest homologue but amino acid 
similarity is low. HCMV UL36 is spliced.
Membership of the US22 gene family depends on the presence of one or more of four amino 
acid sequence motifs that are conserved among family members (Chee et al., 1990). Motif I 
has been defined as GxxoxoxWP (o = any hydrophobic residue, x = any residue) and is
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contained in products from HCMV genes UL23, UL24, UL28, UL29, UL36 and UL43 
(Efstathiou et al., 1992). Motif I is poorly conserved in HCMV US and TRS1 /IRS members; 
the motif oxoxxPxxW is found in products from HCMV genes US22, US23 and US24 
(Efstathiou et al., 1992). Motif II has been defined as ooCCxxxLxxoG (Kouzarides et al., 
1988; Chee et al., 1990) and is highly conserved, being found in all of the HCMV US22 family 
members except products from genes UL28, UL29 and TRS1 /IRS. Motifs III and IV are 
less well defined and consist of long regions of sequence containing short runs of charged 
and hydrophobic residues located towards the carboxy-terminal regions of the protein 
(Kouzardies et al., 1988; Chee et al., 1990). HCMV gene products pUL23, pUL24, pUL36 and 
pUL43 have all four conserved amino acid motifs.
The function provided by the motifs are unknown but their existence argues for some 
similarity in biochemistry or biology of US22 family gene products. Interestingly, the spacing 
of US22 motif I and II in HCMV appears to be conserved (20-28 amino acids) among family 
members and this may reflect some similarity in protein folding and/or function (Table 10). 
The direct repeat (DR) regions of HHV-6 appear to be related to sequences located in the US 
region of HCMV and contain many of the US22 gene homologues (Gompels et al., 1995). 
Likewise in HHV-7, several US22 family genes, are located at the genomic termini (Table 3) 
(Megaw et al., 1998). Homologues of the HCMV UL36 exons 1 and 2 exist in both HHV-6 
and HHV-7 and the positions of the splice donor/acceptor sequences are well conserved 
(Nicholas, 1996). Splicing may also be important for expression of some gene family 
members in HHV-7 since it has been predicted that splicing of DR1 to DR2 and DR6 and 
DR7 would result in proteins containing US22 motifs in their usual order (Megaw et al., 1998).
Approximately twelve MCMV ORFs have homology to members of the HCMV US22 gene 
family (Rawlinson et al., 1996). MCMV US22 gene family motif ooCCxD/E(x)1_40xxoG 
appears to be related to the HCMV US22 family motif ooCCxxxLxxoG and occurs first in 
the peptide sequence of all MCMV US22 family members except M43 and Ml 28 and is only 
partially conserved in M25.1 (Rawlinson et al, 1996). Motif GxxoxoxWP is found only in 
MCMV M24 and M36 (exon 1). The major immediate-early locus of MCMV is co-linear with 
that of HCMV and MIE splicing patterns are maintained (HCMV IE1/IE2, MCMV
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IE1/IE3). However, in the case of MCMV a gene (IE2), which is a member of the US22 
gene family, is expressed in the opposite orientation from the major IE products (IE1 and 
IE3). MCMV IE2 has no functional counterparts in HCMV, HHV-6 or HHV-7, although a 
homologous gene (rl28) is coded for by rat CMV (Vink et a l 2000). MCMV IE2 is a trans- 
activator of the MCMV MIEP, but is dispensable (Cardin et al., 1995; Manning and Mocarski, 
1988).
As was the case with HCMV little is known of the functions provided by the MCMV US22 
family genes. MCMV M43 (UL43 homologue) has, however, been shown to be a 
determinant for viral growth in the salivary gland (Xiao et a l 2000). M139, M140 and M141 
(US22, US23 and US24 homologues, respectively) are early proteins that are distributed 
throughout the infected cell. Gene Ml 39 codes for two proteins of 72 kDa and 61 kDa, 
while MHO and Ml 41 each encode a single protein of 56 kDa and 52 kDa, respectively. 
Ml 39 does not appear to be required for replication in macrophages, whereas deletion of 
MHO or M141 results in impaired replication in macrophages and spleen tissues. MHO is 
dominant and when deleted resulted in reduced expression of M141 protein. Thus, MHO 
and Ml 41 appear to act both co-operatively and independently to regulate MCMV replication 
in a cell-type specific manner and are predicted to influence cell tropism and viral 
pathogenesis (Hanson et al., 2001).
To date only one viral mutant with a defect in a HCMV US22 family gene, (UL36), has been 
generated (Patterson and Shenk, 1999), although a naturally occurring mutant with a partial 
deletion of gene UL43 has been identified (Dargan et al., 1997). Few antibodies have been 
generated to identify US22 family gene products; those generated are against pTRSl/pIRSl 
(Romanowski et al., 1997), pUS22 (Mocarski et al., 1988) and pUL36 (Patterson and Shenk, 
1999).
The HCMV gene US22, after which the US22 gene family was named, was predicted to code 
for a 66.9 kDa (593 amino acid) protein (Chee et al., 1990), but a protein of ~76 kDa has been 
detected in infected cells and also in pUS22 expressing bacterial cell extracts, using an anti- 
US22 antibody (Mocarski et al., 1988; Dal Monte et al., 1998). The discrepancy is size could, 
in-part, be due to a recently discovered DNA sequencing error in the published A D I69
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sequence (Chee et al., 1990), since the corrected sequence indicates that translation 
commences at an upstream methionine (Parvis Akter, personal communication). The US22 
gene is expressed with early gene kinetics and pUS22 can be detected from 24 h PI (Mocarski 
et al., 1988). At both early and late times in infection pUS22 was located by 
immunofluroescence in the nucleus of infected cells. Confusingly, however, cell fractionation 
studies showed that most pUS22 separated with the cytoplasmic fraction with a proportion 
released from cells as a soluble protein at both early (24 h) and late (72 to 120 h) times in 
infection.
The UL36-38 gene locus is complex, coding a number of gene products, only one of which 
(pUL36) is a member of the US22 gene family, and contains all four of the US22 family 
amino acid sequence motifs. Proteins from the UL36-38 locus have previously been shown 
to be essential for transient complementation of HMCV ori-Lyt-dependent DNA replication 
(Pari et al, 1993; Pari and Anders, 1993). One or more protein products from the UL36-38 
locus are also reported to co-operate with the major immediate-early genes IE1 (72 kDa) and 
IE2 (86 kDa) to synergistically enhance transcriptional trans-activation from some cellular 
(heat shock protein 70 (hsp70) and brain creatine kinase) and HCMV gene (UL112) promoters 
(Colberg-Poley et al., 1992). The UL36-38 gene locus encodes four products, pUL36, 
gpUL37, pUL37 exon 1 (pUL37xl) which are expressed with I-E gene kinetics and pUL38 
which is expressed with E gene kinetics (Tenney and Colberg-Poley, 1991a; Tenney and 
Colberg-Poley, 1991b). A smaller spliced variant of gpUL37, called gpUL37M, has also been 
described (Goldmacher et al, 1999). The 1.65 kbp UL36 ORF is spliced and the junctions of 
exon 1 and 2 occur immediately prior to US22 gene family motif II (Kouzarides et al., 1988). 
An intron of the UL36 gene contains an element (S’-TGGAAAG-S5) that is identical to the 
SV40 enhancer core element. The UL36 mRNA is 3’ co-terminal with that of 3.4 kbp UL37 
mRNA and is contained entirely within the non-coding region of UL37 mRNA. UL37 
mRNA is predominately transcribed at immediate-early times, but only at low abundance 
because expression is stringendy regulated. UL37xl mRNA, which is initiated from the same 
promoter, and UL36 mRNA, which is initiated from a downstream promoter, are more 
abundant messages. UL36 mRNA is detectable in the cytoplasm of infected cells by 4 h PI, 
increased by 8 h PI and remains abundant through 24 h PI (Colberg-Poley, 1996).
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The extent to which transcriptional /ra«r-activating activity of the UL36-38 locus resides in 
the UL36 gene product has yet to be investigated. However, the UL36 ORF has two regions 
with sequence homology to the bulky hydrophobic residues that are located in the activation 
domain of HSV-1 VP16, suggesting that pUL36 might function as a transcriptional trans- 
activator. In one region (UL36 exon 2, amino acids 389 to 423) homologous to VP16 
activation domain, five out of six bulky hydrophobic residues and six out of ten acidic 
residues are conserved. In the other region (UL36 exon 1, amino acids 7 to 32) of sequence 
homology with VP16, bulky hydrophobic residues (two identical and two conservative 
substitutions) and critical acidic residues (one identical and six conservative substitutions) are 
also conserved (Colberg-Poley et al, 1992). An alternative protein that might account for the 
/ram-activating properties of the UL36-38 locus and the synergism observed in the presence 
of IE1/IE2 is the gpUL37 gene (Colberg-Poley et al., 1998). Zhang et al, (1996), have shown 
that gpUL37 exhibits /m»r-activating activity and that the acidic domain of pUL37xl is 
dispensable for /ra#r-activation of the bsp70 promoter but is required for IE1/IE2 synergism.
gpUL37 is a type I membrane-glycoprotein, modified by N -linked glycosylation (Al-Barazi 
and Colberg-Poley, 1996). After being processed through the secretory apparatus gpUL37 is 
depositied in mitochondria (Colberg-Poley et al, 2000). Recendy, each of the spliced variants 
of UL37 (gpUL37, pUL37xl and gpUL37M) have been shown to function as mitochondria- 
localised inhibitors of apoptosis (vMIA), inhibiting Fas-mediated apoptosis (Goldmacher et 
al, 1999). Curiously, the Towne strain of CMV does not express gpUL37 or gpUL37M, 
indicating that pUL37xl alone is sufficient to block apoptosis during infection.
The HCMV UL36 gene is first expressed at I-E times, and is continuously present 
throughout the replication cycle. While pUL36 is a tegument protein it has been shown to be 
dispensable for replication and infectivity (Patterson and Shenk, 1999).
The role of the pUL36 tegument protein immediately after its delivery to the cell is almost 
certainly to inhibit the initiation of apoptosis by the newly infected cell. The UL36 gene 
product inhibits caspase-8 activated (vICA) apoptosis by binding the pro-domain of caspase-8 
to prevent activation of Fas-mediated apoptosis. vICA does not share sequence homology 
with FLICE-inhibitory proteins (FLIPs) or other known suppressors of apoptosis and
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therefore UL36, like UL37, appears to encode a new class of cell-death suppressor 
(Skaletskaya et al, 2001).
A further two members of the US22 gene family, pIRSl (91.0 kDa) and pTRSl (84.0 kDa), 
are known to be tegument proteins (Romanowski et al., 1997). The TRS1 gene is transcribed 
as a 2.7 kbp message that is unspliced. The presence of either pTRSl or pIRSl is essential 
for transient complementation of ori-Lyt-dependent DNA synthesis (Pari et al., 1993), 
although pIRSl has been shown to be dispensable for virus replication in cultured cells (Jones 
and Muzithras, 1992). pIRSl and pTRSl are present throughout the infected cells at 
immediate-early and early times PI, but become more abundant and accumulate in the 
cytoplasm at late times PI (Romanowski and Shenk, 1997). Overall, pIRSl and pTRSl are 55 
% identical and despite divergence after amino acid 549 the C-terminus of both proteins is 
charged, and this may be important for protein-protein or protein-DNA interactions. The 
/nz«j-activadon properties of pIRSl and pTRSl are considered in section 1.6.
1.6 Transcriptional fra/zs-activation in HCMV infected cells
HCMV encodes several proteins that function as transcriptional #mr-actdvators of viral and 
cellular genes. Such /ra^-activators are thought to operate as part of a complex regulatory 
network that controls viral and cellular gene expression, to co-ordinate virus replication and 
cell biochemistry so that an optimal intracellular environment is provided for virus 
replication. The activity of /ra«.r-activators might also influence whether the virus enters the 
lytic or latent infection pathway. Some /ra^-activators are particle components (pIRSl, 
pTRSl, pUL69, pp71 (pUL82)), while others are expressed at immediate-early times PI (IE1 
72, IE2 86) (Romanowski et al, 1997; Winkler et al., 1995; Liu and Stinski, 1992). Curiously, 
pIRSl and pTRSl are both delivered to the infected cell as particle components and also 
expressed at immediate-early times.
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1.6.1 The major immediate-early (MIE) gene locus
The MIE locus is under the control of the MIE promoter (MIEP), which is subject to both 
positive and negative regulation and contains a large number of binding sites for cellular 
transcription factors and for some viral proteins (Mocarski, 1996). Analogous promoter- 
enhancers are found upstream of the predominant I-E gene locus in MCMV and SCMV and 
homologous enhancer elements control expression of US3 (Kim et al., 2002; Biegalke, 1999; 
Colberg-Poley, 1996). The MIEP can be separated into the enhancer region (-500 to + 1, 
relative to the IE1/IE2 transcription start site), specific NF-1 binding region (-800 to -500) 
and modulator region (-1,100 to —800). Numerous cellular transcription factors (e.g. p53, 
YY1, NF-kB, ATF, CREB, API, Spl, C/EBP, SREB, NF1, TNF-a) are known to bind 
within and upstream of the enhancer region and downstream of the transcription start site 
(Mocarski, 1996; Prosch et a l 2001; Zhang et a l 2001). The enhancer contains repeated 
sequence elements (16-, 18-, 19- and 21- bp repeats) that are involved in binding cellular 
transcription factors, interspersed with unique sequences. This complex array of binding sites 
permits the MIEP to operate in the context of a broad range of different cell types and to 
respond to a changing intracellular environment. Deletion of the MIEP distal enhancer 
region (-300 to —582) resulted in a decrease in expression from the MIEP and the IE US3 
promoters, but only during low m.o.i. infections (Meier and Pruessner, 2000). The distal 
enhancer is composed of at least two components, which function independently but co­
operate to activate transcription from the MIEP and hence viral replication. One part, a 47 
bp segment, has binding sites for CREB/ATF, Spl and YY1, which at low m.o.i. are thought 
to function to activate the MIEP and to promote virus replication (Meier et al., 2002). The 
modulator region appears to be dispensable, since a mutant virus lacking the modulator 
exhibited only slightly delayed growth kinetics in human fibroblasts (Meier and Stinski, 1997). 
Early experiments suggested that the modulator region was involved in repression of the 
MIEP in non-differentiated Tera-2 and THP-1 cells (Nelson et al., 1987; Shelbourn et al, 
1989; Kothari et al., 1991; Huang et al, 1996). However, when the modulator deletion mutant
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was grown in undifferentiated cells IE gene expression from the MIEP remained at a minimal 
level, suggesting that differentiation-dependent control of the MIEP is complex and involves 
regulatory mechanisms other than, or additional to, that associated with the modulator region 
(Meier and Stinski, 1997).
The principal HCMV #mr-activators are the nuclear phosphoproteins IE1 72 kDa (IE1 72) 
and IE2 86 kDa (IE2 86), which are expressed by differential splicing from the MIE gene 
locus and share 85 amino acids at their amino terminus (Stenberg et al, 1989; Stenberg, 1996). 
The less abundant IE2 product IE2 55 kDa (IE2 55), produced when an intron in exon 5 is 
removed, is only transiently expressed reaching maximum levels at 1-6 h PI. IE2 55 is a trans- 
activator of the MIEP and is functionally antagonistic to IE2 86; IE2 55 relieves repression of 
the MIEP induced by IE2 86 binding to the crs element in the promoter. However, IE2 55 
does not bind the crs element and appears to operate via another region in the promoter 
(Baracchini et al., 1992). Another variant form of IE2 is IE2 40 kDa (IE2 40), an unspliced 
product expressed from exon 5 alone. IE2 40 is the most abundant IE2 product made late in 
the infection cycle and functions both a repressor of I-E gene expression and a /ra/w-activator 
of E and L genes (Mocarski, 1996).
1.6.2 The major immediate-early protein IE1
The most abundant I-E gene product from the MIE locus is coded for by MIE exons 1, 2, 3 
and 4 (gene UL123), giving rise to a 72 kDa protein (IE1 72). IE1 72 is produced throughout 
infection, peaking at 5-8 h PI and dipping to a low level at the start of DNA replication 
(Mocarski, 1996). The functions provided by IE1 72 appear to be multifarious and are not 
yet fully understood, although it plays an important role in initiating lytic cycle replication. In 
cells infected at high m.o.i. IE1 72 was dispensable but in cells infected at low m.o.i. IE1 72 
was required, since the replication of a IE1 72 deletion mutants was severely impaired at low 
m.o.i. (Greaves and Mocarski, 1998).
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IE1 72 /ra/w-activates the MIEP (Table 4), indirectly via a mechanism involving binding of 
NF-kB to the 18 bp repeats in the MIEP promoter (Cherrington and Mocarski, 1989). It is 
thought that in the absence of virus particle fotfw-activators (i.e. when cells are transfected 
with naked infectious HCMV DNA) that NF-kB binding to the MIEP is responsible for 
initiating IE1 expression from the promoter (Mocarski et al, 1996). By itself IE1 72 is a weak 
/rattr-activator of heterologous promoters (Table 4), but in transient transfection experiments 
the level of transcription of some target promoters was synergistically enhanced when IE1 72 
and IE2 86 were co-expressed (Hagemeier et al, 1992a; Klucher et al, 1993). The mechanism 
by which IE1 72 operates to /ra».r-activate gene transcription is complex, depending on the 
promoter structure and interactions with different proteins involved in the transcription 
complex (Table 4). In the case of heterologous promoters IE1 72 operates in a TATA-box 
independent manner (Hagemeier et al, 1992b). For example, IE1 72 interacts directly with 
the CCAAT box-binding factor CTF1 and augments activation of the TATA-less DNA 
polymerase alpha promoter (Hayhurst et al, 1995), while activation of the TATA-less 
dihydrofolate reductase (DHFR) promoter involves an interaction between IE1 72 and the 
E2F binding factor (E2F1) (Margolis et al, 1995) (Table 4).
IE1 72 is also involved in the control of cell cycle regulation through various protein/protein 
interactions. For example, IE1 72 indirectly influences activity of the transcription factor 
E2F, which is required for activation of cellular genes in the S phase of cell growth. HCMV 
infection induces expression of pi 07 (a retinoblastoma protein) known to complex with E2F 
to prevent E2F-dependent gene activation. By directly binding to p i07 IE1 72 overcomes 
the transcriptional repression on E2F-responsive promoters (Poma et al, 1996) (Table 4). 
Another route by which IE1 72 influences the cell cycle is via IE1 72 mediated activation of 
activator protein-1 (AP-1) expression. AP-1 is a cellular transcription factor (largely 
composed of c-fos and c-jun subunits) which is important for regulation of cell growth and 
differentiation. IE1 72 activates AP-1 at the post transcriptional level through interactions, 
with a cellular protein kinase (mitogen-activated protein kinase or extracellular signal- 
regulated kinase kinase kinase 1 (MEKK 1) (Kim et al, 1999).
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Although IE1 72 does not appear to bind DNA direcdy, it is associated with cellular 
chromatin where it probably interacts with nuclear DNA-binding proteins, such as cellular 
transcription factors Spl, E2F1 and CTF-1 and components of TFIID (Lukac et al, 1994; 
Lukac et al., 1997; Margolis et al, 1995; Xu et al, 2001). The association with chromatin 
requires a C-terminus acidic domain of IE1 72 (amino acids 421-486), although this domain is 
not required for disruption of PODs (Wilkinson et al, 1998). Several cellular proteins are 
associated with PODs, including SplOO, NDP-55, NDP-52, PIC-1, Int-6. HAUSP, Daxx, 
small ubiquitin-like modifier (SUMO-1) and promyelocytic leukaemia protein (PML), a 
growth and tumour suppressor protein (reviewed in Wilkinson et al, 1998; Xu et al, 2001). 
IE1 72 localises to PODs within 1-2 h PI and prior to IE2 86 appearance in PODs. IE1 72 
interacts with PML, by a mechanism that involves the IE1 72 ring finger motif, and which 
results in displacement of PML from PODs and its redistribution in a diffuse form in the 
nucleoplasm. IE1 72 is sumoylated at position 450 (lysine) by SUMO-1 to generate a 90 kDa 
IE1 isoform in both infected cells and in transiendy transfected cells in which IE1 is 
expressed by itself (Xu et al, 2001). IE2 86 is also modified by SUMO-1 by a mechanism 
involving the SUMO-conjugating enzyme, Ubc9, although this enzyme does not appear to be 
involved in sumoylation of IE1 72 (Ahn et al, 2001). In the case of HSV-1, PML displaced 
from PODs by interaction with ICP0 results in degradation of PML in proteosomes 
(Parkinson and Everett, 2000). In contrast, displacement of PML from PODs by HCMV 
IE1 72 does not result in proteosome degradation in HCMV infected cells. In uninfected 
cells PML is normally involved in repression of gene transcription, but the function of both 
HSV-1 ICP0 and HCMV IE1 72 is to overcome this PML-mediated repression to permit 
viral gene expression (Xu et al, 2001).
1.6.3 The major immediate-early protein IE2
HCMV IE2 86 (UL122), coded for by exons 1,2,3 and 5 is the second most abundantly 
expressed I-E protein. IE2 86 can bind DNA via sequences in the C-terminus of the protein 
(Schwartz et al, 1994), binding to a 15 bp ^-repression signal (crs) near the MIE transcription
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start site. IE2 86 binding to the crs negatively regulates MIEP activity resulting in auto­
repression of IE2. The crs sequence is orientation independent and can confer IE2 
responsiveness of heterologous promoters (Cherrington et al., 1991; Macias and Stinski, 1993; 
Spector, 1996) (Table 4). IE2 86 induced repression of MIEP activity via binding to the crs is 
not simply due to steric hindrance, since IE2 86 appears to alter RNA polymerase II so that 
the transcription complex is unable to form on the promoter (Lee et al, 1996).
IE2 86, unlike IE1 72, is a strong promiscuous /ra«x-activator that can enhance transcription 
from a number of viral (E and L) and cellular promoters (Table 4), in a TATA box dependent 
manner (Lukac et al, 1994; Haymeier et al, 1992b; Sommer et al, 1994; Kim et al, 2000b). 
The ability of IE2 86 to activate transcription correlates with its ability to bind the TATA 
binding protein (TBP), a component of the basal transcription factor TFIID, and with its 
ability to bind transcription factors, such as c-jun and jun& (Scully et al, 1995), which 
themselves bind sequence elements located upstream of the promoter (Hagemeier et al, 
1992b) (Table 4). IE2 86 /ra/w-activation may also arise from abrogation of transcriptional 
repression: for example, alleviation of histone mediated repression (Klucher et al, 1993), or 
Dr-1 mediated repression (Caswell et al, 1996). The ability of IE2 86 to engage in protein- 
protein interactions is extremely important and facilitates the formation of multiprotein-DNA 
complexes on viral or cellular promoters.
IE2 86 expression levels are tightly regulated by auto-repression, but also influenced by the 
presence of the early virus protein pUL84. pUL84, a 75 kDa protein (He et al, 1992; Spector 
and Tevethia, 1994) functions as a /ra«r-dominant inhibitor of immediate-early mediated trans- 
activation (Gebert et al, 1997). pUL84 binds pIE2 86 to promote binding of IE2 86 to the 
crs resulting in down regulation of the MIEP. Since high levels of IE2 expression are 
cytotoxic, pUL84 may fulfil an important regulatory function maintaining IE2 at non- 
cytotoxic levels. Another HCMV gene product, pUL76, appears to /ra^i-activate the MIEP 
when present in low concentrations in transfected cells but, curiously, functions as a repressor 
of the MIEP when present at high levels. The mechanism, whether direct or indirect, 
remains obscure (Wang et al, 2000b).
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The carboxy terminal half (amino acids 290-579) of IE2 86 is required for binding to the crs, 
while both the amino and carboxy termini are required for IE2 86 /ra/w-activation activity 
(Spector, 1996). Precise mapping of the domains within IE2 86 required for DNA binding 
has been problematic since binding seems to be promoter dependent. The domain of amino 
acids 86-542 appears to be important for protein/protein interactions, since this region binds 
a number of cellular regulatory proteins (Spl, Tef-1, c-jun, jutiR, ATF-2, NF-kB, protein 
kinase A-phosphorylated delta-CREB, p300, CBP, Nil-2A, CHD-1 and UBF) which are 
important for RNA transcription (Spector, 1996). The ability of IE2 86 to engage in 
protein/protein interactions is modified by its phosphorylation state. ERK2, a member of 
the MAPK family, is known to phosphorylate IE2 86 at several different sites (Spector, 1996; 
Harel and Alwine, 1998). In this regard it is of interest to note that binding of HCMV to its 
cellular receptors induces intracellular signalling that leads to stimulation of the MAPK 
pathway and to the up-regulation of ERK2 (Fortunato et al., 2000).
IE2 86 is a partner is several important protein/protein interactions (Table 4). IE2 86 binds 
the tumour supressor retinoblastoma (Rb) protein, via interactions with the A/B pocket or 
the C-terminus of Rb (Hagemeier et al, 1994; Sommer et al., 1994; Fortunato et al., 1997). 
likewise, IE2 86 contains two domains (amino acids 241 to 369 and amino acids 1 to 85) that 
can independently affect Rb function (Fortunato et al., 1997). Rb is intimately involved in the 
regulation of cell cycle progression. During the transition to Gi, Rb becomes progressively 
more phosphorylated. In its under-phosphorylated state, Rb operates to suppress growth 
during the Go-Gi phase of the cell cycle. This under-phosphorylated Rb forms a range of 
complexes with different transcription factors, including the cellular transcripition factor E2F, 
which is required for the activation of some cell genes required for S phase induction. Hence, 
Rb functions to control cell proliferation. The direct binding of Rb by HCMV IE2 86, results 
in alleviation of Rb-induced repression of promoters bearing E2F binding sites. The complex 
of Rb/IE2 86 results in the sequestration of both proteins and has the effect of alleviating 
IE2 86-mediated self repression of the MIEP and suppressing IE2 86-induced trans-activation 
of promoters (Hagemeier et al., 1994). Interestingly, IE2 86 by itself has a role in cell cycle 
control, since it can block cell cycle progression in an Rb-independent manner (Murphy et al.,
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2000). Based on its interaction with IE2 86, it has been suggested that Rb might control the 
HCMV lifecycle and account for the slow growth of HCMV in cells (Choi et al, 1995).
IE2 86 also binds to cellular p53 to inhibit p53-dependent /ra/w-activation. Two domains of 
the IE2 86 protein are involved, the N-terminal region of the protein binds p53 but has 
negligible effect on the ability of p53 to bind specific DNA sequences; the C-terminal 
sequences also bind to p53 and this interaction leads to a reduction in the /ra/w-activation 
activity of p53 (Tsai et al., 1996). p53 is an important negative regulator of transcription, 
cellular DNA synthesis and cell proliferation. p53 transcription is enhanced in cells under 
stress and the p53 protein /ra«j--activates several cellular genes coding transcription factors, 
including p21WAF, Cipl, bax and hdm2. p21WAF and bax are involved in the induction of 
apoptosis, while hdm2 is a negative regulator of p53 activity. HCMV infection results in up- 
regulation of hdm2 and p53 is sequestered into the cytoplasm (Wang et al, 2000a). Although 
IE2 86 was shown to bind p53, it appeared not to be responsible for sequestering p53 into 
the cytoplasm and binding of IE2 86 to p53 does not appear to abrogate the p53-induced Gi 
checkpoint (Bonin and McDougall, 1997).
An IE2 deletion mutant virus has recently been isolated using an IE2 expressing cell line 
transfected with a mutated HCMV (ADI69) BAC, and confirms the long held assumption 
that UL122 (IE2) is an essential gene. The UL122 BAC mutant never generated plaques, and 
although mRNA and proteins from the other I-E genes could be detected, mRNA from early 
genes could not be detected by RT-PCR. Therefore these experiments confirm that IE2 86 is 
responsible for /ra^-activation of most viral promoters and that IE2 86 is essential for 
switching from E to L gene expression (Marchini et al, 2001).
1.6.4 Synergy between IE1 and IE2
Many transient transfection assays have shown that co-expression of IE1 72 and IE2 86 
resulted in synergistic /ra«j-activation of a variety of cellular and viral promoters (Lukac et al,
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1994). The mechanism, by which, synergy is obtained is not clear. No direct protein/protein 
interaction between IE1 72 and IE2 86 has been demonstrated. However, IE1 72 and IE2 86 
may perform functions similar to those of TBP associated factors (TAFs) and both have been 
reported to interact with TAFs. IE1 72 and IE2 86 can simultaneously bind to human TAF 
(11)130, suggesting that this TAF may provide bridging interactions between the two proteins 
for transcriptional activation and synergy (Lukac et al, 1997). The cellular transcription factor 
Spl can also bind TAT(11)130 and recruit the TF11D complex, and co-transfection 
experiments have shown that recruitment of Spl, or TBP, to the MIEP markedly decreased 
the synergistic effect of IE1 on IE2-mediated /ra^-activation (Kim et al, 2000a).
Table 4. Viral and cellular gene promoters frtfws-activated by IE1 and/or IE 2.
COMMENTS
Viral
Promoters
Indirect Activation by HCMV IE172
MIEP IE1 72 induces NF-kb binding to 18 bp repeats, stimulating expression from MIEP 
(Cherrington and Mocarski, 1989)
UL54 Promoter activation dependent on air-acting sequence containing a novel 18 bp inverted repeat 
sequence (IR1) and an ATF binding site. The IR1 site was important for gene regulation only at 
early times while the ATF site was used at late times. pTRSl/pIRSl and UL112-113 proteins 
/ra«r-activate the UL54 promoter in association with IE1/IE2. (Kerry et al.1, 1996; Kerry et at, 
1997).
UL44 IE1 required for promoter expression (Greaves and Mocarski, 1998).
UL83
(pp65)
Activation dependent on octamer sequence in promoter. Activated by IE1 or IE2 (Depto and 
Stenberg, 1989)
HIVLTR 10-base pair element of HIV LTR is absolutely required (Walker et al1,1992).
Cellular
Promoters
Indirect Activation by HCMV IE1 72
c -fos 
c-jun 
hsp70
A minimal inducible promoter element was contained 50-60 bp upstream of transcription start 
site, while IE2 86 alone induced expression. Synergy observed with IE1 72 and IE2 86 
together. hsp70 - Promoter constructs containing a variety of different TATA elements 
activated by IE1 72 or IE2 86 (Hagemeier et at, 1992a)
DHFR Dihydrofolate reductase (DHFR) transcription activated modestly by IE2 86 and IE2 55 (E2F 
independent). Activation by IE1 72 is E2F dependent (Margolis et al, 1995).
DNA 
polymerase 
| alpha
Not activated by IE2. Strongly activated by IE1. Removal of CCAAT box abolishes high level 
activation by IE1. IE1 interacts with CCAAT box binding protein CTF1. IE1 72 augments 
CTF1-mediated activation of promoter (Hayhurst et al, 1995).
TNF-alpha IE1 or IE2 up-regulate expression (Geist et al, 1994)
Rb pi 07 IE1 interacts with p i07 and relieves pl07-mediated transcriptional repression of E2F- 
responsive promoters (Poma et al, 1996)
PML IE1 72 interacts with PML and disrupts PODs in a proteosome-independent manner. 
Sumoylation of IE1 is not required for this. IE1 can overcome PML induced transcriptional
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repression (Wilkinson et al., 1998; Xu et at, 2001)
Viral
Promoters
Direct Activation by HCMV IE2 86
MIEP Interacts with cis acting signal (crs) to down regulate its own transcription (Cherrington et al., 
1991)
UL4 UL4 promoter has upstream negative element located -168 bp to -134 bp that binds a cellular 
protein or IE2 86. Binding of IE2 86 lifts repression (Huang et al., 1995).
Indirect Activation by HCMV IE2 86
UL112-113 Activated by IE1 72 alone but synergistically enhanced by IE2 86 (Colberg-Poley et al., 1992). 
Sequences between -113 and -58 required for activation by IE2 86. 3 regions of promoter (-286 
to -257, -248 to -218 and -148 to -120) bind strongly to IE2 86 and show homology to crs 
repression sequence in MIEP (Schwartz et al., 1994). CREB and CBP required for activation of 
the promoter in conjunction with IE2 86, possibly a multiprotein complex including CREB, 
p300 or CBP (Schwartz et al, 1996). One product of the UL112-113 gene (pp43) responsible 
for IE2 dependent activation of UL54 promoter (Li et al., 1999).
HIVLTR Activation of HIV LTR by IE2 is TATA box dependent (Hagemeier et al., 1992b). IE2 86 
terminal region (amino acids 99 to 194) and carboxy region (amino acids 170 to 579) necessary 
for activation (Yeung et al., 1993).
Cellular
Promoters
Indirect Activation by HCMV IE2 86
huRNP Al Hetergeneous ribonucleoprotein Al (huRNP Al). IE2 86 N-terminal sequences (amino acids 
1-290) and C-terminal (amino acids 291-579) required (Wang et al., 1997).
HDAC-1 Histone deacetylase-1 (HDAC-1) IE2 86 region 280-380 aa required for HDAC-1 binding. IE 
72 does not bind to HDAC-1. In presence of HDAC-1 IE2 86 can activate the cyclin E 
promoter (Murphy et al., 2000).
ICAM-1 Intracellular adhesion molecule -1 (ICAM-1). Direct activation by IE proteins on promoter. 
Deletion of promoter revealed that 5' flanking sequence required for maximum activation 
(Bums et al., 1999)
Direct Activation by HCMV IE  86
c -Jos 
c -jun 
juriQ 
hsp70
IE2 86 has preference for specific TAT elements and Tef-1, Sp-1 CAAT and ATF transcription 
factor binding sites. Not significantly activated by IE1 72 alone but synergy in activation 
between IE1 72 and IE2 86. No activation of transcription factors API or OCT (Lukac et al., 
1994). IE2 86 protein interacts with c-jun and jurfo. Three independent regions of IE2 86 
shown to interact in vitro with c-jun, two of which are essential for activation. IE2 86 binds 
directly to c-jun promoter through a sequence located just upstream of the AP-1 site between 
nucleotides -125 to -97. This discrete domain shares sequence homology with the cis-repression 
signal on the IE gene (Scully et al., 1995)
1.6.5 The role of other HCMV proteins (pp71, pUL69, pIRSl, pTRSl) in 
transcriptional fratts-activation
UL82 is expressed from a 1.9 kbp mRNA, that is 3' co-terminal with the 4 kbp UL83 
transcript, to produce pp71 (Nowak et al, 1984). pp71 is a tegument protein which is thought 
to be attached to the major capsid protein and its SCMV homologue is also thought to be
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similarly located (Trus et al, 1999). The pp71 tegument protein is translocated to the nucleus 
immediately after infection (Hensel et al, 1996). Although only a minor particle component, 
pp71 appears to be critical for initiating lytic cycle replication, since it is a potent trans- 
activator of the MIEP (Liu and Stinski, 1992). pp71 may also function as a more general 
/rawr-activator, since pp71 alone, or in combination with other viral proteins (e.g. UL69), can 
activate promoters from different viruses (Homer et al, 1999; Winkler et al, 1995). pp71 
appears not to interact directly with the MIEP but promotes binding of transcription factors 
ATF or API to the MIEP (Liu and Stinski, 1992). Since, naked HCMV DNA is infectious, 
pp71 cannot be strictly required for infectivity. However, co-transfection of pp71 expression 
plasmids with naked infectious HCMV DNA enhanced the infectivity up to 80-fold (Baldick 
et al., 1997). A pp71 deletion mutant exhibited a multiplicity dependent phenotype; at high 
input multiplicities (10 p.f.u./cell) pp71 was not required, but a low m.o.i. the virus mutant 
was severely restricted, confirming that the gene plays an important role during virus 
replication. During low input m.o.i. infection the immediate-early genes (TE1, IE2, UL37xl, 
UL38, UL106-UL109 and UL115-119) could not be detected. After a single passage of the 
pp71 deletion mutant virus in a complementing cell line the progeny virus recovered its ability 
to replicate in normal cells when infected at low m.o.i., indicating that the pp71 delivered to 
cells as a tegument component was critical (Bresnahan et al, 2000; Bresnahan and Shenk, 
2000b).
Interestingly, both the IE1 72 (Mocarski et al, 1996) and pp71 virus mutants exhibit 
multiplicity dependent phenotypes. Since the tegument delivered pp71 functions downstream 
to induce IE1 72 expression the phenotype of both mutants may be due to failure to produce 
sufficient IE1 72 to initiate sustained activation of the MIEP.
The HCMV UL69 gene is a herpesvirus core gene (homologous to UL54 in HSV-1) 
(Davison, 1993) (Table 1). The literature is confused with regard to the kinetic class of UL69 
gene expression. Mocarski, (1996), reported that pUL69 is expressed with immediate-early 
kinetics, while Winkler et al, (1994), and Chambers et al., (1999), report early-late kinetics. 
pUL69 is a tegument protein but of the three isoforms of pUL69, (105 kDa, 110 kDa, 116 
kDa), only the 110 kDa isoform is incorporated into HCMV particles (Winkler and
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Stamminger, 1996). The UL69 tegument protein is delivered to cells at the time of infection 
and is presumed to function at I-E or pre-I-E times PI. pUL69 alone or synergistically in 
combination with pp71 can stimulate activation of the MIEP. The pUL69/pp71 effect on 
the MIEP may be transitory, since IE1 72 is the major protein involved in auto-stimulation of 
the MIEP (Winkler et a l, 1995). pUL69 exhibits a broad range of /ra/w-activation activity, 
/raw-activating several HCMV and heterologous viral or cellular promoters. By itself pUL69 
was capable of /razzr-activating expression from some early HCMV (UL112) promoters but 
not the UL86 late promoter (Winkler et al, 1994). pUL69 localises to DNA replication 
compartments in the nucleus and is thought to interact with a cellular protein, hSPT6, 
thought to regulate chromatin structure. It has been suggested that /razzr-activation of 
promoters by pUL69 is due to competition between pUL69 and histones for DNA binding 
sites. Mutagenesis of the central conserved domain of pUL69, resulted in loss of the 
interaction between pUL69 and the hSPT6 protein and the /razzr-activation potential of 
pUL69, suggesting that the interaction is essential for the pUL69 /razzr-activation function. 
The carboxy terminus of hSPT6 normally interacts with histone H3 and leads to nucleosome 
assembly, which is thought to be repressive for transcription. pUL69 was shown to 
antagonise the interaction of the hSPT6 protein with histone H3, and therefore inhibit 
nucleosome assembly. Thus, pUL69 exhibits broad range /razzr-activating properties due to 
de-repression of a chromatin regulatory protein (Winkler etal, 2000).
The tegument proteins pIRSl and pTRSl, (US22 family members), /zmr-activate I-E, E and 
L promoters when expressed alone or gave enhanced levels when in combination with 
IE1/IE2 in transient transfection assays (Romanowski and Shenk, 1997). pTRSl is 
absolutely required, in combination with IE1 and IE2, for activation of the late ICP36 
promoter (Stasiak and Mocarski, 1992). In summary, pIRSl/pTRSl do not appear to be 
strong or broad range trans-activators, although they can synergise with IE1 and IE2 to 
activate a range of heterologous promoters. The mechanism by which pIRSl and pTRSl 
operate as accessory proteins in IE1/IE12 mediated /razzr-activation is not known.
pIRSl263 is a truncated version of pIRSl, expressed from a promoter within the IRS1 ORF 
and entirely encoded within the C-terminal domain and same reading frame as pIRSl.
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pIRSl263 is entirely located in the nucleus and is part of a regulatory loop, antagonizing 
transcriptional /razzr-activation associated with pIRSl and pTRSl (Romanowski and Shenk, 
1997).
The complex interactions between the various different HCMV #mr-activators, which 
together control HCMV gene expression, are not fully understood. The tegument proteins 
pp71, pUL69, pIRSl and pTRSl are delivered to the cell immediately after infection and are 
likely immediately translocated to the nucleus. pp71 in combination with pUL69 is probably 
responsible for the initial /razzr-activation of the MIEP. The tegument proteins pIRSl and 
pTRSl are also capable of Amr-activating other I-E promoters (Romanowski and Shenk, 
1997). The IE1 72 produced as a result of tegument protein fozzzr-activation of the MIEP 
then probably takes over responsibility for the sustained /razzr-activation of the MIEP. pp71 
and pUL69 only modestly activate expression of the immediate-early US3 gene, although 
expression is up-regulated by the combination of IE1, IE2, pIRSl and pTRSl. This 
synergistic activation of US3 gene expression is inhibited by products from genes UL37xl, 
UL38, and UL84, the latter also promoting inhibition of MIEP expression, representing a 
critical step in the switch from immediate-early to early gene expression (Biegalke, 1999). At 
late times in infection the IE2 40 product is produced and this is thought to negatively 
regulate the MIEP when I-E products are no longer required (Mocarski, 1996).
1.6.6. HHV-6 frans-activators
In the case of the Betaherpesvirus HHV-6, at least seven genes have been defined as 
transcriptional /zmr-activators on the basis of in vitro chloramphenicol acetyl transferase 
(CAT) assays and several of these are the homologues of HCMV US22 gene family members. 
HHV-6 proteins expressed from the U86-U89 and U16-U19 gene regions are functionally 
analogous to the HCMV IE1 /IE2 and UL36-38 proteins, and therefore are termed IE-A and 
IE-B, respectively (Gompels et al, 1995). U41, a herpesvirus core gene (homologous to 
HCMV UL69) exhibits /razzr-activation activity. Because HHV-6 has been proposed to be a
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co-factor in the progression of HIV infection to AIDs, the ability of HHV-6 trans-activating 
genes to /?mr-activate the HIV-LTR promoter has been investigated (Nicholas and Martin, 
1994). Kashanchi et al., (1994), reported that the HHV-6 DR7 gene region (which has 
homology to HCMV gene US22) could specifically /ra/zj-activate the HIV-LTR and required 
only a minimal promoter element containing the TATA box. Another HHV-6 gene region 
(termed B701), which has weak homology with the HCMV US22 gene family, is similarly 
capable of /ra«x-activating the HIV-LTR promoter, via the NF-kB binding site (Geng et al., 
1992).
Despite the identification of #mr-activators in other Betaherpesviruses, litde light has been shed 
on how all the proteins interact during an infection. To date, towr-activation has been studied 
using transient transfection assays. Such an artificial system cannot reveal the interactions 
that occur in vivo, and indeed may suggest /raw-activating activities that do not exist in vivo. It 
is clear that the situation is complex and viral gene products may interact with cellular 
promoters to create the appropriate cellular environment for viral growth. It is expected that 
the recent introduction of gene micro-array technology will shed more light on the total 
cellular response to HCMV infection and provide a more complete picture of the complex 
pattern of transcript activation.
1.7 Aims of thesis
The US22 gene family is little studied and yet the existence of homologues to most of the 
family genes in other sequenced Betaherpesviruses indicates that the family is important. The 
HCMV US22 family genes UL23 and UL24 were selected as targets for investigation because 
they have not been previously studied and because their ORFs appeared to be relatively 
uncomplicated. There was no evidence of an overlapping ORF and the UL23 and UL24 
ORFs were not spliced. The presence of a non-coding region and TATA boxes between the 
ORFs suggests that each gene might have its own promoter, although the UL23 and UL24
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genes were, however, 3’-co-terminal sharing a poly(A) site (Figure 19). Since antibodies were 
available, the UL43 and US22 genes were included in this investigation to broaden the scope 
of the project, permitting a comparison between several different US22 family members. At 
the outset of this investigation no anti-UL23 or UL24 antibody reagents were available and 
therefore the aims of the investigation were to:
1) Generate antibody reagents (polyclonal and monoclonal) to specifically detect UL23 and 
UL24 gene products.
2) Employ anti-UL23, anti-UL24, anti-UL43 and anti-US22 antibodies to investigate gene 
expression and to characterise the protein products.
3) Investigate the intracellular location of UL23, UL24, UL43 and US22 gene products.
4) To produce cell lines expressing pUL23, pUL24 and pUL43 in order to complement the 
defective mutant viruses.
5) Generate knockout mutants of UL23 and UL24 to investigate gene function.
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Chapter 2
MATERIALS AND METHODS
2.1 Materials
2.1.1 Chemicals
All chemicals were analytical grade and unless otherwise stated were purchased from the 
Sigma-Aldrich Company Ltd., UK, or BDH Laboratory Supplies, UK.
2.1.2 Radiochemicals
All radiochemicals were purchased from PerkinElmer Life Sciences, U.S.A.
2.1.3 Restriction Endonucleases
All restriction endonucleases were purchased from New England Biolabs (UK) Ltd. or 
Boehringer Mannheim Ltd., UK, and were supplied with their appropriate buffers.
2.1.4 Antibodies
Antd-VP22 monoclonal (SY34) Ascites fluid Courtesy of Dr. Howard Marsden
Antd-HCV E2 monoclonal (AP33) Courtesy of Dr. Arvind Patel
Anti-HCMV gB monoclonal Capricorn
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Anti-HCMV HWLF1 (US22) monoclonal Advanced Biotechnologies Inc.
Anti-HCMV UL43 monoclonal Courtesy of Dr. Derrick Dargan
Anti-GST monoclonal Amersham Pharmacia Biotech
All HRP, FITC and TRITC conjugated secondary antibodies were purchased from SAPU, 
UK, or Sigma-Aldrich Company Ltd., UK.
2.1.5 Composition of Commonly Used Solutions and Buffers
Bacterial Culture:
L-broth 10 g/L NaCl, 10 g/L tryptone peptone (Becton Dickinson)
5 g/L yeast extract (Becton Dickinson), pH 7.5
L-broth Agar L-broth medium with 4 g/L  agar (Becton Dickinson)
2YT broth 5 g/L NaCl, 16 g/L tryptone peptone (Becton Dickinson), 10 g/L  yeast
extract (Becton Dickinson), pH 7.5
Eukaryotic Cell Culture:
PBS 170 mM NaCl, 10 mM Na2H P 0 4, 3.4 mM KC1,
1.8 mM KH2PO4, 6.8 mM CaCl2, 4.9 mM MgCl2, pH 7.5
TP broth 29.5 g/L  tryptose phosphate (Becton Dickinson)
Trypsin 0.25 % trypsin in Tris saline, pH 7.7 (140 mM NaCl, 0.7 mM
NazHPO^ 5.6 mM dextrose (D-glucose), 24.8 mM Tris,
2.5 mM KC1 solution, 1 N HC1 containing 1 % w /v phenol red 
with 0.1 % v/v  penicillin, 0.1 g /L  streptomycin)
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Versene 0.6 mM EDTA containing 0.002 % v /v  phenol red in PBS
SDS-PAGE and Western Immunoblotting:
Resolving Gel Buffer 0.74 M Tris-HCl (pH 8.9) containing 1 % w /v SDS
Stacking Gel Buffer 0.122 M Tris-HCl (pH 6.7) containing 0.1 % w /v SDS
Gel Running Buffer 52 mM Tris, 53 mM glycine containing 0.1 % w /v SDS
Sample Buffer 100 mM Tris-HCl (pH 6.7) containing 20 % v /v  glycerol, 4 % w /v
(2x Concentration) SDS, 2 % v /v  p-mercaptoethanol, 0.2 % v /v  bromophenol blue
Gel Fix/Stain Methanol, deionised water, acetic acid in ratio 50:43:7 containing 
0.2 % w /v Coomassie brilliant blue
Gel De-stain Methanol, deionised water, acetic acid in ratio 50:880:70.
Towbins Buffer 3.02 g/L  Tris-HCl (pH 8.3), 14.4 g /L  glycine containing 20 % v/v  
methanol
Southern Blotting:
Gel Soak 1 0.6 M NaCl, 0.2 M NaOH
(5x Concentration)
Gel Soak 2 0.6 M NaCl, 1.0 M Tris-HCl (pH 8.0)
SSC 3 M NaCl, 0.3 M tri-sodium citrate (BDH)
(20x Concentration)
Hybridization Buffer 0.5 M NaPCL (pH 7.4) containing 7 % w /v  SDS
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TBE Buffer 1.25 M Tris, 27 mM EDTA, 0.4 M boric acid
(lOx Concentration)
2.1.6 Miscellaneous Reagents and Commercial Kits
Plasmid and DNA Handling:
Advantage® cDNA polymerase mix Clontech
dNTP set ultrapure 100MM solutions kit Amersham Pharmacia Biotech
Plasmid maxi kit (+ endofree plasmid maxi kit) QIAgen
High prime DNA labelling kit Roche
Hybaid DNA recovery kit Hybaid
QIAquick nucleotide removal kit QIAgen
DNA Transfection Reagents:
LipofectAMINE Plus™ transfection reagent GibcoBRL
Transfast™ (Tfx™-50) transfection reagent
Top 10 One Shot™ competant E. coli
Promega
Invitrogen
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Protein Handling:
ABTS microwell peroxidase substrate system
DC protein assay kit
ECL detection reagent
E-Zinc reversible stain kit
Rainbow markers RPN 756 kit
2.1.7 Miscellaneous Materials and Plastics
Chromatography paper 3mm
ECL nitrocellulose Western blotting membranes
Hybond-N
Treff‘Micro fuge’ tubes 1.5ml polypropylene 
Ultra-Clear™ centrifuge tubes 50 ,14x95mm 
Photographic paper multigrade IV 16.5x21.6cm 
X-Omat-S-film 
X-Omat duplicating/RA film
Kirkegaard & Perry Laboratories 
BIO-RAD
Amersham Pharmacia Biotech 
Pierce
Amersham Pharmacia Biotech 
Whatman
Amersham Pharmacia Biotech
Amersham Pharmacia Biotech
Anachem
Beckman
Ilford
Kodak Ltd
Kodak Ltd
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2.2 Methods
2.2.1 Cells and Vims Handling Techniques
2.2.1.1 Cells and cell culture
Tissue culture plastics were obtained from Nunc, Bibby, Costar or Falcon. All cell culture 
media were purchased from GibcoBRL, unless otherwise stated.
Human Foetal Foreskin Fibroblast (HFFF-2) cells [Cat.# 86031405: European Collection of 
Cell Cultures (ECACC)] were grown in Dulbecco’s Minimal Essential Medium (DMEM) 
supplemented with 10 % v/v  foetal calf serum (FC), 1 % v /v  non-essential amino acids 
(NEAA) and 1 % v /v  L-glutamine (L-glut) (DMEM-FclO). 100 Units/ml of 
penicillin/streptomycin was added when cells were used for vims propagation or titration.
Human Telomerase Reverse Transcriptase (hTERT) immortalised BJ-Human Foreskin 
Fibroblast (hTERT-HFF) cells, (Gift of Dr. J. Shay and Dr. W. Wright, University of Texas, 
Southwestern Medical Center, Courtesy of Geron) were grown in DMEM/Medium 199 
(ratio 4:1) supplemented with 10 % v /v  FC, 1 % v /v  NEAA and 1 % v /v  L-glut.
hTERT immortalised Retinal Pigmented Epithelial (hTERT-RPE) cells, (Gift of Dr. J. Shay 
and Dr. W. Wright, University of Texas, Southwestern Medical Center, Courtesy of Geron) 
were grown in DMEM/NUT MIX F-12 medium supplemented with 10 % v /v  FC, 1 % v/v  
NEAA and 1 % v /v  L-glut.
Mouse hybridoma cells were grown in DMEM-FclO containing 4 % v /v  HAT supplement.
59
U373-MG Astrocytoma cells [Cat.# 89081403: ECACC] were grown in DMEM-FclO 
containing 1 % v /v  sodium pyruvate.
PT67 RetroPack™ cells [Cat.# K1060-D: Clontech] were grown in DMEM-FclO.
Baby Hamster Kidney (BHK-21, C13) cells were grown in Eagles Minimal Essential Medium 
(EMEM) supplemented with 10 % v /v  new born calf serum and 10 % v /v  tryptose 
phosphate broth (EMEM-C10).
2.2.1.2 Detection of Mycoplasma in cell cultures
Cell cultures were checked for Mycoplasma contamination at each passage. Approximately 
5x104 cells were transferred to a culture dish containing a sterile 16 mm coverslip and 
incubated at 37 °C with appropriate medium for 4-5 days. The coverslip with attached cells 
was removed, drained by touching the edge with a dry tissue and placed cell side up in a fresh 
tissue culture plate. A drop of methanoliacetone (2:1) solution was added to the coverslip and 
left for 3  min at RT, before draining. 50 j lx I  Hoescht stain (Boehringer Mannheim) was added 
to the coverslip and left for 10 min at RT, before draining. The coverslip was carefully 
washed with distilled water, drained and allowed to air dry at RT. A drop of mounting fluid 
(Mowiol: Harlow Chemical Company Ltd.) was placed onto a glass microscope slide and the 
coverslip mounted cell face down. Coverslips were examined using a Nikon UV microscope 
fitted with a 395 nm filter.
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2.2.1.3 Viruses and virus propagation and storage
The ADI69, Davis and Towne strains of HCMV were obtained from American Type Culture 
Collection (ATCC) [Cat.# VR-538, VR-807, VR-977, respectively].
HCMV stocks were prepared by infecting HFFF-2 cell monolayers (4x106 cells) with HCMV 
at an m.o.i. of 0.01 p.f.u./cell, and when extensive CPE was evident, seeding the virus 
infected cells on to subconfluent monolayers of HFFF-2 cells in roller bottles (at ~105 
infected cells/bottle) at 37 °C. At 24 h post-infection (PI) the culture medium was replaced 
and the infected cultures re-incubated at 37 °C. Cytopathic effect was usually apparent by the 
fifth day PI and became extensive by the ninth day. The supernatant medium containing cell- 
free HCMV was harvested every day between the ninth and fifteenth day PI, clarified by low 
speed centrifugation and stored at —196 °C in liquid nitrogen (long-term) or -70 °C (short­
term). The infectivity of stored samples was then determined by titration.
2.2.1.4 Virus titration
HFFF-2 cells (2x105 cells/35 mm dish) were seeded overnight at 37 °C. Serial 10-fold 
dilutions of the virus stock were made in PBS containing 5 % v /v  FC. The medium was 
removed from the plates and 100 pi of virus dilutions added to the cells and incubated (1 h at 
37 °C) with occasional gentle shaking to spread the virus. The infected cell layer was then 
overlaid in DMEM-FclO containing antibiotics and incubated at 37 °C. At 5 days PI the 
medium was removed and replaced with fresh DMEM-FclO. At 7 to 10 days PI the medium 
was replaced with DMEM-FclO containing 1 % v /v  carboxymethylcellulose. When plaques 
were of sufficient size for counting, the cell layers were fixed/stained by adding 2 ml Giemsa 
stain (BDH) directly into the culture dish. The plates were incubated for at least 2 h at RT,
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after which the stain was decanted and the plates gently rinsed with tap water and dried 
upside down overnight, at RT prior to counting of plaques. Only those plates containing 
between 1 and 500 plaques/35 mm dish were counted. The virus titre was calculated as the 
average of the estimations obtained from each of the virus dilutions yielding countable 
numbers of plaques.
2.2.1.5 Virus plaque purification
The medium was removed from the infected cell layer, which was then washed with DMEM. 
Plaques were picked from the damp cell layer using a micropipette tip. The harvested 
infected cells were pipetted into 0.5 ml DMEM-FclO containing 5 % v /v  sterile glycerol, as 
cryo-protectant, and stored at -70 °C. Before plating of plaque purified virus the thawed 
infected cells were sonicated to release intracellular virus.
2.2.1.6 Purification of virions, dense bodies and NIEPs from the culture medium of H C M V  infected cells
The supernatant culture medium of infected HFFF-2 cells was clarified by centrifugation in 
the Sorvall GSA rotor (8 k/0.5 h/4  °C). Virus related particles in the clarified supernatant 
were then pelleted using the Sorvall GSA rotor (12 k/2 h /4  °C). The pelleted particles were 
re-suspended in a small volume (500 jul) of EMEM lacking phenol red (EMEMpr ). The 
virus-related particles (non-infectious enveloped particles (NIEPs), virions and dense bodies) 
were layered on top of a negative viscosity, positive density, glycerol/potassium tartrate 
gradient, prepared in TN buffer (0.05 M Tris-HCl, pH 7.4, 0.10 M NaCl) (Irmiere and 
Gibson, 1983). The gradient was prepared in a Beckman ultra-clear™ centrifuge tube using a 
standard two-chambered gradient maker, with 5 ml of 30 % (w/w) glycerol in TN buffer
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containing 15 % (w/w) potassium tartrate in the feeder chamber and 4 ml of 35 % (w/w) 
potassium tartrate in TN buffer in the mixing chamber. The particles were then banded by 
centrifugation in the Sorvall TST41 rotor (40 k/15 min/4 °C) operating at slow acceleration 
and braking settings. Banded material was carefully removed by side-puncture of the 
centrifuge tube with an 18G-needle, drawing off the particles into a 5 ml syringe. The 
separated particle types were diluted with EMEMpr, pelleted using the Sorvall TST41 rotor 
(20 k/2 h /4  °C), re-suspended in 50-100 pi EMEMpr and stored at —70 °C.
2.2.2 Plasmid cloning and DNA analysis techniques
2.2.2.1 Preparation of ampicillin! agar plates
Ampicillin (amp) was added to hand-hot (37 °C — 40 °C) molten L-broth/agar at a final 
concentration of 100 pg/ml and —20 ml then aliquoted into 100 mm plates. A bunsen flame 
was used to eliminate surface bubbles. The plates were allowed to set at room temperature, 
dried at 37 °C for 1 h and stored at 4 °C for up to 4 weeks.
2.2.2.2 Small scale preparations ofplasmid D N A  from bacteria
A single bacterial colony, picked from an agar plate, was inoculated into 2 ml L-broth 
containing the appropriate antibiotic and incubated with shaking overnight at 37 °C. The
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bacteria were pelleted in a microfiige (6 k/2 min/RT), then re-suspended in 100 pi of lysis 
buffer (50 mM EDTA, 10 mM Tris, 230 mM sucrose, containing 0.5 % v /v  Triton X-100 
and 1 mg/ml lysozyme). The tube was heated to 100 °C for 1.5 min and the cell debris 
pelleted (13 k /10 min/RT). The supernatant was transferred to a new microfiige tube 
containing 400 pi of 0.3 M NaAc pH 7.0 and then 500 pi isopropanol was added to 
precipitate the DNA. The samples were mixed by inversion and then placed at -20 °C for at 
least 1 hour. The DNA was pelleted (13 k/5 min/RT), allowed to air dry at RT for ~20 
minutes and then re-suspended in 33 pi of distilled water.
2.2.2.3 Preparation of glycerol stocks of bacterial cultures
1 ml of bacterial culture grown overnight (~16 h) was added to 1 ml sterile glycerol, mixed, 
and stored at —70 °C. When recovering bacteria from the frozen stock, the vial was moved to 
dry ice and a scraping taken, using a sterile toothpick, which was then deposited into 2 ml of 
L-broth containing the appropriate antibiotic.
2.2.2A Restriction endonuclease digestion of D N A
Restriction enzyme digests were typically of 20 pi reaction volume and contained 10 units of 
enzyme and 0.2-1.0 pg DNA. RNase A was added for digests of small-scale plasmid DNA 
preparations. Digests were usually incubated for 2-4 h at 37 °C, depending on the 
temperature requirement of the enzyme used, and the reaction terminated by addition of 5 pi 
restriction enzyme stop buffer (10 mM Tris-HCl pH 7.5, 50 mM EDTA containing 10 % v /v  
Ficcoll® 400 and 0.25 % v /v  bromophenol blue).
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2.2.2.5 Agarose gel electrophoresis of D N A  fragments
The concentration of agarose gel employed depended upon the sizes of the DNA fragments 
that had to be resolved. Typically a 0.8 % gel was used (0.8 g agarose dissolved in 100 ml of 
lx TBE by boiling). 10 pi of a 10 mg/ml ethidium bromide solution was added to the cooled 
agarose solution, which was then poured into the gel mould to set at RT. Gel electrophoresis 
was at 60-120 mA during the day or 12 mA overnight. Gels were viewed under short wave 
UV (302 nm), when a photographic record was required, or long wave UV (365 nm) when 
DNA fragments were to be excised.
2.2.2.6 Dephosphorylation of5 ’ ends of D N A  fragments
Typically the reaction contained 1-2 pi alkaline phosphatase (0.01 u/pmol of ends) and 10 pi 
Reaction Buffer (lOx concentration) in a final volume of 100 pi. The reaction was incubated 
at 37 °C for 1 h and the dephosphorylated DNA then recovered using the ‘QIAquick’ 
Nucleotide Removal kit. The picomoles of ends of linear double-stranded DNA was 
calculated according to the formula:
(pg DNA/kb size of DNA) x 3.04 =pmol of ends
2.2.2.7 Ligation of D N A  fragments
Typically DNA ligation reactions used Insert:Vector ratios 1:1 and 3:1 and included a 
linearised vector plasmid control for ligation efficiency. Transformation efficiency was also
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checked using uncut plasmid as control. The ligation reaction volume was usually 10 pi and 
contained 200 ng vector DNA, 2 pi of 5x concentration ligase buffer and 0.5 pi high 
concentration T4 ligase (2,000,000 units/ml) (New England Biolabs). Ligations were 
conducted at 16 °C overnight. DNA concentrations were measured using a 
spectrophotometer operating at 260 nm and the amount of insert DNA required calculated 
according to the formula:
([ng of vector x kb size of insert]/kb size of vector) x molar ratio of insertrvector = ng of 
insert required.
2.2.2.8 Plasmid preparation for D N A sequencing
A single colony of E. coli cells harbouring the plasmid to be sequenced was picked from an 
agar plate and inoculated into 5 ml L-broth containing the appropriate antibiotic and grown 
overnight at 37 °C. The bacteria were pelleted (microfiige; 6 k/2 min/RT), re-suspended in 
100 pi GTE buffer (50 mM D-glucose, 25 mM Tris-HCl pH 8, 10 mM EDTA containing 4 
mg/ml lysozyme) and incubated for 10 min at RT. 200 pi of 200 mM NaOH containing 1 % 
w/v SDS was added to each tube, mixed by gentle inversion and then incubated on ice for 10 
min. 150 pi of 3 M KAc pH 5.0 was added and the tube gently inverted to mix, and then 
incubated on ice for 10 min. The cell debris was pelleted (microfuge; 12 k/5 min/RT) and 
the supernatant drawn off and the DNA extracted by treatment with phenol/chlororform 
(1:1). The DNA was precipitated by addition of 2 volumes ethanol and the DNA pelleted (12 
k/5 min/RT). The DNA pellet was air dried, re-suspended in 100 pi TE buffer (10 mM Tris 
pH 8.0, 1 mM EDTA) containing 100 pg/ml RNase A and incubated for 30 min at 37 °C. 
120 pi of PEG/NaCl (2.5 M NaCl containing 20 % w /v polyethylene glycol (PEG) 6000) 
was added to each tube, which was gently inverted to mix and incubated on ice for 1 h. The 
DNA was pelleted as before, washed in 70 % ethanol, pelleted again and allowed to dry at
66
RT. The DNA pellet was re-suspended in 50 pi TE buffer (2 mM Tris-HCl pH 8, 0.2 mM 
EDTA). 6 pi of the plasmid preparation was mixed with 0.5 pi of 1/1000 dilution of 
oligonucleotide sequencing primer and sent for automated DNA sequencing.
2.2.2.9 D N A  sequencing
Automated DNA sequencing was performed on an ABI Prism ™ 377 DNA Sequencer using 
Sequencing Analysis Software version 3.0 (ABI) and operated by Miss. Lesley Taylor. Files 
were transferred to UNIX, converted to SCF format (Bonfield and Staden, 1995), compiled 
using preGap4 1.1 and Gap4 v4.5 software (MRC, UK) and analysed using Wisconsin 
Package™ Version 10 software (Genetics Computer Group, USA). The FastA function was 
used to run a Pearson and Lipman search for similarity between the compiled sequence and 
the reference sequence.
2.2.2.10 Polymerase Chain Reaction (PCR)
PCR reactions were performed using a PTC-200 Peltier Thermal Cycler. The reaction 
volume was 50 pi, and was comprised of 1 pi 50xdNTPs, 1 pi cDNA polymerase mix, 2 pi 
primer mix (50 pmol of each primer made to final volume with water), 5 pi template (1 ng), 5 
pi lOx buffer and 36 pi deionised water. Unless otherwise stated PCR conditions were as 
follows: 94 °C for first 5 min; then 94 °C for 1 min, 55 °C for 1 min, 72 °C for 1 min x 29 
cycles; then 72 °C for 5 min followed by cooling to 4 °C.
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2.2.2.11 Preparation of competent bacterial cell cultures
10 ml cultures of E. coli cells (strain DH1 or BL21) in L-broth (no ampicillin), grown 
overnight, were used to inoculate 80 ml L-broth (no ampicillin) and the culture was grown for 
a further 2 hours. The bacteria were pelleted in the Sorvall GSA rotor (5 k/10 min/4 °C), re­
suspended in 25 ml ice-cold 100 mM CaCL and kept on ice for at least 1 h. The cells were 
then pelleted in the Sorvall SS-34 rotor (5 k/10 min/4 °C) and re-suspended in 0.5 ml of ice- 
cold 100 mM CaCh. Competent cells were kept on ice at all times and were used within 2 
hours of preparation.
In some experiments Top 10 One shot™ competent E.coli (Invitrogen) were used.
2.2.2.12 Transformation of competent bacterial cell cultures
DNA for transfection was added to 50 pi of competent cell preparation and the mixture 
incubated on ice for at least 1 h. The cells were then subject to a heat shock (42 °C/1 min), 
added to 0.5 ml L-broth (no ampicillin) and incubated at 37 °C for 1.5 h. 100 pi cell 
suspension was plated on agar plates containing the appropriate antibiotic, and incubated 
overnight at 37 °C.
Electroporation of bacterial cells, an alternative transformation method, was also employed in 
some experiments. Gene Pulser cuvettes with 0.1 cm electrode gap (BIO-RAD) were cooled 
at —20 °C overnight and dried before use. DNA (0.1 — 1.0 pg) and 40 pi electro-competent 
E. coli (strains DH1 or BL21) were gently mixed, transferred to the cuvette and 
electroporated, using the Gene Pulser™ machine (BIO-RAD) set at a capacitance of 25 pFD, 
resistance of 400 ohms and 1.6 volts. Immediately after electroporation the cells were added
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to 1 ml L-broth (no ampicillin) and grown for 1 h at 37 °C and then 50 pi cell suspension was 
plated onto agar plates containing the appropriate antibiotic and incubated overnight at 37 °C.
2.2.2.13 Transfection of mammalian cells
LipofectAMINE Plus™ transfection reagent was used according to the manufacturers 
instructions (transfection efficiency of 0.1 % to 4.0 % as determined by pcDNA3.1His 
B/lacZ reporter plasmid). Optimal conditions were determined for transfection of HFFF-2 
cells (2xl05 cells/35 mm plate): 0.25 pg DNA was mixed with 30 pi ‘Plus’ reagent in a total 
volume of 60 pi and the solution was incubated for 15 min at RT, while 2.5 pi 
LipofectAMINE reagent was mixed with 57.5 pi serum-free DMEM and this solution was 
also incubated for 15 min at RT. The DNA preparation and LipofectAMINE solutions were 
mixed and incubated for 30 min at RT. Cells were washed twice and then overlaid with 200 
pi serum free DMEM and the transfection mix was then also added to the cells, which were 
incubated for 3 h at 37 °C. The cells were finally overlaid with DMEM-FclO and incubated 
for 48 h at 37 °C.
Transfast™ transfection reagent was used according to the manufacturers instructions 
(transfection efficiency of 0.005 % to 0.45 %). Optimal conditions were determined for 
transfection of HFFF-2 cells (5x104 cells/well): 0.1 pg DNA was mixed with Optimem 1 
(GibcoBRL) and 6 pi Transfast™ reagent in a total volume of 250 pi and the mix was 
incubated for 10 min at RT. The medium was removed from the cells, which were then 
overlaid with the transfection solution for 4 h at 37 °C. The transfection solution was 
removed and the cells were overlaid with DMEM-FclO for 48 h at 37 °C.
Calcium phosphate transfection of mammalian cells, an alternative transfection method, was 
also employed in some experiments. 0.2-0.5 pg plasmid DNA was mixed with 2.75 pg calf
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thymus DNA and water in a final volume of 57 pi and mixed with 66 pi of 2xHEBS (50 mM 
HEPES pH 7.1, 280 mM NaCl, 1.5 mM Na2H P 0 4) and 9 pi of 2 M CaCl2. The medium was 
removed from the cell layer and the DNA/HEBS/CaCl2 solution added drop-wise to the 
cells, which were then incubated for 40 min at 37 °C. 2 ml medium was added to the cells 
and they were incubated for a further 4 h at 37 °C.
The medium was then removed from the cells and the cell layer bathed in pre-warmed (37 
°C) 10 % v /v  DMSO in lx HEBS for 2.5 min. The DMSO solution was decanted, the cell 
layer washed once with pre-warmed DMEM, overlaid with growth medium and the cultures 
returned to 37 °C.
2.2.2.14 Assessing transfection efficiency using fi-gal staining reagent
Transfection efficiency was assessed by transfecting cell layers with plasmid 
pcDNA3.1HisB/lacZ (Invitrogen). At 48 h post-transfection the medium was removed and 
the cell layer fixed by treatment with 1 % gluteraldehyde in PBS for 1 h at RT. The 
gluteraldehyde solution was removed and the cells washed twice with PBS. The (3-Gal 
staining reagent (100 mM potassium ferrocyanide, 100 mM potassium ferricyanide, 100 mM 
MgCl containing 0.1 % NP40 and 40 mg/ml x-gal in DMSO) was added and the cells 
incubated at 37 °C for approximately 2 to 3 h. The cells were periodically inspected and 
when blue coloured cells could be detected the staining solution was removed and the cells 
washed with de-ionised water. The percentage transfection efficiency was estimated as the 
percentage of blue cells compared to total cell number in the culture.
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2.2,2.15 D N A  extraction from virus infected mammalian cells
HCMV infected HFFF-2 cells on 35 mm tissue culture dishes were harvested when 100 % 
CPE was reached. The culture medium was replaced with 200 pi of cell lysis buffer (20 mM 
Tris-HCl pH 7.5,1 mM EDTA) containing 0.5 % w /v SDS and 100 pg/ml proteinase K and 
incubated for at least 3 h at 37 °C. 15 pi of 5 M NaCl and 200 pi of phenol/chloroform (1:1) 
solutions were added to the DNA sample, gently mixed by inversion and the DNA recovered 
by centrifugation in a microfuge (13 k/2 min/RT). The upper phenol layer was transferred to 
a new tube containing 200 pi chloroform and the extraction repeated. The upper layer was 
again transferred to a new tube and the DNA precipitated by addition of 1ml ethanol. The 
DNA was pelleted in the microfuge (13 k/5 min/RT), washed with 0.5 ml ethanol and 
pelleted as before. The DNA pellet was air dried for ~20 min at RT and re-suspended in 25 
pi water.
2.2.2.16 Southern blotting
Agarose gels containing resolved DNA fragments were placed in gel soak 1 for 1 h, then gel 
soak 2 for 45 min, and finally 20xSSC for 1 h. The treated gel was placed on top of Hybond- 
N membrane and dry paper towels and incubated overnight at RT. The DNA fragments that 
had transferred to the Hybond-N membrane were fixed to the membrane using a UV 
Stratalinker™ 1800 machine (Stratagene) operating on auto cross-linking setting. Membranes 
were stored at 4 °C in a sealed hybridisation bag until required.
The radioactive probe was made with the High Prime random priming kit (Roche) using 200 
ng of template DNA and 50 pCi of a -32P-dCTP. Hybridisation was conducted overnight at
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65 °C. The membrane was washed extensively at 65 °C, twice with 2xSSC and then once 
with lxSSC and then dried at 80 °C for 10 min, before exposing the membrane to X-ray film.
2.2.2.17 Extraction of total cellular R N A  for use in Northern blotting
Pelleted cells (~ lxl07 cells) were re-suspended in 1 ml Trizol (Life Technologies) and 
incubated for 5 min at RT. 200 pi chloroform was then added and incubation at RT 
continued for a further 3 min, after which the sample was pelleted in a microfuge (12k/15 
min/4 °C). The RNA containing aqueous (upper) phase was transferred to a new vial to 
which 0.5 volume isopropanol was added. Following incubation for 10 min at RT the RNA 
was pelleted (12 k/10 min/4 °C) and rinsed with 75 % ethanol. The RNA was allowed to air 
dry and re-suspended in 20 pi sterile TE at 55 °C for 10 min and immediately stored at -70 
°C.
2.2.3 Protein analysis techniques
2.2.3.1 SDS-PAGEpolypeptide electrophoresis
The Mini-PROTEAN II Cell apparatus (BIO-RAD) was used for preparation of SDS-PAGE 
gels. Typically a 10 % gel (1.5 mm thickness) was prepared. The resolving gel solution 
contained 5 ml resolving gel buffer, 8 ml distilled water, 7 ml 30 % Acrylamide/BIS (37.5:1), 
20 pi TEMED and 80 pi of 25 % w /v ammonium persulfate. The stacking gel solution
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contained 3 ml stacking gel buffer, 7 ml distilled water, 2 ml 30 % Acrylamide/BIS, 20 jlxI 
TEMED and 80 jj.1 of 25 % w/v ammonium persulfate. Electrophoresis was at 100 V.
2.2.3.2 Staining of proteins resolved on SDS-PAGE gels with Coomassie brilliant blue dye
SDS-PAGE gels containing resolved polypeptides were immersed in gel fix/stain containing 
0.2 % v /v  Coomassie brilliant blue dye for 2-3 hours, on a slowly rocking platform and then 
transferred to de-stain solution overnight.
2.2.3.3 Recovey of proteinsfrom gel slices by electro-elution
SDS-PAGE gels on which the GST fusion proteins were resolved were negatively stained 
with the E-Zinc reversible-stain kit (Pierce) and the GST fusion protein band excised. The 
fusion protein was electro-eluted from the gel slice using the Biotrap apparatus (Schleicher & 
Schuell) with electrophoresis at 120 V overnight. The concentration of the electro-eluted 
protein was then determined using the DC protein assay kit (BIO-RAD).
2.2.3.4 Western immunoblots
Western blotting of proteins resolved on SDS-PAGE gels was accomplished by 
electrophoretic transfer to ECL nitrocellulose membranes at 50 V for 2-3 h using the BIO­
RAD Mini Trans-Blot apparatus. The blots were then treated with blocking buffer (PBS with
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0.00005 % Tween 20 (PBS/T) containing 5 % w /v dried "Marvel11 milk powder) overnight at 
4 °C or for 2 h at 37 °C. The membranes were then washed (5 cycles of 3 min washes in 
PBS/T) and treated with the primary antibody. Polyclonal antibodies were typically diluted 
1/500 in PBS/T containing 1 % w /v bovine serum albumin (BSA) and incubated with the 
membrane for 2 h at 37 °C. Hybridoma culture supernatants were used undiluted. The 
primary antibody was decanted and the membranes were again washed as before. The 
secondary HRP conjugated antibody was diluted 1/1000 in PBS/T containing 1 % w /v BSA 
and incubated with the membrane for 1 h at 37 °C. The secondary antibody was decanted 
and the membrane washed as before, treated with the ECL reagents and the membrane 
exposed to photographic film.
2.2.3.5 Isolation of bacterial inclusion bodies containing the GST-UL24 fusion protein
A I L  culture of E. coli (strain BL21) containing the plasmid pGEX-6P-l/UL24 was grown in 
L-broth at 37 °C until a cell density of 0.6 OD600 units was reached. IPTG was then added 
(to 1 mM) to induce expression of the GST fusion protein and the culture incubated for a 
further 4 h at 37 °C. The bacteria were pelleted using the Sorvall GS-3 rotor (8 k/10 min/4 
°C) and the pellet frozen at —20 °C.
The bacterial pellet was thawed, re-suspended in 50 ml ice cold PBS, lysozyme added (to 1 
mg/ml) and the cells then incubated for 20 min at RT. The culture was sonicated at 4 °C (3 x 
10 second bursts) and the insoluble material pelleted (6.5 k/10 min/4 °C). The pellet material 
was re-suspended in 5 ml ice-cold buffer 1 (0.1 M NaCl, 1 mM EDTA, 50 mM Tris-HCl pH 
8.0, 2.4 mM sodium deoxycholate) and incubated on ice for 10 min. MgCb and DNase I 
were added to 8 mM and 15 pg/ml, respectively, and the samples then incubated at 4 °C, 
with occasional mixing, until viscosity was eliminated (~30 min). Insoluble material was again 
pelleted (2 k/10 min/4 °C) and washed by re-suspension in 2.5 ml buffer 2 (50 mM Tris-HCl
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(pH 8.0), 2 M Urea) followed by centrifugation, as before. The inclusion body preparation 
was washed by re-suspension in 2.5 ml buffer 3 (50 mM Tris-HCl (pH 8.0), 0.1 M NaCl, 1 
mM EDTA). The final preparation of isolated inclusion bodies was re-suspended in 400 pi 
SDS-PAGE Sample Buffer for SDS-PAGE analysis and electrophoretic separation of the 
GST-UL24 fusion protein. The GST-UL24 fusion protein was recovered from SDS-PAGE 
gel slices by electro-elution, as described above.
2.2.3.6 Methodfor purification of GST-UL23 fusion proteins
A 3 L culture of E. coli (strain BL21) harbouring pGEX-6P-l/UL23 was prepared and 
induced with IPTG to produce the GST-UL23 fusion protein, as described above for GST- 
UL24. Bacterial cell pellets were re-suspended in ice-cold PBS and the cells disrupted by 
sonication (3x10 second bursts). Triton X-100 was added to 1 %, mixed gently for 30 min 
at RT and the insoluble material pelleted (10 k/10 min/4 °C). In order to bind soluble GST- 
UL23 fusion protein the supernatant fraction from lysed bacteria was mixed with glutathione 
sepharose beads, on a rotary mixer for 30 min at RT. The slurry mixture was transferred to a 
column, allowed to settle and then to drain completely. The column matrix was then washed 
extensively with lOx bed volumes PBS and allowed to drain. To recover the GST-UL23 
fusion protein from the glutathione sepharose the column matrix was re-suspended in SDS- 
PAGE sample buffer, and boiled for 10 min. The GST-UL23 fusion protein was then 
separated by SDS-PAGE. The GST-UL23 fusion protein was finally recovered by electro­
elution from gel slices, as described above.
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2.2.3.7 Immunising rabbits for polyclonal antibody production
Rabbit polyclonal antibodies were raised against the GST-UL23 and GST-UL24 fusion 
proteins, in young adult female Dutch lop-ear rabbits. A 3 ml blood sample was taken prior 
to immunisation and allowed to clot for lh  at 37 °C. The clotted blood was pelleted (2 k/5 
min/RT) and the pre-immune serum drawn off, aliquoted and stored at —20 °C. Rabbits 
were immunised by subcutaneous injection of 50 pg of fusion protein emulsified 1:1 with 
Freund’s complete adjuvant (SIGMA) in a 400 pi innoculum. The immune response was 
boosted at 2-3 week intervals (total of 3 times) by additional injection of fusion protein (50 pg 
protein prepared in Freund’s incomplete adjuvant) and test bleeds taken. ELISA reactions 
were used to test the immune serum for fusion protein specific antibodies.
Rabbit polyclonal antibodies were also raised against synthetic branched peptides of UL23 
and UL24 in young adult female Dutch lop-ear rabbits. Pre-immune sera were collected as 
described above. Rabbits were immunised subcutaneously with 100 pg of synthetic peptide 
emulsified 1:1 with Freund’s complete adjuvant in a 400 pi innoculum. The immune 
response was boosted further by injection of 100 pg peptide prepared in Freund’s incomplete 
adjuvant at 2-3 week intervals. A final booster immunisation was conducted 1 week prior to 
the rabbits being bled out. ELISA reactions were used to determine the anti-peptide antibody 
potency.
2.2.3.8 Immunising mice for monoclonal antibody production
Mouse monoclonal antibodies were raised against GST-UL23 and GST-UL24 fusion proteins 
in Balb/C mice by subcutaneous injection of 20 pg of protein emulsified 1:1 in Freund’s 
complete adjuvant in a 100 pi innoculum. Two further injections of protein in Freund’s 
incomplete adjuvant were administered at two-weekly intervals. Three weeks after the last
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boost, the animals were given a final intra-peritoneal injection of 100 pg protein in 100 pi 
PBS. The mice were sacrificed 5 days after the last injection and the spleen cells fused with 
Sp2/0-Ag 14 myeloma cells (ratio 10:1) using 50 % PEG1500 (Koch Light) in DMEM-FclO. 
Cells were re-suspended in HAT medium (DMEM-FclO containing 4 % HAT supplement) 
containing 20 % v /v  conditioned medium. Cells were seeded into 96-well microtitre plates 
and incubated for 12-14 days at 37 °C. Supernatants from colony-containing wells were 
removed and screened by ELISA against GST fusion proteins for protein-specific 
monoclonal antibodies. Cells from positive wells were removed and propagated.
2.2.3.9 Enzyme Linked ImmunoSorbant Assay (ELISA)
96 well flat-bottomed microtitre plates were coated with 50 pi of antigen, either GST fusion 
proteins or synthetic peptides, at 250 ng/well. The plate was closed and incubated overnight 
at RT. Excess antigen was decanted and the plate washed 5 times in wash buffer (145 mM 
NaCl, 7.5 mM Na2HPC>4, 2.8 mM NaH2PC>4 containing 0.5 % Tween 20). The plate was 
dried by tapping on paper towels. 150 pi of blocker solution (PBS + 2 % w /v BSA) was 
added to each well and incubated for 1 h at RT, after which and the plates were dried and 
stored. For the ELISA reactions, 50 pi of primary antibody was added to each well and the 
plate incubated for 1 h at 37 °C. The plate was washed 5 times in wash buffer and 50 pl/well 
of secondary (anti-mouse or anti-rabbit) antibody conjugated to HRP (diluted 1/1000 in PBS) 
was added and the plates again incubated for 1 h at 37 °C. The wells were washed 8 times in 
wash buffer prior to addition of 100 pl/well of ABTS peroxidase substrate. The ELISA 
reaction was incubated for 15-30 min at RT and the OD405 measured using an automated 
plate reader (Titertek Multiskan® Plus).
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2.2.3.10 Extraction of infected cell immediate-early, early and late proteins
For preparation of virus immediate-early (I-E) proteins the medium on HFFF-2 cell layers 
(2x105 cells/35mm dish) was replaced with DMEM-FclO containing 200 pg/ml 
cycloheximide (CHX) for 1 h at 37 °C. The medium was then removed and the cells infected 
with HCMV at a m.o.i. of 10 p.f.u./cell in a 100-200 pi innoculum containing CHX at 200 
pg/ml. The cells were allowed 1 h at 37 °C to absorb the virus and the cell layers were then 
washed 3 times and then overlaid with DMEM-FclO containing 200 pg/ml CHX. 
Actinomycin D (Act D) was added to the cultures at 18 h PI to a final concentration of 5 
pg/ml for 30 min. CHX was then removed by 3 washes with DMEM-FclO containing 5 
pg/ml Act D and the cells were overlaid with the same medium and incubated for 4 h at 37 
°C. Protein extracts were prepared by decanting the medium, washing the cell layer with PBS 
and solubilizing the cells in 250 pi of SDS-PAGE sample buffer.
For preparation of virus early (E) proteins the cell layers were infected with HCMV at 10 
p.f.u./cell, as described above except that CHX was not used. After the 1 h adsorption 
period the infected cells were washed 3 times and then overlaid with DMEM-FclO 
containing 300 pg/ml phosphonoacetic acid (PAA) and incubated for 48 h at 37 °C, prior to 
harvesting the protein extracts as previously described.
To prepare vims late (L) proteins the cell layers were infected, as described above, but no 
drugs were used. Infected cell protein extracts were then harvested at 72 h PI in SDS-PAGE 
sample buffer, as previously described.
In experiments in which the culture medium was probed for secreted vims proteins, the 
medium was removed from infected cell layers and clarified by low speed centrifugation. 
The clarified supernatant was then centrifuged in the Sorvall SS-34 rotor (20 k /2  h /4  °C) 
to pellet vims-related particles and the supernatant medium then mixed with SDS-PAGE 
sample buffer at a ratio of 1:2.
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2.2.4 Light Microscopy
2.2.4.11mmunofluroescence
HFFF-2 cells were seeded on sterile 13 mm glass coverslips in 24 well tissue culture trays at 5 
x 104 cells/coverslip. Following infection with vims, or transfection with plasmids, the cells 
were incubated at 37 °C. After varying periods of time, the medium was removed, the 
coverslips washed twice with PBS and fixed in 0.5 ml fix solution (5 % v /v  formaldehyde, 2 
% w /v sucrose in PBS) for 10 min at RT. An alternative fix was methanol for 5 min at RT. 
The fixed cells were again washed with PBS and either permeabilised immediately or the 
coverslips stored at 4 °C in PBS. Permeabilisatdon was achieved by a 5 min at RT incubation 
of the cells in buffer (0.5 % v /v  N P40,10 % w /v sucrose in PBS) followed by 3 washes with 
PBS. Cells were treated for 1 h at RT with primary antibody (PAbs diluted 1/500, MAbs 
were undiluted) in a volume of 50-100 )il/coverslip. Primary antibody was removed by 3 
washes in PBS and then the cells were treated for 1 h at RT with 100 pi secondary anti-rabbit 
or anti-mouse FITC conjugated IgG (diluted 1/100 in PBS containing 1 % calf serum), as 
appropriate. Secondary antibody was removed by 3 washes in PBS and once in de-ionised 
water after which the coverslips were allowed to air dry. The coverslips were mounted in 
Citifluor mounting solution on glass microscope slides with the edges of the coverslip sealed 
with clear nail varnish. The mounted slides were stored in the dark at 4 °C to preserve 
fluorescence and examined using the confocal microscope under UV illumination.
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2.2.4.2 Confocal microscopy
Confocal microscopy was performed using a Zeiss LSM Confocal Microscope linked to a 
computer operating LSM510 software.
2.2.5 Electron Microscopy
2.2.5.11mmuno-gold labelling of thin sections of H C M V infected cells for electron microscopy
HFFF-2 cells were infected with HCMV strain AD169 at a m.o.i. of 5 p.f.u./cell. At 96 h PI, 
the cells were scraped into PBS, pelleted in a BEEM capsule (TAAB laboratories) and fixed 
with 2.5 % v /v  gluteraldehyde in PBS. The cell pellet was dehydrated through a series of 
increasing ethanol concentrations, up to 100 % ethanol, and then permeated with acrylic resin 
(unicryl) for 8 h at RT. The cell pellet was embedded in fresh resin, and polymerised by 
exposure to UV light for 4 days at -15 °C. Thin sections (70-80 nm) were removed from the 
block, using an ultratome fitted with a diamond knife and the sections placed on non-coated 
nickel EM grids (200 mesh). The cell sections were overlaid with PBS alone, non-HCMV 
control antibody AP33, anti-UL23 MAb 266, anti-UL24 MAb 116, or anti-UL43 Mab 92 
overnight at RT. After extensive PBS washing of the cell sections they were overlaid with the 
secondary anti-mouse antibody, conjugated to 10 nm gold particles (Nanoprobes, Inc.) 
(diluted 1 /30 in PBS) and incubated for 2 h at RT. The labelled sections were post-fixed with 
osmium tetroxide vapour for 2 h at RT, stained with uranyl acetate (saturated solution in 1:1
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ethanol: water), counter stained with lead citrate, then examined in a Jeol 100S electron 
microscope operating at 80 KV.
2.2.5.2 Immuno-gold labelling of virus particle preparations for electron microscopy
Purified virus particles were adsorbed on parlodion coated nickel EM grids and then treated 
for 5 h at RT with PBS alone, non-HCMV control MAb AP33, anti-UL23 MAb 266, anti- 
UL24 MAb 116, anti-US22 Mab (HWFL1) or anti-UL43 MAb 92. The grids were then 
washed extensively in de-ionised water and overlaid with goat anti-mouse IgG conjugated to 
5 nm or 10 nm gold particles (Nanoprobes, Inc.) (diluted 1/30 in PBS) overnight at RT. The 
gold-tagged particles were then negatively stained with phosphotungstic acid (potassium 
phosphotungstate acid (PTA) 3 % in distilled water pH 7.0) prior to examination in a Jeol 
100S electron microscope operating at 80 KV.
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Chapter 3
RESULTS
3.1 Cloning of the HCMV UL23 and UL24 ORFs
3.1.1 PCR Amplification
The UL23 ORF (nucleotides 28717-27864, Chee et al.^  (1990)) was amplified by PCR from 
the cloned A D I69 Hind III Y fragment (Oram et al., 1982) using 5’ and 3’ specific 
oligonucleotide primers (Table 5). The 5’-primer (RA2) had EcoR I and Sal I linker sequences 
abutting the UL23 start codon, while the 3’-primer (RA1) had an Xho I linker sequence 
abutting the stop codon. Following amplification, in this and all subsequent PCR reactions, 2 
pi of the final PCR reaction product was electrophoresed on a 50 ml 1 % agarose gel and 
examined under UV illumination to check the size and number of DNA bands. The UL23 
PCR reaction produced a single band of the expected size of ~0.9 kbp.
The UL24 ORF (nucleotides 30009-28933, Chee et al, (1990)) was amplified by PCR from an 
A D I69 cosmid fragment (Cos 64, nucleotides 23495 — 66934, provided by Dr. Derrick 
Dargan) using 5’ and 3’ specific oligonucleotide primers (Table 5). The 5’-primer (RA4) had 
EcoR I and Sal I linker sequences abutting the UL24 start codon, while the 3’-primer (RA3) 
had an Xho I linker sequence abutting the stop codon. The PCR reaction produced a single 
band of the expected size of ~ 1.1 kbp.
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Table 5. Oligonucleotide PCR primers designed for amplification of HCM V (AD169) ORFs or for use 
in DNA sequencing. Start (ATG) and Stop (TCA) codons are marked in bold in the oligonucleotides.
PCR
PRIM ER
NAM E
PRIM ER
USAGE
OLIG O N U CLEO TID E SEQ U EN CE
RA1 Amplify UL23 
ORF
5’-ATA CTC04GTCACGCGTCGTCAAAAAGTTGGTGGTC 
Xho I
RA2 Amplify UL23 
ORF
5’-CCGGAATTCGTCGACATGTCGGTAA'TCAAGGACTGTTTTCTC  
EcoR I Sail
RA3 Amplify UL24 
ORF
5’-ATT CTCGylGTCAACGGTGCTGACGTCCTTTGGGGCA 
Xho I
RA4 Amplify UL24 
ORF
5’-ATTGAATTCGTCGACXTGGAGGAGACCCGGGCGGGACGTTAT  
EcoR I Sal I
RA5 DNA sequence
vector
pGEX-6P-l
5’-TACTTGAAATCCAGCAAGTA
RA6 DNA sequence
vector
pGEX-6P-l
5’-TCACCGTCATCACCGAAACG
RA7 DNA sequence 
UL24 ORF
5'-GCTCGCCCACTGACTCGGCG
RA8 DNA sequence 
UL24 ORF
5'-GGCGGATGATGAATCGCGCC
RA9 DNA sequence 
UL23 ORF
5’-CACAGCGTCTGGCCAGCTAC
RA10 DNA sequence 
UL23 ORF
5’-GCTCCAGTCGTACAGCCGAA
RApc3.1 DNA sequence 
vector 
pcDNA3.1 +
5’-TAAGCAGAGCTCTCTGGCTA
RA2pc3.1 DNA sequence 
vector
pcDNA3.1+
5'-AGTGGCACCTTCCAGGGTCA
3.1.2 Cloning the UL23 and UL24 ORFs into the GST fusion vector pGEX-6P-l
The 0.9 kbp UL23 PCR product was digested with EcoR I and Xho I, purified using the 
‘QIAquick’ nucleotide removal kit and cloned into the EcoR 1/Xho I sites in the GST fusion 
vector, pGEX-6P-l (Amersham Pharmacia Biotech) (Figure 3). In this, and all subsequent
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cloning experiments diagnostic restriction enzyme digests were performed to confirm that 
cloning had been successful. For DNA sequencing, oligonucleotide PCR primers were 
designed to amplify sequences from the vector DNA into the UL23 ORF (Table 5): a 
forward primer (RA5) at vector nucleotide 831 and a reverse primer (RA6) at vector 
nucleotide 1030. Oligonucleotide sequencing PCR primers were also designed to amplify 
sequences from the UL23 sequences out into the vector DNA: a reverse primer (RA9) at 
HCMV nucleotide 28551 and a forward primer (RA10) at HCMV nucleotide 28151. 
Oligonucleotide sequencing primers were always selected to allow for at least 200 bp of 
sequencing overlap. DNA sequencing confirmed that there were no errors in the amplified 
UL23 ORF and that it was cloned in-frame with the resident GST gene in the vector. 
pGEX-6P-l/UL23 DNA was transfected by electroporation into protease-deficient E. coli 
(strain BL21) cells to produce the GST-UL23 fusion protein.
The 1.1 kbp UL24 PCR product was digested with EcoR I and Xho I, purified using the 
‘QIAquick’ nucleotide removal kit and cloned into the EcoR I/Xho  I sites in the vector 
pGEX-6P-l (Figure 3). For DNA sequencing, oligonucleotide PCR primers were designed 
to amplify sequences from the UL24 sequences out into the vector DNA: a reverse primer 
(RA7) at HCMV nucleotide 29861 and a forward primer (RA8) at HCMV nucleotide 29337. 
The RA5 and RA6 sequencing PCR primers (Table 5) were used to amplify sequences from 
the vector DNA into the UL24 ORF. DNA sequencing confirmed that the UL24 ORF was 
cloned in-frame with the resident GST gene in the vector, but also showed that there was a 
silent mutation in the amplified UL24 ORF at nucleotide 29623, (codon TTC changed to 
codon TIT', both of which code for phenylalanine). pGEX-6P-l/UL24 DNA was 
transfected by electroporation into protease-deficient E. coli (strain BL21) cells to produce the 
GST-UL24 fusion protein.
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Figure 3. Diagramatic representation for 
the cloning strategy of UL23 and UL24 
PCR products. Plasmid vectors and the 
ends of the PCR products were digested 
with restriction enzymes. E, EcoR I; S, Sal 
I; B, BamR I; X, Xho I. Promoters are 
represented by a black arrow. ORFs are 
represented by an white arrow. The 
sequenced product of cloning UL24 into 
pGEX-4T-His6 is described below.
1
B RGSHis6 S
XU BGH pApCMV
pcDNA3.1+
Neomycin
Desired Sequence of UL24 cloned into pGEX-4T-His6:
CTGGGATCC ATG AGA GGA TCT CAT CAC CAT CAC CAT CAC GTCGAC ATG
Bam H I M  R G S H H H H  H H S ail UL24 ORF
Actual Sequence obtained following cloning:
CTGGGATCC CCG GAATCC GTCGAC ATG
Bam H I EcoR I Sal I UL24 ORF in frame
3.1.3 Cloning the UL23 and UL24 ORFs into vector pGEX-4T-3/RGSHis6
pGEX-4T-3/RGSHis6 is derived from the pGEX-4T-3 GST fusion vector (Amersham 
Pharmacia Biotech) by placement of a RGSHis6 tag sequence after the thrombin cleavage site 
in the vector (generated and provided by Dr. Arvind Patel) (Figure 3). pGEX-4T-3/RGSHis6 
plasmid DNA was prepared for ligation by digesting with Sal I and Xho I and purified using 
the ‘QIAquick’ nucleotide removal kit.
The UL23 ORF was excised from the pGEX-6P-l/UL23 plasmid on a Sal I /  Xho I 
fragment and cloned into pGEX-4T-3/RGSHis6, placing the RGSHis6 sequence at the 5' end 
of the UL23 ORF (Figure 3). DNA sequencing performed using the RA5, RA6, RA9 and 
RA10 PCR primers (Table 5) confirmed that there were no errors in the sequence and that 
the UL23 ORF was cloned in-frame with the GST gene and histidine tag sequence. pGEX- 
4T-3/RGSHis6-UL23 DNA was transfected by electroportation into protease-deficient E. coli 
(strain BL21) cells to produce the GST-RGSHis6-UL23 fusion protein.
The pGEX-6P-l/UL24 plasmid served as donor for the UL24 ORF when cloning into 
pGEX-4T-3/RGSHis6. However, as the UL24 ORF contains an internal Sal I site at 
nucleotide 29134 a Sal I linear partial digest followed by an Xho I digest was required to 
liberate the full length UL24 ORF from the donor vector. The Sal 1/Xho I fragment 
containing the UL24 ORF was cloned between the Sal I and Xho I sites of vector pGEX-4T- 
3/RGSHis6 (Figure 3). Relatively few bacterial colonies were obtained and DNA sequencing 
performed using the RA5, RA6, RA7 and RA8 PCR primers (Table 5) revealed that the 
histidine tag sequence was lacking in the product from the ligation reaction. Nevertheless, the 
UL24 ORF had been cloned in frame with the GST gene in pGEX-4T-3. Although a 
histidine tagged version of the UL24 ORF was not produced this construct proved useful in 
serving as donor of the UL24 ORF when cloning into the eukaryotic expression vector 
pcDNA3.1+.
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3.1.4 Cloning the RGSHis6-UL23 and UL24 ORFs into eukaryotic expression vector
pcDNA3.1+
The RGSHis6-UL23 ORF was excised from the pGEX-4T-3/RGSHis6-UL23 plasmid on a 
BamH l/X hol fragment, purified on an agarose gel and cloned into pcDNA3.1 + (Figure 3). 
For DNA sequencing, oligonucleotide PCR primers were designed to amplify sequences 
from the vector DNA into the UL23 ORF: a forward primer (RApc3.1) at vector nucleotide 
808 and a reverse primer (RA2pc3.1) at vector nucleotide 1101. The RA 9 and RA10 
sequencing PCR primers (Table 5) were used to amplify sequences from the UL23 sequences 
out into the vector DNA. Sequencing confirmed that there were no errors in the cloned 
UL23 ORF.
The UL24 ORF was excised from the pGEX-4T-3/UL24 plasmid on a BamH I/Xho I 
fragment, purified on an agarose gel and cloned into pcDNA3.1+ (Figure 3). DNA 
sequencing performed using the RApc3.1, RA2pc3.1, RA7 and RA8 PCR primers (Table 5) 
confirmed that there were no errors in the cloned UL24 ORF, except for the silent mutation 
described previously.
3.2 Purification of UL23 and UL24 GST fusion proteins from E. coli (strain BL21) cell
cultures
Small-scale cultures (10 ml) were used to optimise conditions for induction of UL23 and 
UL24 GST fusion proteins from the pGEX-6P-l and pGEX-4T-3 based vectors. Variable
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parameters included changes or combinations of changes to IPTG concentration, induction 
temperature, bacterial strain, time of induction, and growth medium (Table 6). None of the 
conditions employed yielded soluble GST-UL23 or GST-UL24 fusion proteins in quantities 
detectable by Coomassie blue stained SDS-PAGE gels or Western immunoblots, probed with 
anti-GST or anti-RGS antibodies (as appropriate). Although 10 ml cultures failed to yield 
detectable amounts of GST-UL23, small amounts of soluble GST-UL23 fusion protein were 
obtained from large-scale (3 L) bacterial cultures grown in 2YT broth and induced by 
treatment with 1 mM IPTG for 4 h at 37 °C. In contrast, soluble GST-UL24 fusion protein 
was never detected, even in large-scale cultures.
3.3 Purification of GST-UL23 fusion protein for antibody production
Soluble GST-UL23 fusion protein was isolated by binding to glutathione beads. The fusion 
protein was removed from the beads by treatment with SDS-PAGE sample buffer and the 
protein purified by SDS-PAGE. The fusion protein was recovered from the excised gel slices 
by electro-elution using the Biotrap apparatus (Schleicher and Schuell). The purity of electro­
eluted fusion protein was checked by Coomassie blue dye staining of proteins resolved in 
SDS-PAGE gels (Figure 4A) and by Western immunoblotting, using an anti-GST antibody 
(Figure 4B). The GST-UL23 fusion protein appeared to run close to its predicted molecular 
weight of 59.0 kDa. Protein concentration assays performed on each sample batch showed 
that generally low levels of fusion protein (<0.1 mg/ml) were recovered. When the 
concentration of a sample batch was <0.1 mg/ml the protein samples were concentrated 
using a YM-10 Centricon® centrifugal filter device (Millipore) that retains proteins with a 
molecular weight > 10 kDa. The final concentration o f the GST-UL23 fusion protein 
preparations was generally 0.3 -1.2 mg/ml.
Table 6. Conditions for induction of GST fusion proteins.
Bacterial
Strain/
Growth
Media
Plasmids Induction
Tem p./
Time
IPTG conc. Soluble Fusion 
Protein Detected?
BL21/
2YT
Controls:
pGEX-6P-l
pGEX-4T-His6
37 ° C /  
4 h
0.5, 1.0, 3.0 
or 5.0 mM
GST detected under all IPTG 
concentrations by Western 
Immunoblots
*BL21/
*2YT
pGEX-6P-l/UL23
pGEX-6P-l/UL24
*37 °C / 
4 h
*1.0 mM Some soluble GST-UL23 on 3 L 
cultures detected by Western 
immunoblot
BL21/
2YT
pGEX-6P-l /UL23 
pGEX-6P-l /UL24 
Control: 
pGEX-6P-l
37 ° C /
0.5 h, 1.0 h 
or 4h
1.0 mM, or
3.0 mM
No, but GST detected from control 
under all conditions by Western 
Immunoblot
BL21/
2YT
pGEX-6P-l /UL23 
pGEX-6P-l /UL24
37 °C, or 
20 °C/
4 h
0.1, 0.5, 1.0, 
1.5 or 2.0 
mM
No
BL21/
2YT
pGEX-6P-1 /UL23 
pGEX-6P-l /UL24
37 °C, or 
28 °C/
4 h
0.1, 0.5, 1.0, 
1.5 or 2.0 
mM
No
BL21/
2YT
pGEX-6P-l /UL23 
pGEX-6P-1 /  UL24 
Control: 
pGEX-6P-l
37 °C, or 
25 °C/
16 h
0.5, 1.0, 2.0 
or 5.0 mM
No, but GST detected from control 
under all conditions by Western 
Immunoblot
BL21/
2YT + 2 % 
glucose 
added 2 h 
prior to 
IPTG
pGEX-6P-l /UL23 
pGEX-6P-l /UL24 
Control: 
pGEX-6P-l
37 °C/ 
4 h
0.0, 0.5, 1.0, 
3.0 or 5.0 
mM
No, but GST detected from control 
under all conditions by Western 
Immunoblot
BL21/
L-broth
pGEX-6P-1 /  UL23 
pGEX-6P-l /UL24
37 °C/
4 h or 6 h
1.0, 1.5 or 2.0 
mM
No
DH-1/
L-broth
pGEX-6P-l /UL23 
pGEX-6P-l /UL24 
Control: 
pGEX-6P-l
37 °C, or 
25 °C/
4 h
0.5, 1.0, 2.0 
or 5.0 mM
No, but GST detected from control 
under all conditions by Western 
Immunoblot
Novablue
DE-3/
2YT
pGEX-6P-l /UL23 
pGEX-6P-l /UL24
37 °C/ 
4 h
0.0, 0.5, 1.0, 
3.0 or 5.0 
mM
No
BL21/
2YT
pGEX-4T-
3/RGSHis6-UL23
pGEX-4T-3/UL24
37 °C/
4 h or 16 h
0.5, 1.0, 3.0 
or 5.0 mM
No
♦-Conditions finally chosen for growth of large-scale cultures for isolation of soluble GST-UL23 fusion protein
and insoluble GST-UL24 (from inclusion bodies).
89
3.4 Purification of GST-UL24 fusion protein for antibody production
Analysis of IPTG induced bacterial cell extracts on Coomassie blue dye stained SDS-PAGE 
gels indicated that a substantial protein band of ~60 kDa, corresponding to the predicted size 
of the GST-UL24 fusion protein, was present in the insoluble pelleted cell debris from 
sonicated bacteria. Preparations of bacterial inclusion bodies were made and the GST-UL24 
fusion protein separated on SDS-PAGE gels. The purity of electro-eluted fusion protein was 
checked by Coomassie blue staining of proteins resolved in SDS-PAGE gels (Figure 4C) and 
by Western immunoblotting, using an anti-GST antibody (Figure 4D).
In experiments shown in Figure 4C and 4D, the GST-UL24 fusion protein recovered from 
the inclusion body preparations had an apparent molecular mass of ~60 kDa in SDS-PAGE 
gels, which is significantly less than the 66.2 kDa predicted. The cause of this discrepancy has 
not been further investigated. In other experiments (e.g. Figure 7D) the GST-UL24 fusion 
protein resolved with the expected 66.2 kDa size.
The concentration of electro-eluted GST-UL24 fusion protein preparations were generally 0.2 
— 1.0 mg/ml. An attempt to purify the GST-UL24 fusion protein from an inclusion body 
preparation by direct binding to glutathione beads was unsuccessful.
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Figure 4. Isolation of UL23 and UL24 GST fusion proteins from  
bacterial cell extracts and investigation of the fusion protein 
preparations prior to immunisation of animals. (A and C) Coomassie 
blue stained gel showing electro-eluted GST-UL23 and GST-UL24 fusion 
proteins, respectively. (B and D) W estern immunoblots, probed with anti- 
GST antibody, to confirm that the eluted proteins are GST fusion products. 
The predicted sizes of GST-UL23 and GST-UL24 were 59.0 kDa and 66.2 
kDa, respectively. MWM, M olecular W eight Marker.
3.5 Synthesis of branched peptides corresponding to the C-terminus amino acid 
sequences of the UL23 and UL24 ORFs
Multiple antigen peptide systems (MAPs), originally developed by Dr. James Tam (Tam, 
1996), can be used for anti-peptide antibody elicitation. MAPs are comprised of small 
immunogenically inert poly-lysine cores onto which peptide antigens can be synthesised. The 
resulting macromolecules possess a high molar ratio of peptide antigen to core molecule and 
are capable of eliciting a strong antibody response, often yielding significantly higher antibody 
titres than obtained with the monomeric counterpart attached to a carrier protein. The inert 
MAP core was attached to a solid phase peptide synthesis support (Fmoc4-Lys2-Lys-(3Ala- 
Wang resin) and the desired peptide antigens were synthesised directly onto the branched 
lysine core. Branched peptides (bold and underlined) from the C-terminus regions of UL23 
(3»- ADDFLOHDVGYPCTPKNLKRMSRTGY) and UL24 (3»- 
RHORGKPCDFVRDYIGNHGSFRRNEF) were prepared by Drs. T. MacDonald and H. 
Marsden, and generated by solid phase peptide synthesis using an Advanced ChemTec 348D 
multiple peptide-automated synthesiser using standard Fmoc chemistry. The homogeneity of 
the peptide product was analysed by high performance liquid chromatography (HPLC).
3.6 Raising anti-UL23 and anti-UL24 antibodies
Rabbits were injected subcutaneously with 50 pg/injection of GST fusion proteins or 100 
pg/injection of branched peptides (see methods). The rabbits were sacrificed when pUL23 
and pUL24 antibody titres were high, as determined by ELISA, and the serum separated to 
provide polyclonal antibodies. Mice were injected subcutaneously with 20 pg/injection of
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GST fusion proteins. Mouse spleen cells were fused with Sp2/0-Ag 14 cells when antibody 
titres were high to provide hybridoma cells and the culture medium from hybridomas was the 
source of monoclonal antibodies (MAbs).
3.7 Testing the specificity of anti-UL23 polyclonal antibodies
The specificity of rabbit anti-UL23 polyclonal antibodies, produced against GST-UL23 fusion 
protein (PAb 678 and PAb 679), was investigated by Western immunoblotting using 
bacterially produced and thrombin cleaved GST-RGSHis6-UL23 protein. GST-RGSHis6- 
UL23 fusion protein bound to glutathione beads was cleaved with human plasma thrombin 
(Sigma) to yield the RGSHis6-UL23 (33.0 kDa) and GST (26.0 kDa) protein components. 
PAb 678 and PAb 679 detected RGSHis6-UL23, GST and residual uncleaved GST-RGSHis6- 
UL23 proteins from the bacterial extract (data not shown). However, these experiments did 
not give a clean result, with many additional E. coli proteins also detected by the polyclonal 
antiserum. SDS-PAGE separation of fusion proteins results in a relatively crude preparation 
of GST-UL23 and rabbit antibodies will have been raised against contaminating bacterial 
proteins.
The specificity of rabbit anti-UL23 polyclonal antibodies, produced against branched peptides 
of UL23 (pep682 and pep683), was investigated by Western immunoblotting using bacterially 
produced RGSHis6-UL23 protein. Pep683, anti-RGS and anti-GST antibodies all detected 
full-length GST-RGSHis6-UL23 fusion protein (Figure 5A). Antibody pep683 did not detect 
GST but did detect the RGSHis6-UL23 protein, which was also detected by the anti-RGS 
antibody. Antibody pep682 gave similar results (Figure 5B). Pep683 and anti-RGS 
antibodies bind the C- and N-termini of the RGSHis6-UL23 protein, respectively, confirming 
that the full-length protein was expressed. Thus, the polyclonal antibodies pep682 and 
pep683 specifically detected pUL23. Specificity of the pep682 and pep683 antibodies was 
further demonstrated by the failure to detect pUL23 by Western immunoblotting following 
pre-adsorption of the antibodies against the UL23 peptide preparation (Figure 5B).
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Figure 5. The anti-UL23 peptide antibodies, (pep682 and pep683), specifically 
identified pUL23 produced in bacterial cultures. RGSHis6-UL23 was cleaved from 
GST by human plasma thrombin (50 cleavage units in 1 ml PBS) at RT overnight. (A) 
Western immunoblot of thrombin cleaved GST-RGSHis6-UL23 fusion protein, using anti- 
RGS antibody and pep683 antibody. (B) Western immunoblot of thrombin cleaved GST- 
RGSHis6-UL23 fusion protein, using antibodies pep682 and pep683 before or after pre­
adsorption with the UL23 peptide used to raise the antibody. To pre-adsorb antibodies 5 
pi serum was incubated with 100 pg branched peptide and 50 pi of 10 % w/v protein A 
sepharose (Sigma) for 1 h at 37 °C, and the sepharose bound UL23 antibodies were 
removed by centrifugation in a microfuge (6 k/2 min/RT).
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Figure 5. The anti-UL23 peptide antibodies, (pep682 and pep683), specifically  
identified pUL23 produced in bacterial cultures. RGSHis6-UL23 was cleaved from 
GST by human plasma thrombin (50 cleavage units in 1 ml PBS) at RT overnight. (A) 
Western immunoblot of thrombin cleaved GST-RGSHis6-UL23 fusion protein, using anti- 
RGS antibody and pep683 antibody. (B) Western immunoblot of thrombin cleaved GST- 
RGSHis6-UL23 fusion protein, using antibodies pep682 and pep683 before or after pre­
adsorption with the UL23 peptide used to raise the antibody. To pre-adsorb antibodies 5 
pi serum was incubated with 100 pg branched peptide and 50 pi of 10 %  w/v protein A 
sepharose (Sigma) for 1 h at 37 °C, and the sepharose bound UL23 antibodies were 
removed by centrifugation in a microfuge (6 k/2 min/RT).
3.8 Testing the specificity of anti-UL23 monoclonal antibodies
GST-
Monoclonal antibodies were screened by Western immunoblotting against bacterially produced 
and thrombin cleaved RGSHis6-UL23 protein. O f 18 ELISA-positive hybridoma culture 
supernatants obtained, 13 appeared to contain UL23 specific monoclonal antibodies (MAbs). 
MAbs 266 and 73 were the most potent, in specifically detecting RGSHis6-UL23 protein (Figure 
6). MAb 266 has been used in subsequent experiments.
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Figure 6. Screening of MAbs against RGSHis6-UL23 fusion protein. (A) Western 
immunoblot against bacterially produced GST-RGSHis6-UL23 (59.0 kDa) cleaved with 
thrombin to yield RGSHis6-UL23 protein (33.0 kDa) and GST (26 kDa). (B, C, D) Western 
immunoblots against bacterially produced GST-RGSHis6-UL23 eluted from the column with 
glutathione for 10 min at RT, and cleaved with thrombin in solution. GST-RGSHis6-UL23 
protein (59.0 kDa) and GST (26 kDa) were in detectable quantities. UL23 specific MAbs 
were 266, 73 (A and B), 66 (B), 263, 77, 157, 289, 335, 107 (C) and 367, 99, 300(2), 243 (D). 
MAbs that did not detect UL23 or were directed against GST were 300, 290, 130, 102 and 88.
3.9 Testing the specificity of anti-UL24 polyclonal antibodies
The specificity of rabbit anti-UL24 polyclonal antibodies, produced against GST-UL24 fusion 
protein (PAb 674 and PAb 675), was investigated by Western immunoblotting using 
bacterially produced UL24 (Figure 7A, B). GST-UL24 fusion protein, bound to glutathione 
sepharose beads, was cleaved with PreScission protease to yield pUL24. The pUL24 was 
then concentrated using a YM-10 Centricon® centrifugal filter device (Millipore) prior to use 
in Western immunoblotting. Antd-UL24 PAb 674 and PAb 675 both detected two closely 
spaced bands in the 40 kDa region of the gel. The lower is the major of the two bands and 
corresponds in size to that predicted for pUL24 (40.2 kDa). The GST protein was not 
detected (or was present in trace amounts) in the PreScission protease treated extract, since it 
remains bound to the glutathione sepharose beads. PAb 674 and PAb 675 do, however, 
detect purified GST (Figure 7A and B). The 40 kDa region bands were not detected by anti- 
GST antibody (not shown). Thus the PAb 674 and PAb 675 antibodies specifically detect 
pUL24.
The specificity of anti-UL24 peptide antibodies (pep684 and pep685) was investigated by 
Western immunoblotting using PreScission protease cleaved GST-UL24 fusion protein 
(Figure 7C). As expected anti-UL24 pep684 and pep685 antibodies did not detect GST. 
However, pep684 and pep685 detected a band of ~30 kDa thought to be related to pUL24. 
Since the rabbits were immunised with C-terminal peptides, the fact that full length GST- 
UL24 fusion protein (Figure 7C, D) is recognised by pep684 and pep685 demonstrates 
specificity for UL24.
PAbs 674 and 675 recognise pUL24 related products of different sizes to those recognised by 
pep684 and pep685. This suggests that pUL24 is either unstable in vitro after its cleavage 
from the fusion protein or that translation of the GST fusion protein terminates prematurely 
to yield truncated products. Since the pep684 and pep685 antibodies are directed against the 
C-terminal amino acid sequences of pUL24, the former appears more likely.
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Figure 7. The anti-UL24 polyclonal antibodies specifically identified pUL24 
produced in bacteria. pUL24 was cleaved from GST by PreScission Protease (PSP) (80 
cleavage units in 1ml cleavage buffer [50 mM Tris-HCl pH7.0, 150 mM NaCl 1 mM 
EDTA, 1 mM dithiothreitol]) at 4 °C overnight. Western immunoblots of PSP cleaved 
UL24 and purified GST proteins, using PAb 674 (A) and PAb 675 (B). Western 
immunoblots of PSP cleaved UL24 (C) and an inclusion body preparation of GST-UL24 
fusion protein (D), probed with pep685 and pep684 antibodies.
3.10 Testing the specificity of anti-UL24 monoclonal antibodies
Due to difficulties in obtaining sufficient pUL24 from PreScission protease cleaved fusion 
protein, hybridoma culture supernatants were screened by Western immunoblotting against 
the GST-UL24 fusion protein and purified GST. By inference, MAbs detecting the fusion 
protein but not the GST protein probably recognise epitopes on pUL24. O f 20 hybridomas 
screened all detected both the full-length GST-UL24 fusion protein and purified GST, 
indicating that diey were directed against the GST portion of the fusion protein. However, 
MAb 116 reacted strongly with the complete fusion protein and only weakly with GST (data 
not shown). This suggests that MAb 116 might recognise an epitope that spans the GST and 
UL24 protein junction.
In conclusion, several antibodies (polyclonal, monoclonal or anti-peptide) were generated 
which specifically recognised epitopes on pUL23 and pUL24. These antibodies were used to 
investigate UL23 and UL24 gene expression, presence of the proteins in the virus particle and 
the intracellular location of the proteins. In order to gain further insight into the function of 
the US22 gene family proteins per se, antibodies directed against HCMV UL43 (provided by 
Dr. Derrick Dargan) and US22 (MAb HWLF1; Advanced Biotechnologies Inc.) were also 
employed.
3.11 Temporal class of pUL23, pUL24 and pUL43 expression
Herpesvirus gene expression is temporally regulated, occurring in three successive phases. 
The first genes expressed are those of the immediate-early (I-E) class, which are transcribed in
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the absence of de novo viral protein synthesis, by cellular RNA polymerase II. The early genes 
(E) are defined as requiring prior IE protein synthesis, but not viral DNA replication for their 
expression. Early gene products are therefore made in the presence of inhibitors of virus 
DNA synthesis such as phosphonoacetic acid (PAA). Late genes may be separated into E-L 
and L subsets, which are transcribed, mainly (E-L) or entirely (L), from progeny genomes. 
An indication of likely gene function can be deduced from this classification of gene 
expression. In general, I-E genes encode regulatory functions; E genes encode enzymes, 
proteins required for viral DNA replication, some virus structural proteins, or proteins with a 
role in viral pathogenesis, while L genes generally encode structural proteins.
Unexpectedly, the polyclonal antibodies raised against the GST-UL24 fusion protein or the 
UL24 C-terminal peptides failed to detect pUL24 in infected cell extracts by Western 
immunoblotting, although UL24 related proteins of various sizes were detected in bacterial 
cell extracts following IPTG induction. However, a monoclonal antibody (MAb 116) raised 
against the GST-UL24 fusion protein recognised a protein band of ~40 kDa in Western 
immunoblots of infected cell extracts (Figure 8). Close approximation in size to the predicted 
UL24 product (40.2 kDa) indicates that MAb 116 specifically recognises pUL24 made in 
infected cells. To investigate the temporal class of UL24 gene expression, HFFF-2 or U373 
MG cells were infected with HCMV (strains A D I69, Towne or Davis) at an m.o.i. of 5 to 10 
p.f.u./cell and grown under conditions for expression of I-E, E and L genes. Western 
immunoblots probed with MAb 116 detected a band of ~40 kDa (pUL24) in infected, but 
not mock infected, HFFF-2 and U373 MG cells (Figure 8A, B and C). Irrespective of the 
HCMV strain used the pUL24 band detected was always the same size and was always 
detected in cell extracts in which late (L) proteins were made. In some experiments (Figure 
8A), pUL24 could also be detected, albeit weakly, in cells treated with 300 pg/ml PAA (i.e. 
expressing E genes) (Figure 8A). It is concluded therefore that pUL24 is expressed with 
kinetics of an early-late (E-L) gene.
pUL24 has proved difficult to detect in infected cell extracts and is almost certainly present in 
relatively small amounts. Differences in antibody potency might explain why pUL24 was not 
detected by the PAbs and anti-peptide antibodies.
99
Monoclonal (MAb 92) and polyclonal antibodies (PAb 616) raised against a GST-UL43 
fusion protein (provided by Dr. Derrick Dargan) were used to investigate the temporal 
kinetics of UL43 gene expression. Infected HFFF-2 cell extracts were prepared as described 
above. PAb 616 recognised a polypeptide band of ~48 kDa (similar to the predicted product 
of the UL43 ORF (47.7 kDa)) in cell extracts in which late proteins were made (Figure 8D). 
pUL43 could not be detected in cell extracts treated with PAA, even upon prolonged 
exposure of the gel. Thus, gene UL43 is expressed with the kinetics of a true-late (L) gene.
pUL23 could not be detected in either HFFF-2 or U373 MG cells infected at high m.o.i. (> 
10 p.f.u./cell) with HCMV strains A D I69, Towne or Davis, or in the supernatant culture 
medium and therefore the temporal classification of UL23 gene expression could not be 
determined by these experiments. Attempts were made to enhance UL23 gene expression by 
incubating infected HFFF-2 cells at different temperatures (33 °C, 39.2 °C or 38.5 °C) or by 
overlaying cells with medium containing 1-5 mM HMBA (N,N’-Hexamethylene-bis- 
acetamide) (Sigma) or 1-5 mM sodium butyrate (Sigma) for the first 24 h PI. HMBA is 
known to affect the pattern of transcription in cells infected with HSV-1 (Preston and 
McFarlane, 1998; McFarlane et al., 1992). Sodium butyrate has been shown to enhance 
HCMV yield in TPC-1 cells (Tanaka et al, 1991), enhance EBV-specific DNA synthesis 
(Saemundsen et al., 1980) and induce HCMV permissiveness in cultured endothelial cells 
(Radsak et al, 1989). Protein extracts were harvested at various time points up to 96 h PI but 
no pUL23 specific bands were ever detected by Western immunoblotting from any of these 
experiments. Nor were pUL23 specific bands detected from experiments in which infected 
cells were fractionated into nuclear and cytoplasmic extracts.
While the polyclonal and monoclonal antibodies raised against the GST-UL23 fusion protein 
and the polyclonal antibodies raised against the UL23 synthetic peptide all recognised pUL23 
made in bacteria none could detect pUL23 in infected cell extracts. This suggested either that 
pUL23 levels were below that which were detectable by the antibodies used, or that the 
reactive epitopes were unavailable, possibly due to some post-translational modification of 
the protein.
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To investigate pUL24 and pUL43 expression throughout the virus replication cycle, HFFF-2 
cell layers were either mock infected or infected with A D I69 at a m.o.i. of 10 p.f.u./cell. 
Protein extracts were harvested every 12 h up to 120 h and examined by Western 
immunoblotting, using MAb 116 (anti-pUL24) or MAb 92 (anti-pUL43) as probe. Neither 
antibody reacted with polypeptides from the mock-infected control cell extracts (not shown). 
pUL24 was first detected at 12 h PI, at very low abundance, and increased in amount 
thereafter (Figure 9A). pUL43 was first detected at 60 h PI and increased in amount 
thereafter (Figure 9B). These findings are in keeping with the designation of pUL24 as the 
product of an early-late (E-L) gene and pUL43 as the product of a true-late (L) gene. None 
of the proteins, pUL23, pUL24 or pUL43 could be detected as secreted proteins in the 
culture medium from infected cells.
Despite numerous attempts to optimise conditions, using several protocols, none of the 
several anti-UL23, UL24 or UL43 antibodies detected their target protein in 
immunoprecipitation reactions. This has hindered attempts to investigate possible post- 
translational modification of the proteins.
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Figure 8. Temporal class of gene expression. W estern immunoblots, probed 
with anti-UL24 MAb 116, against mock infected (MI) cell extracts or HCMV 
infected cell extracts made under conditions for expression of I-E, E or L 
proteins. (A) AD 169 infected HFFF-2 cells extracts. (B) AD 169 infected 
U373 MG cell extracts. (C) Towne and Davis strain infected HFFF-2 cell 
extracts. (D) Western immunoblot, probed with anti-UL43 PAb 616, against 
HCMV infected cell extracts made under conditions for expression of I-E, E 
and L proteins.
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Figure 9. Synthesis of pUL24 and pUL43 during the virus 
replication cycle. Western immunoblots of AD 169 infected HFFF-2 
cell protein extracts, probed with anti-UL24 MAb 116 (A) and anti- 
UL43 MAb 92 (B).
3.12 pUL23, pUL24, pUL43 and pUS22 are components of the virion tegument
To investigate whether pUL23, pUL24, pUL43 and pUS22 were virus particle components, 
cell-released virus-related particles were pelleted in the Sorval GSA rotor (12 k/2 h /4  °C) and 
the particles purified by banding in negative viscosity, positive density (glycerol/potassium 
tartrate) gradients (Irmiere and Gibson, 1983). Three bands were obtained after gradient 
centrifugation, each containing different HCMV particle types. From the top of the gradient, 
the sequence of banded particles was; NIEPs, virions and dense bodies, as determined by 
SDS-PAGE analysis of the protein content of each band (Figure 10). The identification of 
NIEPs was confirmed by the presence of a unique virus protein band of 36 kDa (UL80A). 
All the structural proteins of the particle were present in the banded virion preparation, while 
the banded dense bodies were largely composed of the pp65 matrix protein, with the UL25 
product also over-represented. These designations were subsequently confirmed by electron 
microscopy.
Purified virions, dense bodies and NIEPs were investigated for the presence of pUL23, 
pUL24, pUL43 and pUS22 by Western immunoblotting. pUL24 and pUL43 were contained 
in the banded virions, dense bodies and NIEPs preparations (Figure 11A and B). Curiously, 
both the anti-UL24 and anti-UL43 antibodies detected an additional NIEPs specific band 
running below pUL24 and pUL43. The significance of this observation is not clear and has 
not been investigated further. The anti-US22 (HWLF1 MAb) detected a protein of ~76 kDa, 
slightly higher than the predicted size of pUS22 (66.9 kDa), in both purified virion and dense 
body preparations, suggesting post-translational processing of pUS22 (Figure 11C). pUS22 
was poorly detected unless the gel track was loaded with 10 fold (i.e. 1010 particle equivalents) 
normal levels of protein extract. Unfortunately, there was insufficient NIEP protein extract 
to allow for the 10 fold greater loading, though it is highly likely that pUS22 is also a 
component of NIEPs. Similarly, pUL23 was present in low abundance in purified virions 
(Figure 13) and could only be clearly identified in experiments where 10 fold normal 
concentrations of protein extract were used. Thus all of the US22 gene family proteins 
investigated were associated with gradient purified virus particles.
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In order to establish whether pUL23, pUL24, pUL43 and pUS22 were indeed particle 
proteins, and not simply associated with co-purifying cell debris, the purified virions were 
investigated by immuno-gold negative stain electron microscopy. Rabbit polyclonal 
antibodies were not used during these experiments because the HCMV tegument contains an 
Fc receptor (Stannard and Hardie, 1991) that binds rabbit antibodies with high affinity 
(Antonsson and Johansson, 2001). To eliminate the possibility that our results were due to 
non-specific Fc binding of MAbs, a non-HCMV MAb (AP33) having the same IgGl isotype 
as anti-UL23 MAb 266, anti-UL24 Mab 116 and anti-UL43 MAb 92 (antibody isotyping kit; 
Sigma) was used as a control. Particles treated with the non-HCMV MAb AP33 did not label 
with gold (Figure 12A). pUL23, pUL24, pUL43 and pUS22 were detected in tegument 
material adhering to capsids (Figure 12B, C, D and E respectively), or in matrix material 
issuing from dense bodies (not shown), where the envelope was broken. Particles with an 
intact membrane were not labelled with gold. Thus, pUL23, pUL24, pUL43 and pUS22 are 
confirmed as protein components of the virus particle and are likely contained in the 
tegument structure. To confirm that pUL23, pUL24, pUL43 and pUS22 were tegument 
components, the envelope was removed from purified virions by treatment with detergent. 
After centrifugation, the pelleted capsid/tegument and soluble envelope fractions were 
probed for pUL23, pUL24, pUL43 and pUS22 by Western immunoblot (Figure 13A, B, C, 
D, respectively). As expected, pUL23, pUL24, pUL43 and pUS22 were each present in the 
intact virions (track 1) and in the capsid/tegument fraction (track 2), but not in the envelope 
fraction (track 3). To confirm efficient de-envelopment of the particles, the blots were 
routinely stripped and sequentially re-probed with control antibodies directed against a known 
tegument protein, pp65 (Figure 13E) and a known envelope protein, gB (Figure 13F). pUS22 
and pUL23 were present in low abundance in virions and in the capsid/tegument fraction 
and could only be detected in experiments where > 1010 particle equivalents were loaded in 
each gel track. Since the proteins comprising the capsid structure are well known (Chee et al, 
1990) and do not include pUL23, pUL24, pUL43 and pUS22, they all were deduced to be 
tegument proteins.
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Figure 10. Polypeptide content of banded HCMV particle 
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Figure 11. pUL24, pUL43 and pUS22 are contained in purified  
NIEPs, virions and dense bodies. Western Immunoblots, probed 
with anti-UL24 MAb 116 (A), stripped and re-probed with anti- 
UL43 Mab 92 (B). (C) Western immunblot, probed with anti-US22 
MAb, showing detection of US22 in purified virions and dense 
bodies (NIEPs not shown). The broad band of pp65 protein in dense 
bodies can be seen.
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F ig u re  12. pU L 23, pU L 24, pU L 43 a n d  pU S22 a re  v irio n  
co m ponen ts . Virions were probed with non-HCMV control MAb 
AP33 (A), anti-UL23 MAb 266 (B), anti-UL24 MAb 116 (C ), anti- 
UL43 MAb 92 (D) or anti-US22 MAb HWLF1 (E) for 5 h at RT, 
and subsequently treated with an anti-mouse gold-conjugated 
second antibody (1/30 dilution) overnight at RT. Virions were then 
negatively stained with phosphotungstic acid. Bar represents 
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F ig u re  13. US22 gene fam ily  m em b e rs  a re  v irio n  te g u m e n t p ro te in s . Western 
immunoblots of intact purified virions (1), capsid/tegument (2) or envelope (3) fractions, 
probed with various antibodies against US22 family proteins. (A) pooled anti-UL23 
PAb 679 and pep683, (B) anti-UL24 MAb 116, (C) anti-UL43 MAb 92, (D) anti-US22 
MAb (HWLF1), (E) anti-pp65 MAb control, (F) anti-gB MAb control. The tracks are 
loaded with 5 x l0 9 (B, C, E, F) or lx lO 10 (A, D) virions. Particles were de-enveloped by 
treatment with detergent (1.0 %  NP40 in TNE buffer (10 mM Tris-HCl pH 7.4, 100 mM 
NaCl, 1 mM EDTA)), for 30 min at 4 °C.
3.13 Intracellular location of pUL24 and pUL43
To investigate the intracellular location of pUL24 and pUL43, HFFF-2 cells grown on glass 
coverslips were either mock infected or infected with A D I69 at a m.o.i. of 1 p.f.u./cell and 
processed for UV immunofluorescent microscopy at 72 h PI, using anti-UL24 MAb 116, 
anti-UL43 MAb 92 and anti-US22 MAb HWLF1 as probes. Rabbit polyclonal antibodies 
were not used in immunofluorescence due to non-specific binding of rabbit antibodies to the 
HCMV encoded Fc receptor. Mock infected or virus-infected HFFF-2 cells treated with the 
non-HCMV control antibody (MAb AP33) (Figure 14A), or mock-infected cells treated with 
MAb 116 (Figure 14B) or MAb 92, gave only background levels of fluorescence. In infected 
cells most of the pUL24 (Figure 14C) and pUL43 (Figure 14D) was concentrated in an 
intensely staining region or structure, juxtaposed to the nuclear membrane, though punctate 
staining of the perinuclear region, and to a lesser extent the cytoplasm was also observed. 
pUL24 and pUL43 were not detected in infected cell nuclei. Immunofluorescence studies 
using anti-UL23 MAb 266 did not show a clear or consistent fluorescence over background 
level that would permit the location of pUL23 to be determined (data not shown). As 
previously reported (Mocarski et al, 1988) pUS22 was detected by MAb HWLF1 only in the 
nucleus of infected cells (Figure 14 E).
The pUL24 and pUL4-3 containing juxtanuclear structures in infected HFFF-2 cells were 
further investigated by thin section immuno-gold transmission electron microscopy. Cells 
infected at a m.o.i. of 5 p.f.u./cell were harvested and processed for electron microscopy at 96 
h PI. Cell sections were treated with primary antibody (anti-UL23 MAb 266, anti-UL24 MAb 
116 or anti-UL43 MAb 92) then subsequently with secondary anti-mouse antibody 
conjugated to 5 or 10 nm gold particles, as available. Cell sections treated with the non-
110
HCMV control MAb AP33 did not label with gold. pUL23, pUL24 and pUL43 were each 
located in cytoplasmic protein aggregates that manifested in two morphological forms. The 
first, were large complex structures, which ranged in size from 0.3-2.0 pm in diameter, 
appeared to lack a limiting membrane, and were located close to the nuclear membrane 
(Figure 15A, B, D, E). The second, which resembled dense bodies, were smaller (with 
diameters up to about <0.2 pm) and appeared to be bounded by a limiting membrane (Figure 
15C). Evidently, the fluorescent juxtanuclear structure and the immuno-gold-tagged large 
complex type protein aggregates are the same structure. Virus particles, at various stages of 
maturation (B-capsids or DNA-containing capsids; tegumented or non-tegumented and non­
enveloped) were associated with the complex type protein aggregates. Large numbers of 
spherical microvesicle structures (53 nm average diameter) with a concentric double ring 
appearance were embedded within the complex aggregates. The small dense-body like 
membrane-bound aggregates were not associated with virus particles, and were devoid of 
microvesicles and appeared to originate from the complex aggregates by envelopment of 
portions of the matrix (Figure 15D).
I l l
(A) (B)
(C) ( D )
(E)
F ig u re  14. T h e  in tra c e llu la r  loca tion  
o f pU L 24, pU L 43 a n d  pU S22 
d e te rm in e d  by im m u n o flu o rescen ce .
HFFF-2 cells fixed at 72 h PI.
(A) Infected cells probed with non-HCMV MAb AP33 (Mag x 20)
(B) Mock infected cells probed with anti-UL24 MAb 116 (Mag x 20)
(C) Infected cells probed with anti-UL24 MAb 116 (Mag x 60)
(D) Infected cells probed with anti-UL43 MAb 92 (Mag x 20)
(E) Infected cells probed with anti-US22 MAb HWLF1 (Mag x20)
F ig u re  15. G o ld -tag g ed  cy top lasm ic  p ro te in  a g g re g a te . E lectron 
m icrographs o f  H C M V  infected HFFF-2 cells at 96 h PI. Cell sections were 
probed w ith (A) anti-U L24 M Ab 116, or (B) anti-U L23 M A b 266, or (C, D, 
E) anti-U L43 M A b 92 and subsequently labelled w ith anti-m ouse conjugated 
to 5 nm  (A and B) o r 10 nm  (C,D and E) gold particles. (A) Large com plex- 
type protein  aggregate containing gold-tagged pU L24. V irus particles are 
arrow ed; DB, dense-bodies; Teg, tegum ented particle; m icrovesicles, broken 
arrow. (B) Large com plex-type protein aggregate, jux taposed  to the nucleus 
and containing gold-tagged pUL23. Virus particles are arrow ed; NM , 
nuclear m em brane; m icrovesicles, broken arrow. (C ) M em brane bound 
sm all protein aggregate containing gold-tagged pU L43 (double arrow ).
These structures, resem bling H CM V dense bodies, varied greatly  in size. 
V irus particles are arrow ed; NM , nuclear m em brane. (D) V irions and N IEPs 
associated w ith reduplicated  m em brane are em bedded in this large com plex- 
type protein aggregate (arrowed). The ground texture o f  the m em brane- 
enclosed sm all protein aggregates (thin arrow s) is sim ilar to that o f the large 
aggregate-though m icrovesicles appear to be excluded-suggesting that these 
are derived from  the larger structure. (E) N on-enveloped, em pty and DN A- 
containing virus particles (arrows) are associated w ith the peripheral surface 
o f this large, gold-tagged pU L43-containing com plex-type protein  aggregate. 
The tegum ented dense-cored virus particle appears to be detaching from  the 
aggregate (fine arrow). Several gold-tagged virus particles associated  with 
the aggregate are evident.
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Chapter 4 
RESULTS
4.1 Preparation of expressing/complementing cell lines
The existence of homologues for the HCMV UL23, UL24 and UL43 genes in the other 
sequenced Betaherpesviruses suggests that US22 family members provide an important function. 
Consequendy, it was considered that US22 gene products might be essential for virus growth 
in vitro. If so, complementing cell lines are needed for the isolation and propagation of 
mutant viruses. Because they are permissive and give the highest yield of infectious progeny, 
human foetal fibroblast cells are the most appropriate cell type for construction of 
complementing cell lines. However, poor transfection efficiency and a short life span have 
impeded progress in this area until recently. With regard to the latter, two experimental 
approaches have been used to overcome senescence in fibroblast cells; firstly expression of 
the human papilloma virus (HPV) type 16 E6 and E7 transforming genes and secondly 
expression of the human telomerase reverse transcriptase gene (hTERT). Both of these 
systems were used in an attempt to construct cell lines expressing pUL23, pUL24 or pUL43.
4.2 Complementing cell lines based on hTERT-immortalised human retinal 
pigmented epithelial (RPE) cells
Before making complementing cell lines it was necessary to determine whether RPE cells 
were permissive for HCMV. RPE cell layers were infected with HCMV at an m.o.i. of 1 
p.f.u./cell and infected cell cultures harvested at various times during the period 0-120 h PI.
116
The one-step growth curves obtained (Figure 16) confirmed that hTERT-RPE cells are 
permissive for HCMV growth, although the virus replication kinetics were delayed compared 
to HFFF-2 cells and lower final tires were obtained.
Transient transfection assays using a reporter plasmid (pcDNA3.1His B/lacZ (Invitrogen)) to 
assess transfection efficiency showed that hTERT BJ (human foreskin fibroblasts) were 
virtually non-transfectable by electroporation, CaPC>4 or various lipofection techniques 
(transfection efficiencies were never > 0.01 % and were usually —0.001 %). Transfection of 
hTERT-RPE cells was much more efficient (—10 %). Consequently hTERT-RPE cells were 
used to generate expressing cell lines.
In order to generate expressing cell lines, hTERT-RPE cells in 24 well tissue culture trays 
were seeded at 5x104 cells/well overnight at 37 °C and then transfected with 0.1 pg plasmid 
DNA using the LipofectAMINE Plus™ or Transfast™ lipofection reagents. The cells were 
transfected with the empty pcDNA3.1+ vector plasmid, pcDNA3.1+/RGSHis6-UL23, 
pcDNA3.1+/UL24 or pcDNA3.1+/ RGSHis6-UL43 (the latter provided by Dr. Derrick. 
Dargan). At 48 h post transfection the cells from each well were trypsinized and re-seeded 
into the 24 wells of a new tissue culture tray. 24 h later the medium was changed for medium 
containing 300 pg/ml G418 to select for cells expressing the plasmid marker gene. Drug 
resistant cell colonies were obtained for each of the transfected plasmids after —2 weeks of 
G418 selection. Generally, only a few of the 24 wells on a tissue culture tray had colonies and 
usually there was only a single colony present in a positive well. When wells containing drug 
resistant cells were nearly confluent, the cells were trypsinized and re-seeded into a small 
tissue culture flask. Cells transfected with pcDNA3.1+/UL43 yielded eleven drug resistant 
colonies, of which six expressed pUL43 protein as determined by Western immunoblotting 
(Figure 17). Each of the six cell lines has continued to stably express pUL43 after recovery 
from -70 °C storage and following at least twenty cell passages.
Cells transfected with pcDNA3.1+/UL24 and pcDNA3.1+/RGSHis6-UL23 yielded twenty 
one and thirteen drug resistant colonies in the first experiment, respectively. However, none 
of these colonies appeared to express the pUL23 or pUL24 proteins when cell extracts were
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probed in Western immunoblots using the full range of available anti-UL23 and anti-UL24 
antibodies. Repeated transfection experiments yielded further drug resistant colonies, so that 
a total of thirty (pUL24) and twenty six (pUL23) colonies were finally obtained, however, 
without a single cell line expressing detectable amounts of pUL23 or pUL24 being obtained.
To eliminate the possibility that the pcDNA3.1+ plasmid constructs were defective HFFF-2 
cells were transiently transfected with the pcDNA3.1+/RGSHis6-UL23 plasmid and prepared 
for immunofluorescence at 48 h post transfection. The transfected cells were probed with 
mouse monoclonal antibody directed against the RGSHis6 tag and with the rabbit anti-UL23 
pep682 antibody. Confocal images (Figure 18) show that pUL23 is expressed from the 
pcDNA3.1+/RGSHis6-UL23 plasmid, at least in HFFF-2 cells, and that the same protein, 
distributed in a region close by the nuclear membrane, is recognised by the two antibodies 
(Figure 18A, B, C). Cells transfected with the pcDNA3.1+/ RGSHis6-UL43 plasmid and co­
labelled with anti-RGS MAb and anti-UL43 PAb 616 show that pUL43, like pUL23, is 
expressed and is also located in a region close by the nuclear membrane (Figure 18D, E, F).
To check if UL23 or UL24 transcripts were being produced in the G418 resistant RPE cell 
lines, mRNA was extracted from a representative drug resistant cell line for each of the UL23 
and UL24 plasmids. Northern blot experiments in which total mRNA was probed with 
UL23 and UL24 sequences (previously shown to detect UL23 and UL24 transcripts in 
Northern blots) failed to detect UL23 or UL24 mRNAs (Parvis Akter, personal 
communication).
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Figure 16. One-Step Growth Curves of HCMV (AD169) Growth in RPE cells and HFFF-2 cells (1
p.f.u./cell)
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Figure 17. pUL43 is stably expressed by hTERT-RPE cells. Western 
immunoblot, probed with anti-UL43 MAb 92, against cell protein extracts 
from G418 resistant hTERT-RPE cells at cell passage number 6. pUL43 
runs according to its predicted molecular weight of 47.7 kDa.
Figure 18. pUL23 and pUL43 are expressed in mammalian cells. (A, B, C)
Confocal images of pUL23 in HFFF-2 cells transiently transfected with the 
eukaryotic expression vector plasmid pcDNA3.1+/RGSHis6-UL23. The cell was 
probed with anti-RGS antibody (A) and anti-UL23 pep682 antibody (B). Merged 
image (C ) shows co-localisation (yellow), indicating the primary antibodies 
were detecting the same protein. (D, E, F) Next Page
Figure 18. pUL23 and pUL43 are expressed in mammalian cells. (D, E, F)
Confocal images of pUL43 in HFFF-2 cells transiently transfected with the 
eukaryotic expression vector plasmid pcDNA3.1+/RGSHis6-UL43. The cell was 
probed with anti-RGS antibody (D) and anti-UL43 PAb 616 antibody (E). 
Merged image (F) shows co-localisation (yellow), indicating the primary 
antibodies were detecting the same protein.
4.3 Complementing cell lines based on hTERT-HFF (BJ) cells
Since pUL23 was expressed from the pcDNA3.1 + vector in transiently transfected human 
foreskin fibroblasts, it seemed appropriate to attempt to make expressing cell lines in the 
hTERT-HFF (BJ) cell line. hTERT-HFF cells were seeded (5x104 cells/well) overnight at 37 
°C and then transfected with 1.0 jug plasmid DNA (pcDNA3.1/RGSHis6-UL23 or 
pcDNA3.1+/UL24) using the LipofectAMINE Plus™ or Transfast™ lipofection reagents. 
The medium was changed 48 h after transfection for medium containing 300 pg/ml G418. 
After approximately two weeks a small number of drug resistant colonies were obtained from 
cells transfected with either plasmid, but these never expanded beyond a few hundred cells, 
despite attempts to stimulate cell growth by various methods, including removal of cells from 
drug selection, use of conditioned medium, overnight change in incubation temperature or 
addition of an HFFF-2 feeder cell layer. Such drug resistant colonies survived for at least a 
four-month period and bromophenol-blue dye exclusion viability tests confirmed that the 
cells were still viable, though in a quiescent non-replicating state.
4.4 Cloning the RGSHis6-UL23 and UL24 ORFs into the LXSN16E6E7 amphotropic
retrovirus vector
Since UL23 and UL24 complementing cell lines were not obtained using the hTERT cell 
systems it was decided to try to make the expressing cell lines using the pLXSN16E6E7 
amphotropic retrovirus vector (kindly provided by Dr. Denise Galloway). This vector carries 
the HPV-16 E6 and E7 transforming genes for cell immortalisation and a G418 resistance
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gene for cell line selection. The UL23 and UL24 ORF were cloned, under the control of the 
HCMV I-E promoter, into the vector at a site between the E6/E7 and G418 genes.
The RGSHis6-UL23 ORF was excised from pGEX-4T-3/RGSHis6-UL23 plasmid on a 
BamH 1/Xho I fragment, purified on an agarose gel and cloned into LXSN16E6E7. DNA 
sequencing performed using the RApc3.1, RA2pc3.1, RA9 and RA10 PCR primers (Table 5) 
confirmed that there were no errors in the sequence of LXSN16E6E7/RGSHis6-UL23.
Similarly, the UL24 ORF was excised from pGEX-4T-3/UL24 plasmid on a BamH 1/Xho I 
fragment, purified on an agarose gel and cloned into LXSN16E6E7. DNA sequencing 
performed using the RApc3.1, RA2pc3.1, RA7 and RA8 PCR primers (Table 5) confirmed 
that there were no errors in the sequence of LXSN16E6E7/UL24.
4.5 Complementing cell lines based on the LXSN16E6E7 retrovirus vector
The LXSN16E6E7/RGSHis6-UL23 or UL24 plasmid was transfected (see methods) into 
PT67 Retropack packaging cells, which provide all the proteins (gag, pol, amphotropic env) 
required for replication and packaging of the vector into vims particles.
The amphotropic retrovirus packaging cell line, PT67, was seeded (2x105 cells/35 mm dish) 
overnight at 37 °C and then transfected with 1 pg plasmid (LXSN16E6E7/RGSHis6-UL23 
or LXSN16E6E7/UL24) DNA using the Transfast™ reagent. 48 h post transfection the 
medium containing the released vector retrovirus was removed from cells, clarified by low 
speed centrifugation and filtered (0.45 pm). The vims innoculum was mixed 1:1 with 
DMEM-FclO containing 4 pg/ml polybrene and used to infect HFFF-2 cells for 2 h at 37
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°C. The innoculum was decanted and replaced with DMEM-FclO containing 4 pg/ml 
polybrene and the cells were incubated for 5 h at 37 °C. The medium was then replaced with 
DMEM-FclO and the cells incubated at 37 °C. At 48 h PI the cells were trypsinized, re­
seeded in to 24 well tissue culture plates, and 24 h later the medium was changed for DMEM- 
FclO containing 300 pg/ml G418.
Several experiments produced in total three UL24 colonies and one UL23 colony. These 
colonies expanded in size to a few hundred cells (by 2 weeks PI) but then ceased to 
propagate. As was the case with hTERT-HFF (BJ) cells, removal of G418 from the medium 
had no effect on HFFF-2 colony expansion. At approximately ten weeks PI only one (UL24) 
colony had expanded further, in the absence of G418, and the cells were seeded onto a 35 
mm plate. However, pUL24 could not be detected by MAb 116 in Western immunoblots of 
protein extracts from this expanded cell line.
Clearly the retrovirus vector system was functional in these experiments since G418 resistance 
was acquired by the target HFFF-2 cells. The low number of drug resistant colonies obtained 
may reflect lower efficiency of the retrovirus vector system compared with the hTERT 
system.
In summary, three different cell lines using two experimental approaches have been used to 
attempt to produce a complementing/expressing cell line for pUL23 and pUL24. Each 
system has been shown to be functional since drug resistant colonies were obtained, and in 
the case of hTERT-RPE cells the system successfully yielded pUL43 expressing cell lines. 
The inability to produce an expressing cell line for pUL23 or pUL24 could be due to the 
proteins having a toxic effect on cells. The possibility that pUL23 and pUL24 may be 
cytotoxic is in keeping with the observation that they are expressed at low abundance in 
infected cells.
An attempt was made to demonstrate the putative toxic effect of pUL23 or pUL24 by 
directly transferring VP22-UL23 or VP22-UL24 fusion protein to HFFF-2 cells using the 
"Voyager’ system (Invitrogen). The RGSHis6-UL23, UL24 and RGSHis6-UL43 ORFs were
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cloned into the plasmid VP22/myc-His (Invitrogen) to produce VP22-RGSHis6-UL23, 
VP22-UL24 and VP22-RGSHis6-UL43 fusion proteins, respectively. Numerous 
immunofluorescence experiments were conducted, probed with anti-VP22 MAb SY34 
(kindly provided by Dr. Howard Marsden). BHK-21 cells transfected with the plasmids 
showed cytoplasmic fluorescence and when selected in G418 yielded drug resistant cells 
exhibiting large nuclear fluorescent aggregates, indicating that the VP22 proteins were present 
in the cell nucleus without killing the cells. HFFF-2 cells overlaid with filtered (0.45 pm) 
medium containing the VP22-UL23 or VP22-UL24 fusion protein and fixed 3-4 h later 
exhibited nuclear fluorescence (data not shown). Thus the VP22-UL23 and VP22-UL24 
fusion proteins did not appear to be cytotoxic. These experiments, however, do not rule out 
the possibility that pUL23 or pUL24 expressed in their native state are cytotoxic proteins.
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RESULTS
5.1 Strategy for the generation of UL23 and UL24 gene knockout mutants
In order to investigate the functions provided by genes UL23 and UL24 it is necessary to 
make knockout mutants for each gene. Since UL23 and UL24 are located adjacendy in the 
genome it is possible to also produce a double knockout mutant. An deletion-insertion 
mutagenesis strategy was employed; replacing a DNA fragment that coded for the conserved 
US22 motifs I and II in the UL23 and UL24 ORFs with the drug-selectable E .coli guanosine 
phosphoribosyl transferase (gpt) gene. The gpt gene product provides the capacity to salvage 
xanthine when cellular de novo guanine synthesis is blocked in the presence of the toxic 
compound mycophenolic acid (MPA). The use of gpt as a selectable marker for mutagenesis 
of MCMV (Vieira et al, 1994) and HCMV (Greaves et al., 1995) has been described 
previously. Drug selection for gpt expression is not absolute and wild type virus 
breakthrough is common. However, growth of recombinant viruses carrying the gpt gene is 
reported to be 1000 fold higher than that of the wild type virus, when grown in the presence 
of MPA and xanthine. Recombinant viruses expressing gpt are therefore isolated after several 
rounds of enrichment and plaque picking in the presence of MPA and xanthine.
A diagrammatic representation of the cloning strategy employed for the generation of plamids 
with UL23, UL24 and the double UL23/UL24 knockout mutations is shown in Figure 19.
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5.2 PCR amplification of DNA fragments required for generation of UL23 and UL24
plasmid mutants
All the DNA fragments needed for constructing the mutants were amplified by PCR, cloned 
sequentially into plasmid pUC18 (Amersham Pharmacia Biotech) and checked by DNA 
sequencing. The UL23 ORF and flanking DNA fragments (Fragments 1 and 2, see Figure 
19) were amplified from the cloned A D I69 Hind III Y fragment (Oram et al’ 1982) by PCR 
using oligonucleotide primers (Primers Richl, 2, 3 and 4, see Table 7 and Figure 19). The 
UL24 ORF and flanking DNA fragments (Fragments 3 and 4, see Figure 19) were amplified 
from an ADI69 cosmid fragment (Cos 64, described previously) by PCR using 
oligonucleotide primers (Primer Rich 5, 6, 7 and 8, see Table 8 and Figure 19). Each primer 
was abutted by restriction enzyme linker sequences to facilitate cloning (Tables 7 and 8). The 
UL23 and UL24 amplified DNA fragments were designed to have ~ 1 kbp of DNA 
sequence upstream and downstream of the UL23 or UL24 ORFs, respectively, to facilitate 
homologous recombination between plasmid contained HCMV sequences and wild type 
virus DNA. The gpt ORF and its associated HSV-1 Tk promoter (300-1187) were amplified 
by PCR from the pONllO l plasmid (kindly provided by Dr. Richard Greaves) using 
oligonucleotide primers (Primers Richgpt and Richgpt2, see Table 7). The SV40 poly(A) tail 
of gpt was not amplified.
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Table 7. Oligonucleotide PCR primers for amplification of UL23 or gpt D N A  fragments or for use in
DNA sequencing.
Primer 
Name /  
Position
Primer Usage 
/  Forward or 
Reverse primer
Oligonucleotide sequence
Richl /
HCMV
26855
Amplify UL23 3’- 
end (fragment 1) /  
Forward
5’-AATGG/4T(XATGAGAGAGGCGCCGCACGCTGCATGG 
BamH I
Rich2 /
HCMV
28128
Amplify UL23 3’- 
end (fragment 1) /  
Reverse
5’-AATGGATCCTCD4Gy4TGGTCGGCAGTAACCACGTGGAACCTT 
Xba I
Rich3 /
HCMV
28640
Amplify UL23 5’- 
end (fragment 2) /  
Forward
5’-AATCrGC4GGGATCCGGGTTTCCACGGTCGCGACGTCTTAGG
Pstl
Rich4 /
HCMV
29706
Amplify UL23 5’- 
end (fragment 2) /  
Reverse
5’-GACAAGCTTGAGATCGAGACGGACGAGGACTYCAAA  
Hind III
Richgpt /  
pONllOl
300
Amplify gpt ORF /  
Forward
5’-GGAAGATCTCTGG4GGAGCTTCAGGGAGTGGCGCAGCTGCTT
Pstl
Richgpt2 /
pONllOl
1187
Amplify gpt ORF /  
Reverse
5’-GCC TGXdG^TTAAAGCGGGGnTGAACAGGGTTTCG 
Xba I
RAPUC1/
pUC18
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DNA sequence 
vector pUC18 /  
Forward
5’-ATTAGGCACCCCAGGCTTTA
RAPUC2/
pUC18
361
DNA sequence 
vector pUC18 /  
Reverse
5’-TGTGCTGCAAGGCGATTAAG
23Dell /
HCMV
27201
DNA sequence 
UL23 fragment 1 /  
Forward
5’-GAATCTGGGGAATTCAACAC
23Del2 /
HCMV
27606
DNA sequence 
UL23 fragment 1 /  
Forward
5’-TGTATrCGGCACGCGAAACA
gptseql /
pONllOl
718
DNA sequence gpt 
ORF /  Forward
5’-GTGCGTTACTGGCGCGTGAA
gptseq2 /
pONllOl
760
DNA sequence gpt 
ORF /  Reverse
5’-GTATCGACATGACGAATACC
34Seql /
HCMV
29139
DNA sequence 
UL23 fragment 2 /  
Reverse
5’-GTCGACCTTATCCCCATCGT
34Seq2 /
HCMV
29038
DNA sequence 
UL23 fragment 2 /  
Forward
5’-GAACGTGTTGAGATTATCTC
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5.3 Cloning to produce a HCMV UL23 knockout plasmid mutant
The ~1.3 kbp UL23 3’-end (fragment 1) PCR product was digested with BamH I/Xba  I, 
purified on an agarose gel and cloned into pUC18. DNA sequencing performed using the 
RAPUC1, RAPUC2, 23Dell and 23 Del2 PCR primers (Table 7) revealed that there were 3 
PCR related errors in the DNA sequence of fragment 1; a silent mutation at position 28085 in 
ORF UL23 (codon AGC changed to codon AGT, both coding for Serine), and two point 
mutations at positions 27616 and 27468 in the UL22 and UL23 inter-genic region.
The ~0.9 kbp gpt PCR product was digested with P stl/X ba  I, purified on an agarose gel and 
cloned into pUC18 upstream of UL23 fragment 1. DNA sequencing performed using the 
RAPUC2, gptseql and gptseq2 PCR primers (Table 7) revealed that the sequence contained a 
silent mutation at pON llO l position 773 (codon TCC changed to codon TCT, both coding 
for Serine).
The ~1.1 kbp UL23 5’-end (fragment 2) PCR product was digested with Hind III/Pst I, 
purified on an agarose gel and cloned into pUC18 upstream of fragment 1 and gpt. DNA 
sequencing performed using the RAPUC2, 34Seql and 34Seq 2 (Table 7) PCR primers 
revealed that there were 2 PCR amplification errors in fragment 2, comprising of a silent 
mutation at position 28984 in ORF UL24 (codon AAC changed to codon AAT, both coding 
for Asparagine) and a point mutation at position 29347 in ORF UL24 (codon TTC, coding 
for Phenylalanine, changed to codon TTA, coding for Leucine).
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Table 8. Oligonucleotide PCR primers for amplification of UL24 D N A  fragments or for use in DNA
sequencing.
PCR 
Primer 
Name /  
Position
Primer Usage 
/  Forward or 
Reverse primer
Oligonucleotide sequence
Rich5 /
HCMV
29782
Amplify UL24 5’-end 
(fragment 3) /  Forward
5’-AATCTGC4GCAGACAGCCCAGGCCGAACTCGGCCGT 
Pst I
Rich6 /
HCMV
31155
Amplify UL24 5’-end 
(fragment 3) /  Reverse
5’-GCO!y4GCT7TATAGAAGAGCACGTTGTAATCGCGTA 
Hind III
Rich7 /
HCMV
29758
Amplify UL24 3’-end 
(fragment 4) /  Reverse
5’-CTATGE4G^GAAGAAGACCGCTGTGTGCCTCATCTC
Xbal
Rich8 /
HCMV
28450
Amplify UL24 3’-end 
(fragment 4) /  Forward
5’-CTAGG^4TGGGCACGTTGTGATCGCCCTTGTGTl[TAA 
BamH I
56Seql /
HCMV
29801
DNA sequence UL24 
fragment 3 /  Forward
5’- TCGGCCGTGAGCGCCAGGCT
56Seq2 /
HCMV
30499
DNA sequence UL24 
fragment 3 /  Reverse
5’- CTGCTACCGCCGCTGCTGCT
56Seq3 /
HCMV
30442
DNA sequence UL24 
fragment 3 /  Forward
5’- TGCCCGAGAACGGCGCCGGC
56Seq4 /
HCMV
30797
DNA sequence UL24 
fragment 3 /  Reverse
5’- TAAGACGGGGTCGACGAGGC
56Seq5 /
HCMV
30742
DNA sequence UL24 
fragment 3 /  Forward
5’- ACGAATGCATACCCATGCCG
56Seq6 /
HCMV
31149
DNA sequence UL24 
fragement 3 /  Reverse
5’- AGAGCACGTTGTAATCGCGT
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5.4 Cloning to produce a HCMV UL23/UL24 double knockout plasmid mutant
The HCMV UL23/UL24 double knockout mutant cloning strategy was to clone the UL24 
5’-end (fragment 3) upstream of gpt and UL23 fragment 1. The -1.4 kbp UL24 5’-end 
(Fragment 3, see Figure 19) PCR product was digested with Hind III/Pst I, purified on an 
agarose gel and cloned into the pUC18 plasmid containing gpt and UL23 fragment 1. DNA 
sequencing performed using the RA7 (Table 5), RAPUC2 (Table 7), 56Seql, 56Seq2, 56Seq3, 
56Seq4, 56Seq5 and 56Seq6 (Table 8) PCR primers revealed that UL24 fragment 3 contained 
no sequence errors.
5.5 Cloning to produce a HCMV UL24 knockout plasmid mutant
To produce the HCMV UL24 knockout mutant, the UL23 fragment 1 was excised by BamH 
1/Xba I digestion of the UL23/UL24 double mutant plasmid construct and replaced with the 
UL24 3’-end (fragment 4) using the same restriction enzyme linker sites (Figure 19).
The —1.1 kbp UL24 3’-end (Fragment 4, see Figure 19) PCR product was digested with 
BamH 1/Xba I, purified on an agarose gel and cloned into the pUC18 plasmid downstream of 
gpt and fragment 3. DNA sequencing performed using the RA8, RA9 (Table 5), RAPUC1, 
34Seql and 34Seq2 (Table 7) PCR primers revealed that there were 2 PCR amplification 
errors in fragment 4, comprising of a point mutation at position 28727 in the UL23-UL24 
inter-genic region and a deletion mutation (consisting of a single adenosine base pair) also in 
the UL23-UL24 inter-genic region at position 28762.
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5.6 Enriching for HCMV UL23 and UL24 gene knockout mutants
The protocol used for enrichment of recombinant viruses containing the gpt gene was as 
described by Greaves et al, (1995). HFFF-2 cells (2x105 cells/35 mm plate) were transfected 
with l-8pg plasmid DNA (for each mutant plasmid construct) by the calcium phosphate 
method and infected 24 h later with HCMV at a m.o.i. of 3 to 5 p.f.u./cell. Alternatively, the 
cells were infected with HCMV at a m.o.i. of 3-5 p.f.u./cell and then transfected with mutant 
plasmid constructs by lipofectdon (Transfast™) immediately after the 1 h virus adsorption 
period. In either case, progeny vims was harvested 5 days after infection and the infectivity 
titrated. For the first and subsequent rounds of enrichment for gpt expressing viruses plates 
of HFFF-2 cells were infected at ~0.1 p.f.u./cell. After vims adsorption for 1 h at 37 °C, the 
medium on cells was replaced with DMEM-FclO supplemented with antibiotics and 
containing 10 pg/ml MPA (GibcoBRL) and 250 pg/ml xanthine (Sigma). Vims was 
harvested 5 days after the cultures exhibited 100 % CPE. After four rounds of enrichment 
for gpt expressing viruses, the vims was cloned by four rounds of plaque purification. 
Plaques were picked from those plates that yielded well-defined and separated plaques. 
Picked plaques were sonicated and immediately plated on HFFF-2 cell layers, which were 
then overlaid with DMEM-FclO containing 10 pg/ml mycophenolic acid and 250 pg/ml 
xanthine. After the four rounds of plaque purification the infected cells were trypsinized, re­
suspended in DMEM-FclO and used to infect a small flask of HFFF-2 cells, to provide a 
vims stock. Plaque purified recombinant vims stocks were used to infect a 35 mm plate of 
HFFF-2 cells, which was harvested to provide infected cell DNA extracts for Southern 
blotting when 100 % CPE was reached. The DNA pellet was re-suspended in 25 pi sterile 
distilled water and digested with Hind III overnight at 37 °C. To screen for the presence of 
the gpt gene 5-10 pi of the Hind III digested DNA was further digested with Pst l/X ba  I for 
~4 h at 37 °C and the fragments separated by electrophoresis on an agarose gel, which was 
then processed for Southern blotting. The UL24 mutant plasmid construct was used as 
probe throughout, since it hybridized well to wild type vims DNA and should hybridize to 
bands of unique sizes for each of the recombinant vimses (Table 9).
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Table 9. Expected D NA band sizes in Southern blots probed with the UL24 mutant plasmid construct, 
following Hind III then Pst I/Xba I digestion of picked plaque infected cell D NA extracts.
Type of viral DNA Expected DNA band sizes in bp
Wild type virus 64,1432, 3790
UL23 knockout virus 64, 888,1071,1432
UL23/UL24 double knockout virus 888,1425
UL24 knockout virus 888,1425, 3657
Conclusion
No recombinant knockout viruses were isolated. O f the 79, 57 and 97 plaque purified 
“recombinant” virus infected cell extracts obtained for the UL23, UL24 and double 
UL23/UL24 mutant plasmid constructs, respectively, all gave the band pattern expected for 
wild type virus in Southern blotting experiments. A representative Southern blot with 
accompanying agraose gel is shown (Figure 20). The possible reasons for failure to isolate a 
recombinant virus are outlined in the discussion section of this thesis, section 6.6.
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Representative agarose gel (A) showing total cellular and viral DNA extracted 
from 35mm plates of infected HFFF-2 cells at 100% CPE, and digested with 
H in d  III and then with P st l/X b a  I. Track UL23 is a putative UL23 knockout 
mutant; UL24 is a putative UL24 knockout mutant and double is a putative 
knockout mutant in both UL23 and UL24. The accompanying Southern blot (B) 
for the gel, probed with the plasmid constructed for UL24 knockout mutant, 
shows that all 3 samples gave the wild-type virus profile. The expected band 
sizes for wild-type virus were 3790 bp and 1432 bp.
Chapter 6
DISCUSSION
Antibodies were generated to identify the HCMV UL23 and UL24 gene products. Polyclonal 
and monoclonal antibodies were raised against GST fusion proteins and polyclonal antibodies 
were also raised in rabbits against branched peptides of pUL23 and pUL24. The anti-UL24 
antibodies specifically recognized a 40 kDa protein in extracts prepared from pUL24 
expressing bacterial cells and from HCMV infected HFFF-2 cells. The anti-UL23 antibodies 
specifically recognized a 33 kDa protein in purified HCMV particle and in pUL23 expressing 
bacterial cell extracts. Antibodies previously raised against pUL43 specifically recognized a 48 
kDa protein both in pUL43 expressing bacterial cell and HCMV infected HFFF-2 cell 
extracts. The anti-US22 MAb specifically recognized pUS22 (76 kDa) from HCMV infected 
HFFF-2 cell extracts (Mocarski etal., 1988; Chee et al., 1990).
The molecular masses of pUL23, pUL24 and pUL43 did not differ significantly when made 
in prokaryotic and eukaryotic cells and were close to the size expected from the published 
DNA sequence (Chee et al., 1990), suggesting that none of the proteins were extensively 
modified by post-translational processing. Nevertheless, it is possible that some post- 
translational modification of pUL24 occurs, since pUL24 in infected cell or in virus particle 
extracts resolved as a broad fuzzy band or occasionally as a doublet of closely spaced bands in 
SDS-PAGE gels. The HHV-6 U3 gene (UL24 homologue) may also be post-translationally 
modified, since the pU3 made in eukaryotic cells has a higher molecular weight than that 
made in bacterial cells (Mori etal., 1998). Other members of the US22 family are also thought 
to be post-translationally modified. For example, pUL36 consistently migrated as a doublet 
in SDS-PAGE gels, although the nature of the modification has yet to be established 
(Patterson and Shenk, 1999). Furthermore, pUS22 migrated in SDS-PAGE gels at an 
apparent molecular resolution of 76 kDa, which is significantly higher that the 67 kDa protein 
predicted from the DNA sequence. In part the difference in size is due to a mistake in the 
published A DI69 US22 sequence (Chee etal., 1990), that shortened the predicted US22 ORF,
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but this cannot, by itself, account for the entire difference in the observed and predicted sizes 
-  suggesting that pUS22 may also be post-translationally modified. Unfortunately, immuno- 
precipitation experiments using the anti-UL23, anti-UL24 or anti-UL43 antibodies failed to 
work, possibly because in each case the proteins are present in protein aggregates in infected 
cells and so may not have been solubilized, and this has limited the investigation of post- 
translational processing of these gene products.
6.1 Kinetic class of gene expression
Western immunoblots revealed that pUL24 was expressed with early-late (E-L) gene kinetics, 
while pUL43 was expressed with true-late (L) gene kinetics. Time course experiments 
showed that pUL24 could be detected from as early as 12 h PI, while pUL43 was not 
detectable before 60 h PI, confirming the kinetic class designations for pUL24 and pUL43 
synthesis. Due to low levels of expression the 33.0 kDa UL23 protein could not be detected 
at all in infected cell extracts and consequently the kinetics of UL23 protein synthesis could 
not be determined. pUS22 has been reported to be expressed with early (E) gene kinetics 
(Mocarski et al, 1988).
The kinetic class of transcript expression for most HCMV genes has been investigated using a 
HCMV gene array system, which confirmed that the US22 and UL43 genes were expressed 
with early and late kinetics, respectively, but failed to detect mRNA transcripts for genes 
UL23 or UL24, or indeed for some other US22 family genes (UL28, IRS1 or TRS1) 
(Chambers et al., 1999). More recently, however, UL23 and UL24 mRNA transcripts have 
been detected, using the highly sensitive techniques of SMART-RACE PCR and Northern 
blotting. The results indicate that the UL23 and UL24 genes are both expressed with early- 
late (E-L) gene kinetics (Parvis Akter, personnal communication). Interestingly, the UL23 
transcript was even less abundant than the UL24 transcript, which itself was a rare mRNA. 
Thus, the relative transcript levels appear to correlate with the relative levels of pUL23 and
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pUL24 protein expression as detected by Western immunoblotting. The apparent paucity of 
UL23 and UL24 transcripts probably explains failure of transcript detection by the gene array 
system, as Chambers et al., (1999), arbitrarily set sensitivity levels to detect more abundant 
messages. By analogy with UL23 and UL24, the gene array data could also indicate that the 
UL28, IRS1 and TRS1 transcripts will also be rare. Interestingly, the HHV-6 gene U3 
transcript, detected by Northern blotting, was also rare. Like HCMV UL23, the HHV-6 U3 
protein product was not detected in infected cell extracts by Western immunoblot, although it 
was detected in infected cells by immunofluorescence. The authors concluded that the U3 
gene, like its HCMV UL24 counterpart, was expressed with early-late (E-L) gene kinetics 
(Mori etal., 1998).
US22 family gene members are represented in each of the temporal classes of gene 
expression; UL36, TRS1 and IRS1 are I-E genes (Tenney and Colberg-Poley, 1991a); 
Romanowski and Shenk, 1997; Chambers et al., 1999); US22, US23, US24 and US26 are E 
genes (Mocarski et al., 1998, Chambers et al., 1999), while UL23, UL24, UL29 and UL43 are L 
genes (Chambers et al., 1999; this thesis). Thus the different expression kinetics among family 
members allows for a US22 gene family role at each phase of HCMV gene expression.
6.2 US22 family gene products are tegument components
pUS22, pUL23, pUL24 and pUL43 were detected in protein extracts prepared from purified 
virions and dense bodies and pUL24 and pUL43 were also contained in protein extracts from 
NIEPS. pUL23 and to a lesser extent pUS22 appeared to be in low abundance in virions and 
dense body preparations, and were only detected unambiguously when the gel was loaded 
with 10-fold normal protein concentration (1010 particle equivalents/gel track). Since 
insufficient NIEPs were obtained in these experiments to allow for this increased loading, it 
was not possible to demonstrate the presence of pUL23 and pUS22 in NIEPs, though it 
seems highly probable that they would be present. In order to corroborate that pUS22,
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pUL23, pUL24 and pUL43 were indeed particle components and not simply associated with 
co-purifying cell debris, the purified virions were investigated by immuno-gold negative stain 
electron microscopy. As expected, pUS22, pUL23, pUL24 and pUL43 were particle 
components as evidenced by gold-tagging of tegument material adhering to capsids, or in 
matrix material issuing from dense bodies, where the envelope was broken. Final 
confirmation that pUS22, pUL23, pUL24 and pUL43 were indeed tegument proteins was 
obtained by demonstrating that these proteins were retained with the pelleted 
capsid/tegument structure after removal of the virus envelope by detergent treatment. 
Although others have suggested that pUS22 (HWLF1) is a non-structural protein (Mocarski et 
al, 1988; Dal Monte et al., 1998) the data reported here clearly show that pUS22 is a structural 
protein and a component of the tegument.
6.3 Intracellular location of pUS22, pUL23, pUL24 and pUL43 and models for particle
maturation
The intracellular locations of several US22 family proteins have been investigated by 
immunofluorescence. pIRSl and pTRSl are present throughout the infected cell at 
immediate-early and early times PI, but are predominately cytoplasmic at late times 
(Romanowski and Shenk, 1997), although neither has been reported to be located in the 
juxtanuclear structure reported by Sanchez et al, (2000b). Another protein, pIRSl263, entirely 
encoded within the C-terminal region of IRS1, is predominately nuclear throughout infection. 
This is consistent with the proposed function of pIRSl263, which is thought to antagonize 
pIRSl and pTRSl-induced transcriptional /raw-activation of pIRSl/pTRSl responsive gene 
promoters. Another US22 family gene product, pUL36, made at IE times, is present 
throughout the virus replication cycle in AD 169 infected cells. Like pIRSl and pTRSl, 
pUL36 was distributed all through the infected cell but occasional intense spots of 
fluorescence were present in the cytoplasm (Patterson and Shenk, 1999). The pattern of
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pUL36 intracellular fluorescence differed between A D I69 and Towne or Toledo infected 
cells. In the latter case there was little nuclear fluoresence but the cytoplasm contained 
intensely fluorescent spots and/or ‘worm-like’ structures of unknown origin. 
Immunofluorescence experiments using the HWLF1 (anti-US22) antibody and ADI 69 
infected HFFF-2 cells (not shown) confirmed earlier reports that pUS22, detected by 
antibody CH41, was located in the nucleus at both early and late times post-infection 
(Mocarski et al, 1988). Confusingly, however, Mocarski etal, (1988), also reported that in cell 
fractionation studies pUS22 was cytoplasmic with a proportion released from cells as a 
soluble protein at both early (24 h) and late (72 to 120 h) times in infection. The pUS22 
amino acid sequence does indeed exhibit characteristics consistent with a secretory protein, 
including putative N-linked glycosylation sites and the lack of a hydrophobic transmembrane 
region. In EM immuno-gold thin section experiments pUS22 could not be located 
unambiguously, since gold was scattered all over the sectioned cells, including the nucleus, 
cytoplasm and protein aggregates (data not shown) and could not reliably be differentiated 
from the pattern obtained with antibodies giving a non-specific reaction.
In immunofluorescence experiments pUL24 and pUL43 were non-nuclear proteins located in 
a cytoplasmic juxtanuclear region or structure, resembling that reported by Sanchez et al, 
(2000b), which was located close to, or involving, the micro tubule organising centre and 
associated with the post-Golgi network. The fluorescent juxtanuclear structures were further 
investigated by thin section immuno-gold transmission electron microscopy. These 
investigations correlated the fluorescent juxtanuclear structure with large protein aggregates 
with a complex structure. Smaller membrane-bound protein aggregates reminiscent of 
HCMV dense bodies were also present. The complex-type protein aggregates did not appear 
to be bound by a limiting membrane, but contained numerous spherical microvesicles with an 
average diameter of approximately 53 nm. pUL23, pUL24 and pUL43 were each located 
both in the complex-type protein aggregates and the smaller membrane-bound aggregates. 
Cytoplasmic protein aggregates are well documented in HCMV infected cells (Severi et al, 
1992). They have been reported to contain other viral tegument proteins ppl50 (UL32), 
pp65 (UL83) and pp28 (UL99) and to be associated with the virus envelope glycoproteins gB 
(UL55), gH (UL75) and gp65 (Landini et al, 1987; Hensel et al, 1995; Sanchez et al, 2000b).
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It has been suggested that the juxtanuclear structure is a major site of HCMV tegumentation 
(Sanchez et al., 2000b).
The site, or sites, at which tegument proteins are incorporated into the herpesvirus particle 
has been the topic of much research. To understand the processes by which HCMV 
tegumentation occurs it is necessary to consider what is known regarding the maturation of 
other herpesvirus particles. Most studies have used the A.lphaherpesvirus HSV-1. Two models 
for HSV-1 envelopment have been reported. The first, and earliest, holds that HSV-1 
particles acquire their envelope from the inner nuclear membrane. Such enveloped particles 
are said to be present in the lumen of the nuclear membrane and to travel along it to a 
junction with the ER. From the ER the enveloped particles are thought to pass into the 
Golgi apparatus, where final processing of the envelope glycoproteins occurs. The particles 
are then thought to exit the cell via the post-Golgi network and to be excreted into the 
medium by reverse pinocytosis. The second and more recent model holds that the HSV-1 
particle, enveloped at the inner nuclear membrane, is de-enveloped at the outer nuclear 
membrane and gains its final envelope by budding into a cytoplasmic vacuole from which it is 
released at the cell surface by reverse pinocytosis. These two models have implications with 
regard to the site of particle tegumentation. If the first model were correct then all tegument 
proteins must be acquired in the nucleus, before the particle is enveloped at the inner nuclear 
membrane. If the second model is correct then tegumentation might be a multi-step process 
or even occur exclusively in the cytoplasm.
Evidence is building in support of the second model (Skepper et al!, 2001). It is possible that 
HSV-1 acquires a particular subset of tegument proteins that are predominately located in the 
nucleus (e.g. the UL25 gene product). On leaving the nucleus this partially tegumented 
particle acquires a primary envelope from the inner nuclear membrane. However, 
investigation of the lipid content of extracellular virions reveals that the final envelope is 
acquired from a Golgi-related source and so the envelope acquired at the inner nuclear 
membrane must be lost (Van Genderen et al!, 1994). Additional envelope glycoproteins, 
gE/I, which are known to facilitate cell-to-cell spread of infection, accumulate in the trans- 
Golgi network (TGN) early in HSV-1 infection prior to re-distribution to cell junctions
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(McMillan and Johnson, 2001). Further support for final envelopment of particles in the 
cytoplasm has been obtained from Pseudorabies virus (an AJphaherpesvirusj, since simultaneous 
deletion of gM and gE /I leads to formation of numerous large intracytoplasmic inclusions, 
containing tegumented but non-enveloped capsids (Brack et al., 2000). Thus, the primary 
inner nuclear membrane is lost when the HSV-1 particle buds from the outer nuclear 
membrane. The de-enveloped partially tegumented particle then acquires an additional set of 
tegument proteins that are present only in the cytoplasm of infected cells. The precise 
location/s at which this second tegumentation step occurs has not been identified but 
probably involves vacuoles derived from the post-Golgi network. Since HSV-1 acquires its 
final envelope by budding into such a vacuole it is likely that the vacuole is coated with 
tegument proteins. The fully mature tegumented and enveloped particle is then transported 
to the plasma membrane and released into the extracellular medium when the vacuole reaches 
the cell surface and the vacuole and plasma membranes fuse (reverse pinocytosis).
That the HSV-1 cytoplasmic envelopment model also applies to Betaherpesviruses was suggested 
by studies with HHV-6. The HHV-6 tegument is electron-dense and readily visualized in the 
EM. HHV-6 capsids present in the lumen of the nuclear membrane have no discernible 
attached tegument structure, but those present in the cytoplasm are evidently tegumented 
(Roffman et al, 1990). More conclusive, however, is the data presented here for HCMV 
pUL23, pUL24 and pUL43. While pUL23, pUL24 and pUL43 are tegument proteins they 
were not detected in the infected cell nucleus or in any other cytoplasmic structure other than 
the cytoplasmic protein aggregates described. These tegument proteins must therefore have 
been acquired by particles maturing in the cytoplasm at the protein aggregates. Others have 
reported similar findings for pp28 (UL99) and ppl50 (UL32) (Sanchez et al, 2000a; Hensel et 
al., 1995). Severi et al, (1992), reported that electron dense structures in the cytoplasm of 
HCMV infected cells contain DNA, RNA and viral proteins. They called these structures 
‘cytoplasmic dense bodies’, but they appear morphologically similar to the protein aggregates 
described here. They suggested that cytoplasmic dense bodies represent sites where surplus 
cellular and viral molecules are stored prior to elimination (aggresomes). The data reported 
here dispute this interpretation for the complex-type aggregate for the reasons stated above. 
Moreover, Sanchez et al, (2000b), investigated the juxtanuclear structures and showed that
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they were stable, did not reorganise cellular vimentin and were not resistant to nocada2ole, 
indicating that they are probably not aggresomes.
In support of the cytoplasmic envelopment model for HCMV, we have observed that in 
infected HFFF-2 cells (at times > 72 h PI), tegumented, but non-enveloped particles were 
frequendy associated with the large complex protein aggregates. Although the complex 
aggregates appeared to lack an enclosing membrane, reduplicated membranes and enveloped 
vims particles embedded within the aggregate were occasionally observed. Spherical 
structures with the concentric double ring appearance of micro-vesicles (Dalton, 1975) were 
embedded within the matrix of large juxtanuclear protein aggregates and these may be derived 
from elements of the post-Golgi network. Interestingly, cryo-electron microscopy has 
revealed that spherical membrane structures, albeit larger at ~75 nm, were located at the 
centre of most HSV-1 L particles (S2ilagyi and Berriman, 1994); a non-infectious virus-related 
structure that is analogous to HCMV dense bodies. The small, membrane bound protein 
aggregates (dense bodies), observed in HCMV infected cells appeared to be generated by 
membrane envelopment of a portion of the large juxtanuclear aggregates.
144
F ig u re  21. M odel fo r  te g u m e n ta tio n  o f fo ta -h e rp e sv iru s  
H C M V . N ucleocapsids (thin lined hexagon) acquire som e 
tegum ent proteins (thick lined hexagon) (1) and are enveloped 
(dark circle) at the inner nuclear m em brane (2) and de­
enveloped by budding through the outer nuclear m em brane 
in to  the cytoplasm  (3). Partially  tegum ented nucleocapsids 
are transported to com plex cytoplasm ic aggregates e ither by 
free cytoplasm ic stream ing or by transport along m icrotubules. 
Further tegum ent proteins (light grey) are acquired at the 
com plex aggregate (4) and final envelopm ent m ay occur in  the 
v icinity  o f  the protein agrregates in a com partm ent derived 
from  the trans-G olgi netw ork or in vacuoles (5). M ature 
virions exit the cell by reverse pinocytosis. T egum ent proteins 
only found w ithin the com plex cytoplasm ic protein  aggregates 
are underlined.
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A schematic representation of a proposed HCMV maturation pathway is presented in Figure 
21. Particles in the nucleus do not appear to possess an electron-dense coat of tegument 
proteins. However, it is possible that HCMV nucleocapsids may acquire a restricted subset of 
tegument proteins, including pp65 (pUL83), pp71 (pUL82) pUS22 and ppl50 (pUL32), 
which are present in the nucleus (Figure 21, step 1). The SCMV homologue of pp71 is 
thought to direcdy bind to the major capsid protein (Trus et al, 1999) and it may be that the 
HCMV protein behaves similarly. Likewise, ppl50 is tightly bound to the HCMV capsid, by 
an interaction of a conserved sequence in the amino one-third of the ppl50 protein with the 
major capsid protein (Baxter and Gibson, 2001). Since pp71 and ppl50 are probably direcdy 
bound to the capsid shell they must be among the first tegument proteins acquired. The 
partially tegumented HCMV particle then enters the cytoplasm after envelopment and de­
envelopment at the inner and outer nuclear membranes as described for HSV-1 (Figure 21, 
step 2 and 3). The non-enveloped particle is then translocated to the vicinity of the large 
complex protein aggregate either by transport of the particle along microtubules to the 
micro tubule organising centre or by cytoplasmic flow. If the micro tubule network is used, 
clearly either a capsid protein or a nuclear located tegument protein must be involved in 
binding to motor proteins on the microtubule. It is likely that nuclear acquired tegument 
proteins form a framework for attachment of additional tegument proteins, which are 
acquired later in the cytoplasm. Non-enveloped particles then acquire an electron-dense, EM 
visible, tegument structure from the peripheral surface of the complex aggregates (Figure 21, 
step 4). The tegumented particles then acquire an envelope from cell membranes originating 
from the Golgi apparatus, possibly by budding into a vacuole. The virus is then released 
from the cell by reverse pinocytosis (Figure 21, step 5). An association of the post-Golgi 
network and the fluorescent juxtanuclear structure has been reported (Sanchez et al, 2000b) 
and occasionally enveloped virus particles and reduplicated membrane embedded in the 
complex type aggregates were seen. Dense bodies may also be generated from the complex 
aggregate by envelopment of the matrix material. It is also possible that virus particles may 
acquire an envelope by a similar mechanism.
146
6.4 Pre-Immediate-Early functions provided by tegument proteins
The finding that pUS22, pUL23, pUL24 and pUL43 are tegument proteins suggests that they 
operate during the initial stages of virus infection. In order to understand the possible range 
of functions performed by HCMV tegument proteins it is valuable to consider the events that 
occur during the period between virus binding to its cellular receptors and initiation of 
immediate-early gene expression. Much of this has been determined using the Atphaherpesvirus 
HSV-1. HSV-1 virions bind to the receptors on the cell surface (including heparan sulphate 
and chondroitan sulfate proteoglycans) through specific interactions with viral envelope 
glycoproteins (primarily gB and gC) and interaction of gD with one of several cellular co­
receptors (Whitbeck et al., 2001). Herpesvirus entry mediator (HVEM or HveA), a member 
of the tumor necrosis family, has been identified as the cell surface protein mediating HSV-1 
penetration into human T cells, although other cellular receptors, such as HveB (Nectin-2), 
HveC (Nectin-1), 3-0-sulfotransferase-3-modified heparan sulphate, may be needed for entry 
into other cell types (Steven and Spear, 1997; Martinez and Spear, 2001). Following binding 
of gD, the cytoplasmic domain of HveA interacts with a subset of adapter proteins in the 
TRAF family, which in turn leads to activation of two pathways: NF-kB and JNK/AP-1 
(Whitbeck et al, 2001). The contact initiates fusion of the viral envelope with the plasma 
membrane mediated by viral membrane glycoproteins gD, gB and gH/gL. After membrane 
fusion, the de-enveloped virus enters the cytoplasm leaving the envelope integrated into the 
host cell plasma membrane. Some tegument proteins may be shed from the virus particle 
immediately after entry while others appear to remain associated with the capsid. The viral 
nucleocapsid becomes attached to the microtubule network and is transported to a nuclear 
pore, where the capsid shell is opened to release the DNA genome, which then enters the 
nucleus (Batterson et al., 1983). Certain tegument proteins, such as VP16 (UL48), activate 
transcription of the viral genome and so enter the nucleus, while others, like virion host 
shutoff factor (Vhs) (UL41) are retained and operate in the cytoplasm. Upon entry into the 
nucleus the linear DNA molecule circularises. Interaction of VP16 with host transcription
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components Octamer-binding protein (Oct-I) and host cell factor (Hcf) results in immediate- 
early gene transcription and initiation of the virus replication cycle (Flint etal., 2000).
Although the individual steps occurring between binding of HCMV particles to their cell 
receptor and expression of I-E genes have been less well characterised, it can be assumed that 
HCMV follows the main features determined for HSV-1.
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Figure 22. Model for initiation of lytic infection of toa-herpesvirus 
HCMV, H C M V  binds surface heparin sulphate and co-receptors (1). 
G lycoprotein com plexes are involved in fusion o f the viral envelope w ith the 
cell m em brane. Som e tegum ent proteins are liberated upon de-envelopm ent 
and entry o f the particle into the cytoplasm  (2). The partially  tegum ented  
nucleocapsid is assum ed to be transported along m icrotubules to dock at the 
nuclear pore (3). Som e tegum ent proteins are transported to the cell nucleus 
and act co-operatively to  stim ulate H C M V  I-E gene expression (4). B inding o f 
H C M V  initiates several cell signalling pathw ays. IRF-3, in terferon response 
factor; CBP, C reb binding protein; ISG, in terferon-stim ulated genes; GCR, G- 
coupled receptor; M A PK , m itogen activated protein kinase; PIA 2, 
phospholipase A2; AA, arachidonic acid; PG H 2, Prostaglandin; R O I, reactive 
oxygen interm ediates; N F-kB , nuclear factor-kB; PLC, phospholipase C; 
IN S(1,4,5)P3, inosito l(l,4 ,5)-triphosphate; DG, d iacylglycerol; PK C , protein 
kinase C; S p l ,  stim ulatory protein 1
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A schematic representation of the recognised steps involved in the initiation of HCMV 
infection of cells in shown (Figure 22). The mechanism by which HCMV enters host cells 
has not been completely elucidated, but like HSV-1, it is a complex process involving 
viral/glycoprotein-host cell receptor interactions. HCMV initially binds heparan sulphate 
proteoglycans expressed on the cell surface, but this is not sufficient of itself to permit virus 
adsorption, co-receptor proteins are required, as with HSV-1. Possible receptors include 
aminopeptidase N (CD 13) or the 34 kDa protein annexin II (Pietropaolo and Compton, 
1997) (Figure 22. step 1). Annexin II specifically binds HCMV virions, is present on the 
envelope of purified virions and has been shown to directly interact with HCMV gB (UL55). 
The mechanism of membrane fusion and liberation of the nucleocapsid into the cytoplasm is 
likely to be analogous to HSV-1. A glycoprotein complex, gcIII, containing HCMV gH, gL 
and gO (UL75, UL115 and UL74) is involved in fusion of the viral envelope with the cell 
membrane. Another glycoprotein complex, gcll, containing HCMV gM (UL100) and gN 
(UL73), appears to bind heparin and may be involved in cell entry and/or cell/cell spread of 
infection (Mach et al., 2000). Some HCMV tegument proteins may be liberated upon de­
envelopment and entry of the particle into the cytoplasm (Figure 22, step 2). Some of the 
tegument proteins (e.g. pp65, pp71, pUL69, pTRSl, pIRSl) are transported to the nucleus of 
the infected cell, where some exhibit /r^j-activating activity. Not all tegument proteins 
appear to be imported into the nucleus of the cell. pUL36 may act at this stage to inhibit 
apoptosis of the newly infected cell (Skaletskaya et a l, 2001). By analogy with HSV-1, it is 
assumed that the HCMV nucleocapsid is transported along microtubules (Figure 22, step 3) 
to dock at the nuclear pore, where the viral DNA is released into the nucleus (Figure 22, step
4).
The functions provided by most HCMV tegument proteins are unknown, however, some 
tegument proteins have protein kinase activity (e.g. pp65) or may activate cell or other 
tegument proteins by phosphorylation. Some tegument proteins might function to modulate 
the intracellular signalling events induced by virus particle binding to cell surface receptors, or 
to induce additional cell signalling pathways. Others may function directly or indirectly as 
/nm-activators of certain cellular (e.g. transcription factors) or viral (I-E) genes. Some 
tegument proteins may operate to abrogate cellular anti-viral defence mechanisms (e.g.
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pUL36), and others to participate in translocation of the infecting virus particle or in release 
of the infecting genome from the capsid.
The HCMV tegument component contains transcriptional /razzr-activators including pTRSl, 
pIRSl, pUL69, pUL36 and pUL82 (pp71), which promote immediate-early gene expression 
and the initiation of lytic cycle replication (Romanowski et al\, 1997; Winkler et a l 1994; 
Patterson and Shenk, 1999; Baldick et al\, 1997). Some of the HCMV US22 gene family 
products are reported to exhibit /razzr-activating activity in transient transfection assays when 
expressed with the major I-E products IE1 and IE2 (Colberg-Poley et al, 1992; Romanowski 
and Shenk, 1997). Several more HHV-6 US22 gene family members have been shown to 
/zmr-activate the HIV LTR promoter in transient transfection assays, suggesting that at least 
some members of the US22 gene family may have a role in regulation of gene expression 
(Nicholas and Martin, 1994; Geng et al., 1992).
In addition to pUL23, pUL24, pUL43 and pUS22, three other HCMV US22 family gene 
products (pUL36, pTRSl and pIRSl) are documented virion tegument components 
(Patterson and Shenk, 1999; Romanowski et al, 1997). Thus seven of the twelve US22 family 
genes code for tegument proteins, raising the expectation that the remaining five, as yet 
unstudied, US22 family genes will encode products that are similarly located. pUL24, pUL36, 
pUL43 and pIRSl are non-essential and cannot be required for virus particle architecture or 
stability (Dr. Peter Ghazal, personal communication; Patterson and Shenk, 1999; Dargan et 
al, 1997; Jones and Muzithras, 1992;). Rather the presence of the US22 family proteins in the 
virus tegument argues for a role during the initial stages of infection. Curiously, pIRSl, 
pTRSl and UL36 are delivered as particle components, but also expressed as immediate-early 
proteins, which argues that the proteins may be multi-functional and/or required at different 
stages of infection. For example, pTRSl cooperates with pUL69 tegument protein to trans- 
activate the HCMV I-E promoters at the initial stages of infection (Romanowski et al, 1997) 
but is also required in combination with IE1 and IE2 to /razzr-activate the L gene product 
ICP36 (UL44) (Stasiak and Mocarski, 1992).
The functions supplied by pUL23, pUL24, pUL43 and pUS22 tegument proteins are not 
known, but clearly the processes that occur in the period between virus binding and virus
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gene expression are very complex and likely affect the ability of the virus to initiate lytic cycle 
replication. Given the wide range of host cells infected by HCMV there is ample scope for 
involvement of US22 family tegument proteins in influencing cell tropism. Infection of cells 
with HCMV results in activation of a range of cellular signalling events (Figure 22), including 
components of the MAPK, interferon reponse and phopsholipase C (PLC) pathways. It is 
possible that US22 family tegument proteins play a role in modulating these induced cell 
responses or in initiating or inhibiting other, as yet, unidentified cell responses to promote 
virus replication.
Surprisingly pUL23, pUL24 and pUL43 were not detected in the infected cell nuclei, although 
the possibility cannot be ruled out that the levels were simply below those that were 
detectable by the techniques employed. Alternatively, pUL23, pUL24 and pUL43 may only 
enter the nucleus when delivered to cells at the time of infection and not at the late times 
investigated here. Clearly, failure to detect pUL23, pUL24 and pUL43 in the nucleus argues 
against a direct involvement in gene regulation. However, at least one other HCMV trans- 
activator, gpUL37, is confined to the cytoplasm (Al Barazi and Colberg-Poley, 1996; Zhang et 
al, 1996). Several mechanisms can be invoked to account for an indirect effect of 
cytoplasmic located US22 gene family tegument proteins on host or viral gene regulation. 
They might interact directly with host cell or viral proteins in the cytoplasm that are 
themselves directly or indirectly involved in gene regulation, particularly of the MIEP, or that 
operate as part of an intracellular signaling pathway, or they might influence transcript stability 
or translation. Alternatively, US22 family proteins might operate by binding to, or otherwise 
inhibiting, the function of cellular proteins that are involved in pathways leading to a cellular 
antiviral defense mechanism. The reported functions provided by the few HCMV US22 
tegument proteins that have been studied to date are in keeping with a role during the initial 
stages of infection.
Recently, a MCMV virus mutant with a transposon insertion in the M43 (HCMV UL43 
homologue) coding sequence has been reported. The mutant grows as well as wild type virus 
in all mice tissues studied, with the exception of the salivary gland where the virus yield was 
100 to 1000 fold lower (Xiao et al, 2000). In contrast, Brown et al (1995), have reported that
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ADI 69 (UK) (identical to the AUL42/UL43 deletion mutant (Dargan et al, 1997)) replicated 
to a level 100 to 1000 fold greater than the ADI69; ATCC stock (wild type; coding for UL43) 
in human thymus/liver implants in SCID mice. Taken together, these data support the view 
that the HCMV UL43 gene and its MCMV homologue are involved in viral tropism (Xiao et 
al, 2000). Thus pUL43, delivered to cells at the time of infection, must have a role in the 
control processes that result in lytic infection, at least in some cell types.
pUL36 has also recently been reported to play a role in initiation of productive infection. The 
pUL36 gene product functions to inhibit apoptosis in infected cells (Skaletskaya et a l, 2001). 
The UL36 viral inhibitor of caspase-8 activation (vICA) inhibits Fas-mediated apoptosis by 
binding the pro-domain of caspase-8 and preventing its activation. vICA does not share 
sequence homology with FLICE-inhibitory proteins (FLIPs) or other known suppressors of 
apoptosis and therefore UL36 appears to encode a new class of cell-death suppressor. Since 
UL36 is dispensable for virus growth in cell culture and laboratory strains can acquire 
inactivating mutations in the UL36 gene, it has been suggested that the there is little selective 
pressure to maintain vICA function. This may be because there is redundancy in the anti- 
apoptotic functions provided by vICA and a viral mitochondria-localized inhibitor of 
apoptosis (vMIA) encoded by UL37, which has been shown to be highly conserved in clinical 
isolates and laboratory strains (Hayajneh et al, 2001a; Hayajneh et al, 2001b). The broad host 
range of cell types infected by HCMV in vivo may account for why HCMV encodes at least 
two anti-apoptotic proteins and so the UL36 gene may also function as a determinant of cell 
tropism.
Transient transfection assays have been used to investigate the function of HCMV US22 gene 
products pIRSl and pTRSl, and have shown that they promote little transcriptional 
activation when present alone, but act synergistically with IE1 and IE2 to enhance expression 
from a variety of viral promoters (Romanowski and Shenk, 1997). One of the two proteins is 
required for transient complementation of <?nLyt-dependent viral DNA synthesis (Pari and 
Anders, 1993). Thus, the function of the tegument pIRSl and pTRSl proteins might be to 
facilitate I-E gene expression at very early stages when the IE1 and IE2 gene products are just 
beginning to be made.
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The function of pUS22 is not known. Curiously, this secreted protein is highly immunogenic 
and stimulates a good IgG response. Indeed, anti-US22 IgG immunoglobulins are detected 
in ~40 % of CMV positive sera, even in patients with relatively low levels of anti-CMV IgGs 
(Dal Monte et al, 1998). Since it is a secreted protein of high immunogenicity it can be 
speculated that it has a role as an immune decoy, allowing infected cells to avoid immune 
clearance by cytotoxic T lymphocytes and natural killer cells. Alternatively, it might bind a 
receptor/s on non-infected cells and initiate an intracellular signaling response that 
predisposes the cell to infection by HCMV and thus facilitates spread of infection in the 
infected individual.
It is possible that US22 gene family proteins might be multi-functional, providing different 
functions at different stages of the virus replication cycle, as implied by the different kinetics 
of gene expression among family members. Indeed, pUL36 has motifs that are homologous 
with the HSV-1 tom-activating protein VP16, and so may function both as a tom-activator 
and as an inhibitor of apoptosis. The disparate range of functions either reported for 
TRS1/IRS1, UL36 or suggested for UL43 lends some support to a recently proposed 
suggestion, based on computer {in silicd) comparisons of US22 protein sequences with a data 
base of protein three-dimensional structures, that US22 family genes do not necessarily 
encode proteins of similar function (Novotny et al., 2001). Nevertheless, conservation of 
US22 family amino acid motifs and gene homologues for most HCMV US22 genes in other 
sequenced Betaherpesviruses provides strong evidence that at least some functional element of 
US22 family proteins are maintained and are presumably important for protein function 
(Table 10).
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Table 10. Spacing between US22 family motifs I and II
HCMV
US22
Gene
HCMV DNA sequence with US22 motif I and II underlined. Motif
Spacing
in
HCMV
Motif Spacing in 
other Beta 
H erpesviruses
UL23 GORVATVWPKDRCTVTRRRWRT.VRDEGRDAORLASYLCCPEPL.RFVG 26 CCMV UL23 = 26 
HHV-6 U2 = 26 
HHV-7 U2 = 26 
Tupaia T23 =  28
UL24 GOVLPWWPPGWNLVLOEIETDEDFKPEDVKAWSHYT.CCOTRLAFVG 26 CCMV UL24 = 26 
HHV-6 U3 = 26 
MCMV M24 = 26 
RatCMV R24 = 26
UL28 GRWLPLOJ/P__N o Motif II (possible spliced gene) N /A
UL29 GSCVSLGWP- ■ ■■ N o Motif II (possible spliced gene) N /A
UL36
Spliced Gene
28 CCMV UL36 = 28 
HHV-7 U17 = 29 
MCMV M36 = 28 
RatCMV R36 = 28
UL43 GTVI.RLSWPNG WFFTYCDI .1 .RVGYFGHT .NTKGT .F.KTFT CCD K, FT J ,pY0 27 CCMV UL43 = 27 
HHV-6 U25 = 27 
HHV-7 U25 =  27 
RatCMV R43 =  27
US22 VAI.RNPANWFLVMRF.OAAIPOIYARSTAADYLCCDDTLEAVG 21 CCMV US22 = 21 
Tupaia T5 = 21
US23 I AT GTPHNWFLO VRPGSTMPF.T .RDQT .1DDVTCCPERLJVLG 20 CCMV US23 = 20 
Tupaia T2 = 23
US24 I .SI GPPKGWHVMT.RTEDGIITAAKOAASKLICCREPLTPLG 20 CCMV US24 = 20 
Tupaia T3 = 19
US26 I.PTSAPPGWRLDFVEFEDIFGSAAVTDGPETPEGOLICCEESLESLG 26 CCMV US26 = 26
TRS1 No Motif I or II N /A
| IRS1 No Motif I or II N /A
The HCMV US22 motifs I and II are underlined with conserved amino acid residues in bold. The right hand 
column gives the spacing -in amino acids - between the motifs. Spacing of Motifs I and II is provided for other 
sequenced Betaberpesvirus genes.
Scrutiny of US22 family gene sequences reveals that the spacing between motif I and motif II 
is well conserved (20-28 aa) among the HCMV members of the family (Table 10). More 
importantly, the spacing of motif I and motif II is identical for HCMV and CCMV 
homologues and well conserved in the HHV-6, HHV-7, MCMV, RatCMV and Tupaia (Tree 
Shrew) US22 gene homologues. Conservation of spacing between the US22 family motifs I 
and II argues for at least local conservation in protein folding, to generate an important
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functional element common to most US22 family members. The fold in the protein induced 
by the motifs might be involved in protein/protein interactions with a cellular protein or with 
different members of a conserved family of cell proteins. Alternatively, though less likely, the 
fold might be involved in US22 family protein interactions with DNA or RNA.
Since most, if not all, US22 family genes encode tegument proteins it may be that one or
more of the US22 family amino acid motifs are required to target the protein to protein
aggregates or for integration of the protein into the complex tegument structure.
The data present in this thesis have demonstrated for the first time a common biological 
feature of US22 family proteins that has implications for the role performed by the family per 
se and focuses future research on early events in the virus replication cycle.
6.5 pUL23 and pUL24 may be cytotoxic proteins
In setting out to study the functions provided by genes UL23 and UL24 it was considered 
that pUL23 and pUL24 might be essential for virus growth in vitro, and that complementing 
cell lines would be required in order to isolate virus knockout mutants. The short life-span of 
human foetal fibroblasts, and their poor transfection efficiency, has until recently hindered 
the production of complementing cell lines for HCMV. Two systems for the generation of 
complementing cell lines were investigated.
The first depended on immortalization of HFF cells due to expression of the HPV type 16 
E6 and E7 transforming genes. E6 and E7 immortalized HFF cells have been shown to be 
permissive for HCMV infection (Compton, 1993) and have served as the basis for an HCMV 
IE1 expressing cell line that was capable of complementing an IE1 null mutant virus (Greaves 
and Mocarski, 1998). E6 functions by binding to, and causing unbiquitination and 
degradation, of cellular p53, which is a nuclear transcriptional regulator that normally induces
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Gi arrest or apoptosis in response to DNA damage or cellular stress (Flint et al, 2000). E7 
exhibits transforming activity by binding to cellular retinoblastoma tumour suppressor 
protein, Rb, preventing its ability to bind substrates such as E2F. The loss of the tumour 
suppressors p53 and Rb imparted by binding to E6 and E7, respectively, results in 
immortalisation of the cell.
The second system depends on the immortalisation of human fibroblast cell lines (HFF-R2, 
MRC-5, HCA2) by expression of human telomerase reverse transcriptase (hTERT) 
(McSharry et al, 2001; Bresnahan et al., 2000). hTERT fibroblasts have been shown to be 
fully permissive for HCMV. hTERT operates to inhibit senescence by preventing the 
shortening of chromosomal telomeres.
Retinal pigmented epithelial (RPE) cells and HFF cells with an extended life-span due to 
expression of hTERT and HPV type 16 E6/E7 transforming genes, respectively, were 
employed in an attempt to construct cell lines expressing pUL23, pUL24 and pUL43. 
hTERT-RPE cells were transfected with the eukaryotic expression vector pcDNA3.1 + 
carrying the UL23, UL24 or UL43 genes and grown in the presence of G418. However, no 
pUL23 or pUL24 expressing cell lines were obtained. In contrast, hTERT-RPE cells 
constitutively and stably expressing pUL43 were obtained, indicating that the hTERT RPE 
system was capable of generating cell lines expressing foreign genes. Failure to generate 
hTERT-RPE cell lines expressing pUL23 or pUL24 was not due to failure to transfect the 
cultures since G418 resistant colonies were obtained. It was considered that either the pUL23 
and pUL24 gene products were expressed at levels that were not detectable by Western 
immunoblotting or that the genes were not expressed at all. Attempts to increase expression 
of UL23 and UL24 drug resistant colonies by growth for in the presence of compounds 
known to alter the transcription pattern in cells (Phorbol 12-myristate 13-acetate (PMA), or 
PMA in combination with Forskolin, or Forskolin alone, or 5 HMBA alone or sodium 
butyrate alone) were all unsuccessful. Failure to detect protein may be due to impairment of 
transcription or translation. Northern blot investigations failed to detect UL23 or UL24 
transcripts from total RNA extracts of hTERT-RPE UL23 or UL24 G418 resistant cell lines. 
Whether the transcripts were not made or whether they were unstable has not been
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investigated. It is possible that the UL23 or UL24 gene products were cytotoxic and so the 
genes were silenced in the surviving drug resistant cell lines. A trivial and less likely 
explanation might be that the UL23 or UL24 ORFs were deleted or disrupted as a 
consequence of transfection of the plasmid into cells.
Similar attempts were also made to produce a complementing cell line for pUL23 and pUL24 
in human foreskin fibroblast cells (hTERT-HFF BJ), again without success. G418 resistant 
colonies were obtained as described above for the hTERT-RPE cell line, indicating that this 
part of the plasmid construct at least was expressed. Attempts were also made to generate 
UL23 and UL24 complementing cell lines in HFFF-2 cells using the pLXSN16E6E7 
amphotropic retrovirus vector system, but again without success, although again G418 
resistant cell lines were obtained. It was noted that the G418 resistant colonies of hTERT- 
HFF UL23 or UL24 cells lines and the pLXSN16E6E7 UL23 and UL24 cell lines all failed to 
propagate beyond a few hundred cells. Intriguingly, the colonies remained viable for at least 4 
months in the continous presence of G418, suggesting a possible effect of pUL23 and pUL24 
on cell cycle regulation.
Protein toxicity was cited as the most likely reason for the inability to produce cell lines 
expressing the HHV-6 U3 (pUL24 homologue) gene product (Mori et al, 1998). In an 
attempt to investigate the presumed toxic effects of pUL23 and pUL24, the ORFs were 
cloned into the Voyager vector system to produce VP22-UL23 and VP22-UL24 fusion 
proteins, which can be directly imported (translocated) into cells from the culture medium via 
the VP22 moiety. Immunofluorescence experiments confirmed the presence of the VP22- 
UL23 and VP22-UL24 fusion proteins in the nuclei of translocated HFFF-2 cells. No toxic 
effects of the fusion proteins were discernable. However, it is possible that the VP22 fusion 
proteins do not have the same characteristics as the native UL23 and UL24 proteins.
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6.6 Site directed mutagenesis of genes UL23 and UL24
In order to investigate the functions provided by genes UL23 and UL24 attempts were made 
to produce virus mutants with knockout mutations in either gene. The strategy was to 
engineer a precise deletion in the UL23 or UL24 ORFs and clone in the E. coli gpt gene, to 
serve as a selectable marker gene. After four rounds of replication to enrich for gpt 
containing viruses and four rounds of plaque picking in the presence of MPA and xanthine all 
of the plaque purified viruses yielded the wild type virus restriction endonuclease DNA band 
pattern in Southern blots.
That no recombinants were isolated was unexpected, since care was taken to avoid operator 
selectivity, by picking all of the plaques on a culture dish irrespective of size. Greaves et aly 
(1995) have successfully used gpt as a selectable marker in HCMV mutagenesis, but also 
reported that the wild type virus can breakthrough the MPA/xanthine selection to give 
infectious vims yield at approximately 1000 fold lower levels than recombinant viruses 
expressing the gpt gene. In addition to wild type vims breakthrough there are several other 
possible explanations as to why no recombinants were isolated. Transfection efficiency is 
notoriously low (<1 %) in the case of HFFF-2 cells, and may have resulted in little or no 
uptake of mutant viral plasmids. To maximise transfection efficiency, circular plasmid 
molecules were used for transfections, although this may have significantly reduced the 
efficiency of recombination between plasmid and viral genome. Choice of HCMV strain 
used may be another key factor that influenced the inability to isolate a mutant vims. Greaves 
et al!, (1995), used the Towne strain of HCMV, rather than A D I69, and since the former 
replicates faster and to higher titres the efficiency of the Towne system might be greater than 
that of ADI 69.
It is possible that UL23 and UL24 are essential for vims growth in culture and in that case 
recombinants cannot be isolated, in the absence of a complementing cell line. However, this 
explanation was apparently ruled out for UL24 when a clinical isolate with a naturally 
occurring deletion of the UL24 ORF was identified, although this has not yet been fully
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characterised (Dr. Peter Ghazal, personnal communication). Finally, one trivial explanation 
might be that an insufficient number of plaques were screened. However, time constraints 
allowed for only a single attempt at these experiments.
Isolation of HCMV mutants using standard molecular biology techniques is a difficult and 
time-consuming task, primarily because of poor transfectability of HCMV permissive cell 
lines and the slow viral replication kinetics. Therefore, relatively few HCMV mutants have 
been documented to date. Overlapping cosmid fragments have been used to generate 
mutants in herpesvirus genomes (Cunningham and Davison, 1993; Cohen and Seidel, 1993; 
Kemble et al, 1996). While this approach eliminates the technical problem of isolating a 
minor population of recombinants from within a mixed pool of wild type virus, it relies on 
transfecting several DNA fragments (up to 8 in the case of HCMV) into cells simultaneously 
and therefore is inefficient. Transposon insertional mutagenesis and bacterial artificial 
chromosomes (BACs) have been used to generate large banks of random mutants in HCMV 
and MCMTV, and several reports have used these approaches to study MCMV mutants in vivo 
(Zhan et al., 2000a; Zhan et al., 2000b; Xiao et al\, 2000). The genomes of several 
herpesviruses have been cloned as BACs, including MCMV; EBV; PRV; HSV-1; HCMV and 
GPCMV (Messerle et al, 1997; Delecluse et al, 1998; Smith and Enquist, 2000; Saeki et al, 
1998; Borst et al, 1999 and McGregor and Schleiss, 2001). Borst et al, (1999) described the 
construction and stable passage of an infectious clone of HCMV maintained as a BAC and 
reported a technique for site-specific mutagenesis, by which they were able to produce a 
UL37 deletion mutant vims. More recently, the BAC technology was used to create an IE2 
knockout mutant (Marchini et al, 2001). The BAC technology represents a major advance in 
the study of herpesvirus genomes, although complementing cell lines are still required for 
analysis of essential viral genes. Future attempts to create UL23 and UL24 knockout mutants 
may be more easily performed using the BAC system.
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6.7 Future work on the US22 gene family
This is the first investigation of HCMV genes UL23, UL24 and UL43, which belong to the 
HCMV US22 gene family and the first time that a common biological feature has been 
demonstrated among family members. The main finding that pUL23, pUL24, pUL43 and 
pUS22 (along with other US22 family members UL36, TRS1 and IRS1), are all tegument 
components has important implications for the overall role of the family per se. Seven of the 
twelve US22 family genes encode tegument proteins, raising the expectation that the products 
of the remaining five genes will be similarly located. This important finding implicates the 
US22 family in events that occur during the early stages of infection and this will be the focus 
of future research on the US22 gene family.
Using yeast two-hybrid systems with cellular and/or viral cDNA library it should be possible 
to investigate protein/protein interactions between pUL23, pUL24, pUL43 and pUS22 
proteins and host cell factors or other viral proteins. The pUL43 expressing cell line might be 
used in gene array experiments to investigate possible effects of pUL43 on cell gene 
regulation. It should be possible to construct the UL23, UL24 and UL43 knockout mutants 
using the HCMV BAC system, though it is possible that the genes will be non-essential for 
growth in tissue culture and have no recognisable phenotype — at least in HFFF-2 cells.
These studies also contribute to the debate regarding the intracellular site at which tegument 
proteins are acquired. It will be important to investigate whether the large protein aggregates 
described here are also present in other cell types infected with HCMV and whether they are 
also present in cells infected with other Betaherpesviruses.
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